/images/logo.png
当前位置： 首页 > 科研团队 > 教授
贾力
来源:CMAPC　作者:admin　更新时间:2020-04-17

 

贾力 博士生导师、博士后导师；福州大学肿瘤转移的预警和预防研究所所长。福州大学能源与环境光催化国家重点实验室生物医药光催化课题组长。福建省药学重点学科福州大学负责人、福建省肿瘤转移药物干预重点实验室主任
学术兼职 他曾兼职担任美国药学会（American Association of Pharmaceutical Scientists, AAPS）药物设计和开发专业委员会（drug design and development, DDD）的副主席、主席（2009-2012）、世界中医药学联合会/ 植物药代谢与临床监测专业委员会委员（2016-）。他是福建药理学会理事，江苏省和福建省“创新创业人才”综合评审员、教育部博士学科点专项科研基金评审员、国家自然科学基金函评和会评评审员、江西省科技厅评审员、科技部创新人才推进计划评审员、参与中国工程院与国家自然科学基金委联合开展的《中国工程科技2035发展战略研究》的咨询工作。2002年4月- 2011年12月，担任美国国立卫生研究院国家癌症研究所（NIH/NCI）的高级项目主管（级别GS14/step9）和高级药理研究员，负责新药研发（主要是抗癌药），指导药理毒理工作和参与新药申报。他参与过美国国立卫生研究院（NIH/ NCI）的12项新药申报，领导或参与过35项新药开发项目，获得和主持过17项新药研究课题。他设计、主持和主讲过50次国际药学学术会议。2008年至今，为中国科学院纳米材料和纳米安全生物效应重点实验室客座教授、中国药科大学讲课教授。先后在加利福尼亚州立大学、圣地亚哥医学院和La Jolla Pharmaceuticals任高级研究员。2000-2002年担任美国德州圣安东尼奥药物开发研究所/癌症治疗和研究中心副主任和Associate Member。受聘为12家专业期刊任副主编、或编委。
论著成果 他在美国纽约州立大学，师从1998年诺贝尔奖获得者、著名药理学教授Robert Furchgott博士获得药理学博士学位。他发表论文和论著>140篇(大多数为一作或通讯作者)，会议文摘110篇。 论文发表在国际自然科学顶尖学术杂志（Nature、Science、PNAS）及专业主流高影响因子学术刊物（Nano Today、Adv. Funct. Mater、Theranostics、Trends Pharm Sci、Trends Biotech、Biotech Adv、Cancer Res、J. Control Release、Blood、Drug Disc Today、Eur.J. Cancer、Oncotarget等）。论文总引用次数>5,000，h-index 28, i10-index 50; 总影响因子IF>750。
获得的重要奖项有：
•  1997年获得全军科技进步一等奖（第一名）；
• 1999年11月，经中国教育部批准，入选为中国医学科学院国家第二批长江学者奖励计划教授（后因故未赴任）；
•  2004年,获得美国国立卫生研究院(NIH)颁发的NIH荣誉奖；
• 2011年荣获美国药学会（AAPS）会士（Fellow）称号,以认可他对国际药学研究的重要影响。
• 2011年福建省引进高层次创业创新“百人计划”人才；
• 2012年福建省高校100领军人物入选者；
•  2014年由福州市第十四届人大常委会第十七次会议审议通过，授予他“福州市荣誉市民”称号，以表彰其“在促进福州市经济社会发展和扩大对外交流合作等方面做出的突出贡献”；
• 2014-2015年二度入选为“2014年、2015年中国高被引学者榜单”。中国高被引学者榜单的研究数据来自Scopus数据库。Scopus是全球最大的同行评议学术论文索引摘要数据库。

Curriculum Vitae
 
Name: Lee Jia
 
Business Address: 523 Industry Road, Science Building, 3FL., Cancer Metastasis Alert and Prevention Center, College of Chemistry, Fuzhou University, Fuzhou, Fujian 350002, China;
 
Business Email and Phone: pharmlink@gmail.com; cmapcjia1234@163.com Phone: 0591-83576912 (China);
 
EDUCATION:
 
1994-1996 Post-Doctoral Fellow, Department of Medicine, Divisions of Respiratory & Cardiovascular Medicine, Duke University Medical Center, Durham, NC, USA
 
1990-1994 Ph.D. (Pharmacology), State University of New York, NY, USA: Mentor Dr. Robert F. Furchgott, the 1998 Nobel Laureate.
 
1984-1987 M.S. (Pharmaceutical Science), China Pharmaceutical University, China
 
1978-1982 B.S.  (Pharmacy), Fudan University, College of Pharmacy, China.
 
PROFESSIONAL & ADMINISTRATIVE Appointments 
  
01/2012-present Distinguished Professor, “The China Recruitment Program of Global Experts” (1000-talent plan); Founding Director, Cancer Metastasis Prevention & Alert Center, Fuzhou University, China.
 
09/2014-present Director, Biopharmaceutical Photocatalysis of State Key Laboratory of Photocatalysis on Energy and Environment, Fuzhou University
 
12/2015-present Director, Fujian Provincial Key Laboratory of Cancer Metastasis Chemoprevention and Chemotherapy (Fuzhou University）
 
4/2005-4/2012 Senior Pharmacologist; Senior Project Officer (Permanent Tenure, GS14/Step 9), Toxicology and Pharmacology Branch, Developmental Therapeutics Program (DTP), Division of Cancer Treatment & Diagnosis, National Cancer Institute/ NIH; Rockville, MD.

4/2002-2005 Senior Pharmacologist; Project Officer (Conditional Tenure, GS14/
Step 6), Developmental Therapeutics Program (DTP), Division of Cancer Treatment & Diagnosis, National Cancer Institute/ NIH; Rockville, MD.
 
2008-Present Visiting Professor, Chinese Academy of Science Key Laboratory for Biomedical Effects of Nanomaterials and Nano-safety, Beijing, China.  
 
2/2000-3/2002 Associate Director, Department of Translational Research; Head, PK/PD Laboratory. Institute for Drug Development/ Cancer Therapy & Research Center, San Antonio, TX;
 
5/2000-3/2002 Associate Member (equivalent to Associate Professor), San Antonio Cancer Institute, San Antonio, TX.
 
1998-1999 Group Leader and Member of IACUC (Institutional Animal Care and Use Committee), La Jolla Pharmaceutical Company, San Diego, CA.
 
1996-1998 Senior Researcher, Dept. of Medicine, Uni. California San Diego, CA.   
            Visiting Scholar, Chinese Academy of Medical Sciences, Beijing, China.
 
1994-1996 Post-doctor, NitroMed Inc. / Department of Medicine, Divisions of Respiratory & Cardiovascular Medicine, Duke University Medical Center, Durham, NC.
 
1990-1994 PhD. Research supervised by Dr. Robert F. Furchgott, the 1998 Nobel Laureate, SUNY, NY.
 
1987-1989  Project Leader, Clinical Pharmacy and Pharmacology, East Hospital, China
 
PROFESSIONAL MEMBERSHIPS, ACTIVITIES AND AWARDS:

· 2015 Most Cited Chinese Researchers selected by Scopus/ Elsevier Research Intelligence 
· 2014 Most Cited Chinese Researchers selected by Scopus/ Elsevier Research Intelligence 
· Committee of Botanic Drug Metabolism and Clinical Monitoring Society/ World Federation of Chinese Medicine Societies 世界中医药学联合会/ 植物药代谢与临床监测专业委员会委员 (2016-present)
· Commission Member of Free Radical Biology and Medicine, The Biophysical Society of China (中國生物物理學會自由基生物學與自由基醫學專業委員會, 2014-president) 
· “Honorable Fuzhou Citizen” (2014) awarded by the Fuzhou City Standing Committee for his outstanding contributions to the promotion of the development and expansion of international exchanges and cooperation to make the economic and social prosper of Fuzhou   
· The China Recruitment Program of Global Experts Award (2011)
· The Fujian Science & Technology Innovation Leadership Award (2011).
· Member, American Association of Pharmaceutical Scientists (AAPS, 135447)
· Committee, Fujian Pharmacological Society, China (2012-present)
· Vice-Chair, Chair-elect, Chair and Past Chair (2009-2013), AAPS Drug Design & Discovery Section
· 2012 AAPS Program Coordination Committee, Award Committee 
· 2011 AAPS annual meeting programming committee
· Chair-elected (2007-2009), and Chair (2009-2010), AAPS CRO Focus Group (600+ members) 
· AAPS Nanotechnology Focus Group Steering Committee
· AAPS Fellow (2011) 
· Member, American Association for Cancer Research (AACR, 75164)
· Member, American Society of Gene & Cell Therapy (ASGCT; 2016- present; Member ID25579; account/code: LeeJia541123)
· Member, American Heart Association (1997-2000)
· Executive Board Member, State University of New York Alumni Association (2004-2010)
· 2004 National Cancer Institute Merit Awards
· 1998 American Heart Society Travelship Award 
· Yangtze River (Changjiang) Scholar Distinguished Professor (1999);
· First-class Army Science and Technology Progress Award: S-nitrosohemoglobin,1997
· Vice Chair, Graduate Student Association, China Pharmaceutical University (1985-1987)  
 
EDITORIAL SERVICES
 
Organize review processes for submitted manuscripts, including identifying and inviting qualified reviewers, analyzing reviewers’ critiques, comments, and overall scores to make final fair justifications, setting criteria for acceptance, rejection, and revision.    
 
1. Associate Editor, Current Drug Metabolism (2005-present);
2. Editorial Advisory Board Member, Current NanoSciences (2005-present); 
3. International Editorial Advisory Board, Therapeutic Delivery (2010-present);
4. Editorial Board Member, Pharmaceutica Analytica Acta (2010-present)
5. Editorial Board Member, Pharmaceutical Regulatory Affairs (OMICS Publishing Group; 2011-pesent)
6. Editorial Board Member, International J. Tumor Therapy; Scientific & Academic Publishing (2011-Present)
7. Associate Editor, Drug Metabolism Letter (2007-present);
8. Editorial Advisory Board Member, Current Bioactive Compounds (2007-present);
9. Editorial Board Member, The Open Drug Metabolism Journal (2008-present);
10. Editorial Advisory Board Member, The Open Drug Delivery Journal (2008-present);
11. 《药物分析杂志》特邀编委(Editor, Pharmaceutical analysis Journal)（2012年--）
12. 《贵阳医学院学报》特邀编委(Editor, Guiyang Medicinal College J.)（2013年--）
13. Advisor to the Science and Technology Group Publishers (2008-present);
  
Invited  or ad hoc Reviewers for the Following 40 Journals:
 
1. Cell Biology & Toxicology; 
2. J. Pharm. Sci; 
3. Brain Research; 
4. Biochem Pharmacol; 
5. Letters in Drug Design & Discovery; 
6. Rapid Communications in Mass Spectrometry; 
7. Biopharmaceutics & Drug Disposition; 
8. J. Pharm. BioMed. Anal; 
9. Clinica Chimica Acta; 
10. NeuroScience Letters; 
11. J. Pharmacol. Exp. Ther; 
12. Molecular Pharmacology; 
13. Anti-Cancer Agents in Medicinal Chemistry; 
14. Current Drug Metabolism; 
15. Bioorganic & Medicinal Chemistry Letters; 
16. Biomedical Chromatography; 
17. J. Chromatography; 
18. Planta Medica; 
19. Xenobiotics; 
20. Molecular Pharmaceutics; 
21. Acta Pharmacol Sin.; 
22. Drug Metabolism Letter; 
23. Curr. NanoScience; 
24. Arch Pharmacol.; 
25. Drug Metabolism and Disposition (ASPET); 
26. Toxicology Letter;
27. Biomaterials
28. Chinese Medicine
29. Current HIV Research
30. J. NanoSci. NanoTech.
31. Therapeutic Delivery
32. Journal of Medicinal Plant Research
33. Drug Discovery Today
34. Biomaterials (IF8.557)
35. Current Medicinal Chemistry
36. Toxicological Sciences
37. Journal of Acquired Immune Deficiency Syndromes (JAIDS)
38. The AAPS J
39. Oncotarget (IF6.63)
40. Science Translational Med (IF 15.8)
41. Chemical Science (IF9.21)
 
Abstracts Reviewer for Annual AAPS Conferences (2008-2010).
 
CONSULTANTSHIPS AND COMMITTEE SERVICES (selected):
 
2005 Reviewer for 5-year NIH/NCI pharmacology/ toxicology contract research applications
 
2009-2010 Peer-reviewer invited by the Medical Research Council (MRC) of South Africa (a statutory science council that is responsible for managing and funding research in South Africa) to evaluate the merit of research proposals submitted for funding.
 
2012-2014 Invited grant reviewer for National Natural Science Foundation of China (NSFC)
 
2011 Invited reviewer for the young 1000-plan award
 
2013 Invited reviewer for Jiangxi Province Science and Technology Innovative Project applications
 
2014-2015   Invited Oncology Study Section Review Site Panel of the National Natural Science Foundation of China (NSFC)
 
2013-2016   Invited Oncology or Pharmacology Study Section Grant Application Reviewer of the National Natural Science Foundation of China (NSFC)
 
10/2014 Committee of the innovative pharmaceutical research of outstanding scientist award
 
2011-2014 Committee of the AAPS annual meeting abstract Award/ travelship
 
2013-2014 Reviewer for 2014 AAPS Research Achievement Award in Drug Discovery and Development Interface (DDDI)
 
 
Invited Speaker, Conference MODerate and ORGANIZER: 
 
1. Presentation entitled “Discovery of nitric oxide/ EDRF and its pharmacological effects” in East Hospital, Fuzhou, China, June, 1997.
 
2. Invited speaker, “S-nitrosylation and related drug discovery and development”, Nov. 1997, in Shenyang PHARON Health Products Co. LTD.
  
3. Invited speaker, presentation title “L-Arginine increases GFR partially by nitric oxide independent mechanism via activity of agmatine”.1998 American Society of Nephrology Annual Conference, Philadelphia, Oct. 25, 1998.
 
4. Invited speaker, presentation title “Nitric Oxide Research: From Hypothesis to Drug Development” State University of New York at Buffalo, Nov., 2001.  
 
5. Speaker, presentation title “EDRF Activity, Anticancer Spectrum and Pharmacokinetics of JS-K” NCI-SAIC Frederick, MD. Oct. 18, 2002.
 
6. Invited speaker, presentation title “Nitric Oxide Research: From Hypothesis to Drug Development” Johnson & Johnson Pharmaceuticals, San Diego, CA. Feb. 2002.  
 
7. Speaker, presentation title ‘Stability of JS-K in Biomatrices’ at NCI-SAIC Frederick, MD. Oct. 16, 2003.
 
8. Speaker, presentation title ‘Public-private partnerships for development of 2nd generation of ethambutol analogs for tuberculosis treatment’. Sequella, Inc. Rockville, MD, Dec. 2, 2003.
 
9. Invited speaker, presentation title “Nitric Oxide Research: From Hypothesis to Drug Development” in Division of Applied Pharmacology Research, OTR/OPS/CDER/FDA, April, 2004.  
 
10. Speaker, presentation title ‘Interspecies pharmacokinetics of SQ109 and its metabolism profile’ Sequella, Inc. Rockville, MD. Aug. 3, 2004.
 
11. Speaker, presentation title “In vitro and in vivo testing of JSK”. NCI-Frederick, MD 10/26/2006
 
12. Speaker, Moderator and Organizer, presentation title “GLP-Regulations and Inspections in USA and China: Differences, Similarities and Case Analysis” in the two-day conference “Pharmaceutical Outsourcing: Regulations, IP, Technology, Capabilities, and Partnership” Shanghai, China, April 2-4, 2007, co-sponsored by Fudan University (SPFDU) and AAPS.
 
13. Speaker, Moderator and Organizer, presentation title “New Drug Applications in USA and China: Acceptability, Data Requirements and Benefit/Risk Analyses” in the two-day conference “Pharmaceutical Outsourcing: Regulations, IP, Technology, Capabilities, and Partnership” Shanghai, China, April 2-4, 2007. I designed topics and agenda, invited prominent experts for presentations.
 
14. Moderator and Organizer of the symposium entitled “Exploratory IND (phase 0 trial) and its practices” at the 2007 annual National Biotechnology Conference. San Diego, CA June, 26. 2007. I designed topics and agenda, invited leaders from the FDA, NIH, and Pharmaceutics who drafted or implemented the Phase 0 trials for presentations.
 
15. Speaker, presented “Differences and similarities between USA and China in new drug application procedures and regulations”. Global R&D Congress, May 29-30, 2008, in Washington, DC,
 
16. Moderator: 2008 AAPS, November 19, 2008. Georgia World Congress Center, Atlanta, Georgia, USA. “Outsourcing Drug Product Development to India and China” (Roundtable).
 
17. Session Chair and Speaker, presented ‘Sino-USA collaboration: challenges and opportunities for advancing nanomedicine’, moderated a brainstorm panel session at The 1st Joint US-China Symposium on Nanobiology and NanoMedicine, Oct. 21-23, 2008; Fragrant Hill, Beijing, China;
 
18. Moderator and Speaker: “Celebrating the Nanotechnology R&D Act: Then, Now and the Future” (Symposium), 2008 AAPS, November, 20, 2008. Georgia World Congress Center, Atlanta, Georgia, USA.
 
19. Interviewed by Pharmaceutical Technology’s Live Vidcast, Nov. 18, 2008, on “Nanotechnology in Pharmaceutical Applications”. 
 
20. Speaker: “From Hypothesis to Discovery: Untold Stories about the 1998 Nobel Prize In Medicine─Maximize Your Research Achievements By Publications And Networking” to the School of Pharmacy, Fujian Medical University, April 2, 2009.
 
21. Invited Speaker: “From Hypothesis to Discovery: Untold Stories about the 1998 Nobel Prize In Medicine─Maximize Your Research Achievements By Publications And Networking” to the Nanobiological Center of Shanghai University, April 6, 2009.
 
22. Invited speaker: “Differences and similarities in GLP-regulations and inspections between USA and China”, presented at Medicilon, Inc. April, 7. 2009.
 
23. Invited Speaker: “Comparison of new drug application procedures and regulations between USA and China” at “China 2009 Pharmaceutical R&D Summit” 4th International Conference & Exhibition, April 7-9, 2009 • Grand Hyatt Hotel • Shanghai, China.
 
24. Invited Speaker: “From Hypothesis to Discovery: Untold Stories about the 1998 Nobel Prize in Medicine─Maximize Your Research Achievements by Publications and Networking” to the School of Pharmacy Fudan University, April 9, 2009.
 
25. Invited Speaker: “From Hypothesis to Discovery: Untold Stories about the 1998 Nobel Prize in Medicine─Maximize Your Research Achievements By Publications And Networking” to the China Pharmaceutical University, April 10, 2009.
 
26. Seminar entitled “The Four-decade War on Cancer: Are We Winning???” presented to South China Center for Innovative Pharmaceuticals, Nov. 18, 2009.
 
27. Speaker, presentation title “Anti-HIV drug development involved in ADME and nanotechnology”, and moderator at International Symposium of NanoMedicine on AIDS/HIV sponsored by Beijing University of Technology, the National Center for Nanosciences and Technology of China, AAPS, Chinese Academy of Sciences and Chinese Ministry of Science and Technology (MOST), Beijing, China; Nov.19-20, 2009.
 
28. “Why we are not winning the war on cancer and how to lead the war to win: my view, my dreams and my strategies” presented at Graduate School of Pharmacy, Shanghai Jiao Tong University. Nov. 20. 2009.
 
29. Invited Speaker, “Contemporary understanding of the Millennium Phytomedicine― Ginseng” in Symposium: The Appalachian Center for Ethnobotanical Studies (ACES) in Tai Sophia Institute in Laurel, MD, on Saturday 26 June 2010. 
 
30. Invited Speaker, “The four-decade war on cancer: are we winning?” in Capital Medical University, Beijing, China. 10/25/2010, afternoon  
 
31. Invited Speaker, “The four-decade war on cancer: are we winning?” in Symposium 6: Advances of Drug Discover against cancers, The 8th Annual Congress of International Drug Discovery Science and Technology. 10/26/2010, 9:45-10:10 am  
 
32. Invited Speaker, “Current understanding of cancer metastasis requires changes in strategies of anticancer drug development”, in symposium 5 of annual Chinese Pharmaceutical Association Conference; Beijing, China, 11/7/2010, 9:15-9:35 am
 
33. Symposium: “Re-Engineering Nanomaterials with Biomolecules: Strategies, In Vivo Stability and Specificity, and Drugability", as both the moderator and speaker for the 2011 National Biotechnology Conference, Wednesday, May 18, 2011, from 1:30 pm - 4:00 pm, at the Hilton San Francisco, CA.
 
34. Invited Speaker, “From understanding the complex of cancer metastasis to designing cancer nanomedicine: what nanomedicines can and can’t succeed” and moderator of Nano-pharmaceutics Session at the International conference of 2011 China Nano, at the National Convention Center, Beijing. Sept.7-9, 2011.
 
35. Designed and Chaired the Hot topic: “The heating-up of pharmaceutical globalization:  current mergers and acquisitions by Chinese Pharma in the USA and basic knowledge of laws about drug importation to China”. October 24, 2011 12:15 PM – 1:30 PM, at the Walter E. Washington Convention Center, Washington, DC. USA (attendees 500)
  
36. Session Chair, Symposium: “Global Competition and Geopolitical Priorities for Bionanotechnology R&D”. 9:00-11:00 am, Oct 25, 2011. Convention Center, Washington DC, USA. The 2011 AAPS.
 
37. Speaker, Jia: “The market and contemporary understanding of the millennium phytomedicine-ginseng” and Session Chair “Evaluating Drug Development Opportunities in Botanical Polymolecular Therapeutics”. Time: Wed. 8:30-11:00 am, 10/26/2011; Place: Washington DC convention CTR.
 
38. Speaker, Jia: “Overview of Global Development of Photodynamic Therapy for Cancer and   China’s First Generation of Photosensitizer ZnPcS2P2” and co-Chaired the session “Nanobiotechnology” with Dr. Chen Wang, Director, National CTR for Nanoscience & Technology; 19:20-22:00, Oct. 31, 2011. 17th International Biophysics Congress, Beijing.
 
39. Invited speaker “Contemporary understanding of the nutraceutical ginseng: its anti-diabetic and cancer preventive effects and possible interaction with Warfarin”, and Session Chair “2012 International Conference on Ginseng”, Jilin, Chair; Sept. 4-7, 2012. (260 Attendees)
 
40. Invited speaker and organizer “The 40-year war on cancer: are we winning or Losing, and our strategies” at Fujian Pharmacological Society Conference (150 attendees), Fuzhou, Nov. 17th, 2012. Fujian Pharmacology Society, China.
 
41. Invited speaker “Re-engineering PAMAM dendrimer for its multivalent binding to colon cancer cells HT29” at The 3rd Joint US-China Symposium on Nanobiology and NanoMedicine, Dec. 5-7, 2012; Fragrant Hill, Beijing, China; 第449次北京香山科学会议、即第3次中美癌症纳米技术和纳米医学研讨会（2012年12月5-7日）
 
42. Invited speaker “Restrain activity of circulating tumor cells: the new strategy for preventing cancer from metastasis” at the China-US translational medicine international forum (250 attendees), 中国科协15届年会 (Chinese Association of Scientists)；Guiyan medical university, May 25, 2013.
 
43. Invited speaker “The new strategy to prevent cancer from metastasis: restrain circulating tumor cells” at the 2013 AAPS@ China Symposium, the Chinese University of Hong Kong, August 17-18, 2013.
 
44. Invited speaker and organizer “From endothelium-derived relaxing factor (EDRF)
to intervention of adhesion-invasion of circulating tumor cells (CTCs) to endothelium: a new horizon in biomedical nitric oxide research” at the 2014 International Nitric Oxide Conference, Shanghai Jiaotong University. July 5-6th, 2014.
 
45. Invited speaker and Section Chair: “Enhanced sensitivity and specificity of capturing and restraining circulating tumour cells in blood with dual antibody-coated nanomaterials” China Nanobiomedicine conference, Chenddu, 2014-11-05 China nanobiology and nanomedicine conference (全国纳米生物与医学学术会议-成都)
 
46. Invited speaker and Section Chair: “Nitric oxide prevents cancer metastasis by interrupting adhesion-invasion of circulating tumor cells to endothelium” in the 8th Pong Ding Yuen International Symposium on Traditional Chinese Medicine cum The 2nd International Chinese Symposium on Free Radical Research & The 6th Symposium for Three Districts of Cross-straits on Free Radical Research; University of Hong Kong, November 14-16, 2014.
 
47. Invited speaker “From endothelium-derived relaxing factor (EDRF) to intervention of adhesion-invasion of circulating tumor cells (CTCs) to endothelium: a new horizon in biomedical nitric oxide research” Chinese Pharm. University. Nov. 17, 2014.
 
48. Invited speaker: “Nitric oxide prevents cancer metastasis by interrupting adhesion-invasion of circulating tumor cells to endothelium” Fujian Chinese Medicine University. Nov. 20, 2014.
 
49. Invited speaker: “From Imitation to Innovation: the Ten-year Chinese Bionanotechnology Development” China Nanomedicine Conference, Hangzhou, April 7-9, 2015
 
50. Invited speaker: “The unique bionanotechnology conception focuses on cancer pre-metastatic prevention for tens of millions of survivorship" Nature Nanotechnology Forum at Fudan University, May 25th, 2015.
 
51. Invited speaker: “Separation, detection, capture and restraining of circulating tumor cells for cancer metastasis prevention for the increasing cancer survivors”BD Shanghai July 2015
 
52. Invited speaker: “Bionanotechnology used for capturing and restraining circulating tumor cells: eliminating the suffering and death from cancer metastasis” Dong, HY., Lu, Y., Xu, JG., Zheng, N., Liu, J. Jia,*L. ChinaNano 2015 meeting; Sept. 3-5, Beijing
 
53. Invited speaker: “Development of theranostical nanomedicine to specifically target circulating tumor cells (CTCs)” Jianguo Xu, Haiyan Dong, Yusheng Lu, Ning Zheng, Jian Liu, Lee Jia* 2015年中华放射学会年会，哈尔滨，9月17-20日“精准与可视化”专题
 
54. Invited speaker: “避孕药美她司酮用于二性预防肿瘤手术后的再转移：研究背景、现状、及其药代动力学的性别特征”. 中国药理学会全国药代动力学会议；济南，2015-10-10/12.分会场主持。
 
55. Invited speaker: “Novel strategy: shifting from traditional anticancer drugs and nanomedicines to circulating-tumor-cell-based metastasis chemoprevention (创新研发战略：从传统的抗癌药和纳米药物向基于循环肿瘤细胞的肿瘤转移的化学预防转变”。Suzhou Institute of Nano-Tech and Nano-Bionics Chinese Academy of Sciences, Oct., 13th, 2015.
 
56. Invited speaker: “Overview of Global Development of Photodynamic Therapy for Cancer and Our Contribution to Biopharmaceutical Photocatalysis” at the 2nd Fuzhou University-Osaka Prefecture Uni. Joint International Symposium. Oct., 30th 2015；Fuzhou Uni.
 
57. Invited speaker: “from the 1971 Cancer Act and NCI founded to today’s global cancer therapy: cancer metastatic alert and chemoprevention”. Aug. 6-7th 2016; Beijing; PLA 302 Hospital. The first NIH/USA overseas returnee scholar forum.
 
58. Organizer and Invited speaker: “Global deregulation of ginseng products may be life-threatening to warfarin takers: solid evidence of serious ginseng-warfarin interaction” International Conference on Ginseng 2016 Jilin, China; Sept. 6-9, 2016; Changchun.     
 
PRE-IND Packages and Meetings with FDA and IND APPLICATIONS: 
 
1. Pyrrolobenzodiazepine (SJG-136), Preclinical pharmacology summary prepared by Jia. (Date filed: July 14, 2004; FDA IND# 70218; FDA approved August 13, 2004)
 
2. Pre-IND packages and meetings with FDA and Sponsors: LIV-1, a novel drug delivery system to deliver 5-FU to hepatocytes and hepatoma cells to treat hepatocellular carcinoma (HCC). Cell-Works, Inc. Feb, 2003.
 
3. R(-)Gossypol (AT-101), FDA IND# 68255: Pharmacology Summary prepared partially by Jia; Sponsor: Ascenta Therapeutics, 2005.
 
4. SQ109, FDA IND# 69597: Pharmacology Summary prepared by Jia; Sponsor: Sequella, Inc. Filed in Sept. 2006.
 
5. MV-NIS virus, a live tissue culture adapted measles virus selectively targeting human myeloma cells. FDA IND# 13023. May 3rd, 2006.
 
6. Batracylin (NSC 320846): Pharmacology and Toxicology Summary prepared by Jia for IND filing; IND# 76254; Sponsor: National Cancer Institute. Completed in March, 2006.
 
7. 1-methyl-[D]-tryptophan (NSC721782; IND#78060): Pharmacology and Toxicology Summary prepared by Jia for IND filing; Sponsors: NCI and NewLink Co. Completed Aug., 2006. IND meeting: July 19, 2007.
 
8. P-28 peptide (IND# 77754) Pre-IND meeting with FDA July, 12, 2007; IND submitted July 8, 2008.
 
9. Development of allopregnanolone in Neiman-Pick type C disease (NP-C) PIND-74900 for treatment of inherited mitochondrial respiratory chain diseases; Pre-IND on Oct 17, 2006; White oak, Building 22/FDA; Sponsor: Edison Pharm.
 
10. Pre-IND meeting with FDA for single chain urokinase plasminogen activator (ScuPA) (PIND 106014) development; Oct. 27, 2009.
 
11. Pre-IND meeting with FDA for SPINALON designed to prevent or reverse chronic immobility-related health problems typically found in spinal cord-injured patients; Jan. 14, 2010.
 
12. Pre-IND meeting with FDA for development of PEG-hemoglobin-based oxygen carriers (HBOC) for AfterShock treatment; Feb., 23, 2010, at FDA Woodmont Office Building, Rockville, MD.
 
PATENTS:
 
1. Jia, L.: Method of synthesis of S-nitrosocaptopril crystals and the use thereof (issued as both the inventor and owner: CO7D207/16).
 
2. Jia, L. Garza, M, Wong, H, Redelmeier, T.E.: Intravenous carbendazim compositions (filed as inventor).
 
3. Jia, L: Method and compounds that prevent circulating tumor cells from adhesion and extravasations to distant organs (filed as the inventor and owner: file # 201110338508.9) 专利授权号：ZL 2011 10338508.9 干预循环肿瘤细胞粘附和浸润到外周组织的药物和新方法。
 
4. Jia, L.: Medicinal combination that prevent cancer metastasis after surgical removal of primary tumors (filed as the inventor and owner: file # 201210379714.9) 专利申请号201210379714.9   预防原发性肿瘤在手术切除后再转移的药用组合物
 
5. 陈海军，贾力(Lee Jia)，刘剑，俞雪梅， 陈晓云，黄惠龄、王继闯，高瑜。一种合成美她司酮的方法专利授权号（patent issued#：ZL 2013 1 0510394.0.‍ (Method of synthesis metapristone;
 
6. 高瑜，李志洪，王超群，陈海军，贾力。具有肿瘤靶向的叶酸-PAMAM-熊果酸纳米药物及其制备方法。专利授权号：ZL201410271351.6。
 
7. 高瑜，吴福强，顾颂恩，李志洪，解晓东，陈海军，贾力。一种米非司酮脂质体制剂及其制备方法。申请号：201410219537.7。
 
8. 高瑜，贾力，顾颂恩。一种抗体偶联的介孔二氧化硅/米非司酮纳米制剂。申请号：201510635471.4.
 
9. 江舟，杨纪娜， 庞雅琼， 王建， 贾力(Lee Jia). “一种九里香香豆素及其提取方法”中国专利授权号(patent issued#：201510003203.0; Method of extracting coumarins from Murraya exotica).
 
10. 贾力(Lee Jia)，卢余盛，于婷，梁海燕。斯诺普利在制备预防肿瘤转移或肿瘤治疗药物中的应用。专利申请号(patent file#：201410609416.3‍; Method of using S-nitrosocaptopril for  cancer metastasis prevention or cancer treatment)
 
11. 贾力(Lee Jia)、谢静静、陈红宁; 专利名称：识别、捕获和抑制循环肿瘤细胞的功能纳米材料载药系统;专利申请号(patent file#：201410639414.9; Functionalized nanomaterial carrier for recognizing, capturing and inhibiting circulating tumor cells)
 
12. 江舟，庞雅琼，周素霞，王建，贾力(Lee Jia); 专利名称：六甲氧基二氢黄酮-鼠李糖基-鼠李糖苷在肿瘤转移预防中的应用（patent file#:201510596604.1）
 
13. 江舟，马骁，张俨君，王锐，王建，余素红，贾力..怀牛膝和川牛膝中的牛膝皂苷 (已公示)。
 
 
Managed and directed NIH Contract research Funding 
 
1. Southern Research Institute (NO1-CM-52203) Total budget $ 2,774,595 from 2005-2011 for preclinical pharmacological studies of antitumor and other therapeutic agents.
 
2. Mayo Clinic (NO1-CM-52206) Total budge $1,828,875 from 2005-2011 for preclinical pharmacological studies of antitumor and other therapeutic agents.
 
3. University of Alabama at Birmingham (NO1-CM-52207) Total budget $ 1,714,794 from 2005-2011 for preclinical pharmacological studies of antitumor and other therapeutic agents.
  
FundingS 
 
1. Title: Nitric Oxide in Apoptosis: S-nitrosocaspases and Cytochrome C (Jan. 1998) PI: Jia, L.
CA-98-003, Outstanding Scholars Program (K22), Supported by NCI. $150,000/year for 4 yr.
 
2. Title: Development of a proteomic database for cancer prevention and treatment (Feb. 2001) PI: Jia, L. 5% effort, Supported by SACI. $21,500 for one year.
 
3. Title: Pharmaceutical development of 301029, an antiviral drug (March, 2000-June, 2001) PI: Jia, L., Supported by The Procter and Gamble Co. P&G 250-259. $350,000
 
4. Title: Pharmaceutical development of FB642 (Carbendazim) as an anticancer drug (May, 2000- Sept. 2001) PI: Jia, L., Supported by The Procter and Gamble Co. P&G 210-233. $ 550,000.
 
5. Title: Dynamic analysis of pharmacoproteomic effects of docetaxel and nitric oxide on prostate cancer cells (March 21, 2001) PI: Jia, L. 25% effort, PC010169; Submitted to Department of Defense, Prostate Cancer Research Program. $326,085 for 3 yrs.
 
6. Title: Urinary proteomic analysis of normal and prostate cancer patients using LC/MS/MS (Nov. 2, 2001) PI: Jia, L. Submitted to SA Area Foundation $34,700 for one year.
 
7. Title: Discovery of novel prostate cancer biomarkers from patient’s specimens by LC/MS/MS-based proteomics (January 30, 2002) PI: Jia, L. Cancer Center Council $46,050/year.
 
8. Title: Anti-tuberculosis SQ109 development (Sept. 2003-Feb. 2005); co-PI: Jia, L 15% effort; $211,900, NO1-CM-07710, NO1-CM-52203;
 
9. Title: PK/PD study with GGTI inhibitor GGTI-2418 (10/2005-1/2007); PI $87,387; NO1-CM-52203;
 
10. Title: Development of Phor21-BCG(ala), a lytic peptide conjugate (04/2004- 10/2004); PI $112,000, NO1-CM-07110.
 
11. Title: Development of pro-apoptotic Apogossypol, a Gossypol metabolite (08/2004- 11/2005); PI $190,000; NO1-CM-52203; NO1-CM-52205; NO1-CM-07110.  
 
12. Title: Anticancer drug 1-methyl-D-trytophan development (02/2004-04/2007); PI, $180,000, NO1-CM42201; NO1-CM52206; NO1-CM-07105.
 
13. Title: Anticancer dimeric pyrrolobenzodiazepine SJG-136 PK/PD characterization (12/2002-06/2003); PI, $183,740; NO1-CM-07105.
 
14. Title: Nitric oxide prodrug JS-K pharmacology and formulation development (08/2002-06/2009); PI, $237,000; NO1-CM-52206; NO1-CM-07105.
 
15. Title: Azurim p-28 toxicology, pharmacology and metabolism (06/2007-05/2008); PI, $92,790; NO1-CM-52203.
 
16. Title: Pharmacology of the novel investigative anti-cancer indolecarboxamide ML-970 (03/2008- 09/2009); co-PI, $363,000; NO1-CM-52207.
 
17. Title: Safety evaluation of new formulations (11/2007-05/2008); PI. $346,560; NO1-CM-52203.
 
18. Title: Patient pharmacokinetics of Topotecan and PARP inhibitor ABT888 (05/2007-12/2009); co-PI. $173,500; NO1-CM-52206.
 
19. Fuzhou University Start-up fund ￥10 millions (01/2012-present)   
 
20. Title：Interference by nitric oxide with adhesion of circulating tumor cells to vascular endothelium (01/2013-12/2016). PI. Natural Science Foundation of China NSFC81273548. ￥650,000.
 
21. Title: Innovative research team start-up fund; PI￥1.5M, 2013-2014; from the China Finance Department of Central Government.   
 
22. 973 program: 项目编号：Ministry of Science and Technology of China (2015CB931804); Project title: Basic research for novel nanomaterial image probes for in vivo lung cancer classification 2015/01—2019/12; Sub-project title: Lung cancer personal treatment and resultant evaluation based on in vivo lung carcinoma classification. 项目名称：肺癌在体分子分型的新型纳米分子成像探针基础研究; 课题组: 基于在体分子分型的肺癌个体化治疗及评价; 项目起止时间：2015年1月-2019年12月; ￥5.25 millions.
 
23. Fujian Development and Reform Commission project# 829054(2014;168); ￥500,000; Development of novel cancer metastasis chemopreventive agent Metapristone; period, 2014-2016.
 
24. NSFC program: Frontier researches on bioactive materials extracted from Murraya paniculata widely-grown in Fujian and Taiwan, their mechanism of actions and drugability used for cancer metastasis chemoprevention after operation(闽台盛产九里香用于预防肿瘤手术后再转移的药效物质基础、作用机制及其成药性的前沿研究) U1505225; ￥2.58M, 2016.01 to 2019.12
 
 
BIBLIOGRAPHY
 
PUBLICATIONS:
 
1. Jia, L*. Chemistry, pharmacology, toxicity and clinical uses of Tripterygium Wilfordii.    J.  Chinese  Pharmaceutical  20: 101-106, 1985
               
2. Jia, L*. Studies on physicochemical stability of triptolide injection.  J. Chinese  Pharmaceutical  20: 629, 1985.                     
 
3 Jia, L* Probit analysis of LD50 of triptolide and its cytotoxicity.  Chinese J. Pharmacol Toxical.  1: 78-80, 1986.
 
4. Jia, L* Studies on angiotensin converting enzyme inhibitors. Prog. Physiol. Sci. 6:229-234, 1985.         
 
5. Jia, L* Hoe, D. H.: Negative chronotropic effects of meglumine cyclic adenylate on cardiac pacemaker in vitro and in vivo.   Acta  Pharmacol  Sin   9: 421-426, 1988.
 
6. Jia, L*, Hoe, D. H.: Antiarrhythmic effects of meglumine cyclic adenylate. Chinese J. Pharmacol. Toxical.  3: 251-255,1989.
 
7. Jia, L*,  Hoe, D. H.: Effects of meglumine cyclic adenylate on contractility, oxygen consumption and excitability of Langendorff heart and cardiac cells.  Chinese J. Pharmacol. Toxicol. 2:16-19,1988.
 
8. Jia, L*. Hoe, D. H.: Effects of meglumine cyclic adenylate on drug-induced positive chronotropic action in rabbit right atria.  Chinese J. Pharmacol  Toxicol.  2: 235-238, 1988.
 
9 Jia, L.: Adenosine Receptors and adenosine pharmacology.    Chinese  Pharmacol.  Bull. 5: 129-133, 1989.
 
11. Jia, L and Furchgott R.F.: Inhibition by sulfhydryl compounds of vascular  relaxation induced by nitric oxide and endothelium-derived relaxing factor  J. Pharmacol. Exp. Ther. 267:371-378, 1993    
 
12. Jia, L* Liu, X., Furchgott R. F.:  Blockade of nitric oxide-induced relaxation of rabbit aorta by cysteine and homocysteine. Acta.  Pharmacol.  Sin. 18(1):11-20, 1997.
 
13. Jia L, Bonaventura, C., Bonaventura, J. and Stamler, J. S.: S-nitrosohemoglobin:  a dynamic activity of blood involved in vascular control.    Nature    380: 221-226, 1996                 
 
14. Simon, D.I., Mullins, M.E., Jia, L., Gaston, B., Singel, D. J., Stamler, J.S.: Polynitrosylated Proteins: Characterization, bioactivity and functional consequences.  Proc. Natl. Acad. Sci. U.S.A.  93: 4736-4741, 1996.
 
15. Day, B J, Jia L, Arnelle DR, Crapo, JD, and Stamler, JS.: Transduction of  NOS activity from endothelium to vascular smooth muscle: involvement of S-nitrosothiols  In  Biology of NO, ed. by Moncada, Stamler, Gross and Higgs, pp. 202-4  Portland Press, London, 1996.
 
16. Jia, L* Clinical trials and therapeutic implications of nitric oxide and its donors.  Pharmaceutical Commun Sin. (Review).     13: (3) 204-206, 1997,  
 
17. Stamler, J.S., Jia, L., Eu, J.P., McMahon, T.J., Demchenko, I.T., Bonaventura, J., Piantadosi, C.A.: Blood flow regulation by S-nitrosohemoglobin in the physiological oxygen gradient.    Science. 276: 2034-2037, 1997.
 
18. Lin, M, Yang X, Wang, J., Jia, B.J., Jia, L*.    Inhibitory effects of S-nitrosocaptopril on vasomotor tone.  Acta Pharmacol  Sin.    1998, 19 (5): 485-488.
 
19. Jia, L* and Stamler, J. S.: Dual actions of S-nitrosylated derivative of vasoactive intestinal peptide as a vasoactive intestinal peptide-like mediator and a nitric oxide carrier.  Eur.  J.  Pharmacol   1999, 366: 79-96.
 
20. Lin, M, Yang X, Wang, J., Jia, B.J., Jia, L. S-nitrosocaptopril preferentially decreases diastolic pressure in hypertensive models. Chinese Pharm. Bulletin  1999, 15(1) 73-76.  
 
21. Jia,L*., Blantz, RC. The effects of S-nitrosocaptopril on renal filtration and blood pressure in rats  Eur  J. Pharmacol. 1998, 354: 33-41.
 
22. Jia, L*. Young, X, Guo, W:  Physicochemistry, pharmacokinetics and pharmacodynamics of S-nitrosocaptopril crystals, a new nitric oxide donor    J.  Pharm.  Sci.  1999, 88: 981-986.
 
23 Jia, L* A design of a novel compound S-nitrosocaptopril possessing the capacities of both angiotensin converting enzyme inhibitors and nitric oxide donors. Prog. Physiol. Sci. 1999, 29: 12-15.
 
24. Jia, L* Nitric oxide research and new drugs: Challenges and success. Commentary on the 1998 Nobel Prize in Medicine.   Science (in Chinese) 1999, 51(2): 49-52.
 
25. Lin, M., Jia, L*. International principles of nomenclature and abbreviations of nitric oxide research. Prog. Physiol. Sci. 1999, 30(4): 376-78.  
 
 26. Jia, L*, Yu, L. Linnik, D.M., Jack, R.M.  Stability and Pharmacokinetics of LJP 920, an octameric Gal (a1-3) Gal conjugate for the inhibition of xenotransplantation rejection.   J. Pharm. Pharmacol. 53: 999-1005, 2001.
 
27. Jia, L*. Wu, C. Young, X: Anti-angiogenetic effects of S-nitrosocaptopril crystals as a nitric oxide donor.  Eur.  J.  Pharmacol.  391: 137-144, 2000.
 
28. Jia, L*. Pei, R. Lin, M. Young, X. Acute and subacute toxicity and efficacy of S- nitrosylated captopril, an ACE inhibitor possessing nitric oxide activities.  Food & Chem.  Toxicol. 39: 1135-1143, 2001.
 
29 Jia, L*. Garza, M. Wong, H. Camden, J. Redelmeier, T. Weitman, S. Pharmacokinetic comparison of intravenous carbendazim and remote loaded carbendazim liposomes in nude mice.  J. Pharm. Biomed Anal. 28(1): 65-72, 2002.
 
30. Wong, H. Jia, L*. Camden, J. Weitman, S. Liquid chromatography-mass spectrometry assay of a thiodiazole derivative in mice: application to pharmacokinetic studies.  J. Chromatogr. 765:55-62, 2001.
 
31. Jia, L*. Wong, H. In vitro and in vivo assessment of cellular permeability and pharmacodynamics of S-nitrosylated captopril, a nitric oxide donor. Br. J. Pharmacol. 134: 1697-1704, 2001
 
32. Jia, L*. Wong, H. Cerna, C. Weitman, S. Effect of nanonization on absorption of 301029: Ex vivo and in vivo pharmacokinetic correlations determined by LC/MS. Pharm. Res. 19:1091-1096, 2002.
 
33. Jia, L*. Wong, H. Wang, Y. Garza, M. Weitman, S. Carbendazim: Disposition, cellular permeability, metabolite identification and pharmacokinetic comparison with its nanoparticle. J. Pharm. Sci. 92:161-172, 2003.
 
34. Jia, L*. Schweizer, J. Cerna, C. Wong, H. Revilla, M. Effect of Nitric Oxide on Cytotoxicity of Taxol: enhanced Taxol transcellular permeability. Biochem Pharmacol. 66:2193-2199, 2003.
 
35. Jia, L*. Tomaszewski, J.E., Noker, P.E., Gorman, G.S., Glaze, E., Protopopova,M. Simultaneous determination of pharmacokinetic properties of three anti-tubercular ethambutol analogs resulting from combinatorial lead optimization. J. Pharm. Biomed Anal. 37(2), 23-33, 2005.
 
36. Jia, L*. Tomaszewski,J., Hanrahan, C. Coward, L. Noker, P. Gorman, L. Nikonenko, B. Protopopova, M. Pharmacodynamic and pharmacokinetic characteristics of SQ109, a new diamine-based antitubercular drug. Br. J. Pharmacol. 144, 80-87, 2005.
 
37. Jia, L*. Coward, L. Gorman, L. Noker, P. Tomaszewski, J. Pharmacoproteomic effects of isoniazid, ethambutol, and N-Geranyl-N'-(2-adamantyl)ethane-1,2-diamine (SQ109) on Mycobacterium tuberculosis H37Rv.  J. Pharmacol. Exp. Ther. 315, 905-911, 2005.
 
38. Saavedra, J.E., Srinivasan, A., Buzard, G.S., Davies, K.M., Waterhouse, D., Inami, K., Wilde, T.C., Citro, L.M., Cuellar, M., Deschamps, J.R., Parrish, D. Shami, P.J., Findlay, V.J. Jia, L., Ji, X., Keefer, L.K., PABA/NO as an anticancer lead: analogue synthesis, structure revision, solution chemistry, reactivity toward glutathione, and in vitro activity.  J. Med. Chem.  49, 1157-1164, 2006.
 
39. Jia, L*. Global governmental investment in nanotechnologies. Curr. NanoScience (Review) 1:(3) 263-266, 2005.
 
40. Jia, L*. Nanoparticle formulation Increases oral bioavailability of poorly soluble drugs: experimental evidences, theory, and approaches. Curr. NanoScience (Review) 1:(3) 237-243, 2005.
 
41. Coward, L.C. Kerstner-Wood, Noker, P., Gorman, G., Pellecchia, M., Reed, J.C., Jia, L*. Quantitative determination of Apogossypol, a pro-apoptotic analog of gossypol, in mouse plasma using LC/MS/MS. J. Pharm. Biomed. Anal. 42: 581-586, 2006.
 
42. Jia, L.*, Noker, P.E., Coward, L. Gorman, G. Protopopova, M., Tomaszewski, J.E. Interspecies pharmacokinetics and in vitro metabolism of SQ109   Br. J. Pharmacol. 147(5):476-85, 2006.
 
43. Buhrow, S.A., Reid, J.M., Jia, L., Covey, J., Kobs, D.J., Grossi, I. M., Ames, M.M. LC/MS/MS assay and dog pharmacokinetics of the dimeric pyrrolobenzodiazepine SJG-136 (NSC 694501).  J. Chromatogr.  2006; 840: 56-62.
 
44. Shami, PJ., Saavedra, J. E., Bonifant, C. L., Chu, J.; Udupi, V.; Malaviya, S.; Carr, B. I.; Kar, S.; Wang, M.; Jia, L.; Ji, X.; Keefer, L. K. Antitumor Activity of JS-K [O2-(2,4-Dinitrophenyl) 1-[(4-Ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate] and Related O2-Aryl Diazeniumdiolates in Vitro and in Vivo.  J. Med. Chem. 2006; 49(14); 4356-4366. 
 
45. Jia, L. Pharmaceutical Globalization: First International CRO/CMO Conference sponsored by the AAPS in China.  AAPS NewsMagazine 7(3): 67, 2007.
 
46. Jia, L*, Wang, Y., Zhu, YZ.  Pharmaceutical globalization urges cooperation between China and USA on GLP regulations. Chinese Medicine & Drugs Newspaper, March 22, 2007
 
47. Jia, L*., Zhu, Y., Wang, Y., Wu, W., Dong, Y.C., Zhang, R., Fu, L., Bi, H., Tam, J. Harmonising GLP rules in the US and China: The globalisation of the pharma industry means China and the US need bilateral agreements on GLP regulations. The Regulatory Affairs Journal  18(3):147-152, 2007.
 
48. Liu, X.D., Jia*, L. The conduct of drug metabolism studies considered good practice (I): analytical systems and in vivo studies. Curr. Drug Metab.  8: 815-821, 2007.
 
49. Jia, L*., Liu, X.D. The conduct of drug metabolism studies considered good practice (II): in vitro experiments. Curr. Drug Metab.  8: 822-829, 2007. 
 
50. Jia, L.*, Schweikart, K., Tomaszewski, J., Reed, J., Ames, M, Page, J., Noker, P., Munn, D. Toxicology and pharmacokinetics of 1-methyl-D-tryptophan: absence of toxicity due to saturating absorption.   Food Chem. Toxicol. 46: 203-211, 2008.
 
51. Jia, L.* Coward, L.C. Kerstner-Wood, Gorman, G., Noker, Kitada S, Pellecchia M P., Reed, J.C., Comparison of pharmacokinetic and metabolic profiling among gossypol, apogossypol and apogossypol hexaacetate.  Cancer Chemotherapy Pharmacol. 61: 63-73, 2008.
 
52. Liu, H.Y., Liu, X.D., Jia, L., Liu, Y.C., Yang, H.W., Wang, G.J., Xie, L.  Insulin therapy restores impaired function and expression of P-glycoprotein in blood–brain barrier of experimental diabetes.  Biochem. Pharmacol. 75: 1649-1658, 2008.
 
53. Jia*, L., Noker, P.E., Piazza, G.A., Leuschner, C., Hansel, W., Gorman, G.S., Coward, L.U., Tomaszewski, J. Pharmacokinetics and Pharmacodynamics of Phor21-βCG(ala), a lytic peptide conjugate. J. Pharm. Pharmacol. 60:1441-48, 2008.
 
54. Liang, X.J., Chen, C.Y., Zhao, Y.L., Jia, L., Wang, P.C. Biopharmaceutics and Therapeutic Potential of Engineered Nanomaterials.  Curr. Drug Metab. 9(8): 697-709, 2008.
 
55. Jia, L*. Drug discovery and development operations in emerging regions: global R&D congress. Thomson-Pharma, June, 2008 (invited conference proceedings)
 
56. Song, M., Wang, L., Hang, T., Wen, A., Yang, L., Jia, L. Rapid and sensitive liquid chromatography-tandem mass spectrometry for rasagiline: assay development, validation and application to a human pharmacokinetic study.  J. Chromatogr. 875:515-521, 2008.
 
57. Jia, L. The Great Meeting Held in the Bitter Cold Economic Climate: 2008 AAPS Annual Meeting and Exposition. Thomson-Pharma, December, 2008 (invited conference proceedings)
 
58. Kitada, S., Kress, C.L., Krajewska, M., Jia, L., Pellecchia, M., Reed, J.C. Bcl-2 antagonist ApoGossypol (NSC736630) displays single-agent activity in Bcl-2 transgenic mice and has superior efficacy with less toxicity compared to Gossypol (NSC19048).  Blood, 2008; 111: 3211 - 3219.
 
59. Zhang, TT., Song, M., Hang, HJ., Xu, XF., Wen, A.D.,Yang, L., Jia, L*. Pharmacokinetic profile of talipexole in healthy volunteers is not altered when it is co-administered with Madopar (co-beneldopa). J. Clin. Pharm. Ther.  33, 1-10, 2009.
 
60. Jia* L. Zhao, YQ. Current Evaluation of Ginseng (I): Etymology, Pharmacognosy, Phytochemistry, Market and Regulations. Curr. Med. Chem. 16: 2475-2484, 2009.
 
61. Jia*, L, Zhao, YQ. Liang, X.J. Current Evaluation of the Millennium Phytomedicine― Ginseng (II): Collected Chemical Entities, Modern Pharmacology, and Clinical Applications Emanated from Traditional Chinese Medicine.  Curr. Med. Chem. 16: 2924-2942, 2009.
 
62. Ni. L., Yu, X.,Yu, Q.，Chen, X., Jia, L*. Effects of cyclosporine A and itraconazole on permeability, biliary excretion and pharmacokinetics of amlodipine.  Drug Metab. Lett. 2(3): 163-168, 2008.
 
63. Meng, J., Wang, D.L., Wang, P.C., Jia, L., Chen, C., Liang, XJ. Biomedical Activities of Endohedral Metallofullerene Optimized for Nanopharmaceutics. J. NanoSci NanoTech., 10: 8610-7, 2010.
 
64. Jia*, L. Soldati, F. Ginseng, Asian (Panax ginseng); In Encyclopedia of Dietary Supplements. Ed by Coates PM. 2nd edition, pp.352-366, 2010; Informa Healthcare, New York, London. (Invited review).
 
65. Jia* L, Gu Y., Zeng E, Linnik, MD, Jones, DS. Biostability, Tissue Distribution and Disposition of LJP 993, a Tetrameric Conjugate of Domain 1 of b2-glycoprotein I for antiphospholipid syndrome. Lupus. 19: 130-137, 2010.
 
66. Kiziltepe, T., Anderson, K.C., Kutok, J.L., Jia, L., Saavedra, J.E., Keefer, L.K., Shami, P.J. JS-K has potent anti-angiogenic activity in vitro and inhibits tumor angiogenesis in a multiple myeloma model in vivo. J. Pharm. Pharmacol 62: 145-151, 2010.
 
67. Liang, XJ., Meng, H., Wang, Y., He, H., Meng, J., Lu, J., Wang, P., Zhao, YL., Gao, X., Sun, B., Chen, CY., Xing, GM., Shen, DW., Yin, JJ., Gottesman M., Jia, L.  Metallofullerene Nanoparticles Overcome Tumor Resistance to Cisplatin by Reactivating Endocytosis. Proc. Natl. Acad. Sci. U.S.A. 107: 7449-7454, 2010.
 
68. Tan, J.J., Cong, X.J., Hu, L.M., Wang, C.X., Jia, L, Liang, X.J. Therapeutic strategies underpinning the development of novel techniques for the treatment of HIV infection. Drug Discovery Today  15: 186-197; 2010.
 
69. Ma, X.W., Wang, D.L., Wu. Y., Ho, R.J.Y., Jia, L., Guo, P., Hu, L., Xing, G.M., Zeng, Y., Liang, X.J., AIDS Treatment with Novel Anti-HIV Compounds Improved by Nanotechnology. The AAPS Journal 12, 272-278, 2010.
 
70. Gorman, G., Coward, L., Kerstner-Wood, C., Noker, P., Beattie, C.W., *Jia, L. A novel and rapid LC/MS/MS assay for bioanalysis of Azurin p28 in serum and its pharmacokinetics in mice J. Pharm. BioMed. Anal. 53: 991-996, 2010.
 
71. Wang, YZ., Ma, XW., Ma, HL, Wang DL., Lu, J., Jia, L., Duan, XL., Liang, XJ. Specific hemosiderin deposition in spleen induced by a low dose of cisplatin: altered iron metabolism and its implication as an acute hemosiderin model. Curr. Drug Metabo. 11, 507-515, 2010.
 
72. Tang, W., Jia, L., Zhao, Y. The newly-found bioactivities and clinical uses of ginseng and ginsenosides. Ginseng Res. 22(2): 32-38, 2010.
 
73. *Jia, L. Qian K. An Evidence-based Perspective of Ginseng as a Preventing or Supplementary Therapy for Cancer Patients. In Evidence-based Anticancer Herbal Medicine., Ed., by W. Cho, Springer Science. 85-95, 2011.
 
74. Jia, L*, Zhao, YL, Liang, XJ. Fast Evolving Nanotechnology and Relevant Programs and Entities in China. Nano Today 6: 6-11, 2011.
 
75. Reid, J.M., Buhrow, S.A., Kuffel, M.J., Jia, L.  Spanswick, V.J., Thurston, D.E., Tomaszewski, J.E., Ames, M.M. Pharmacokinetics, Pharmacodynamics and Metabolism of the Dimeric Pyrrolobenzodiazepine SJG-136 in Rats. Cancer Chemother. Pharmacol. 68: 777-786, 2011.
 
76. Jia, L., Gorman, G., Coward, L., Noker, P., McCormick, D.L., Horn, H.L., Harder, J.B., Muzzio, M., Prabhakar, B., Balaji, G., Gupta, T.K.D., Beattie, C.W. Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination Cancer Chemother. Pharmacol. 68: 513-24, 2011.
 
77. Xu Z., Jia L., Zhao, YQ. Ginseng etymology, pharmacognosy, and the evaluation of its current products and markets. Modern drugs & Clin. 2:1-6, 2011.
 
78. Xu, Z. Jia, L., Zhao, YQ. Constituents of ginseng and quality evaluation of ginseng products.  Drug evaluation research 2011; 34(3),1-5.
 
79. Song M., Zhang, S., Xu, X., Hang, T., Jia, L. Simultaneous determination of three Panax notoginseng saponins by LC-MS/MS at sub-nanograms in dog plasma for pharmacokinetics of compound Danshen Tablets. J. Chromatogr. 878: 3331-7, 2010.
 
80. Rayburn, E., Wang, W., Li, M., Zhang, X., Xu, H., Li, H., Qin, JJ., Jia, L., Covey, J., Lee, M., Zhang, R. Preclinical pharmacology of novel indolecarboxamide ML-970, an investigative anticancer agent. Cancer Chemother. Pharmacol. 69:1423-31; 2012.
 
81. Kummar, S., Chen, A., Ji, J., Zhang, Y., Reid, JM., Ames, M., Jia, L., Weil, M., Speranza, G., Murgo, A.J., Kinders, R., Wang, L., Parchment, R.E., Carter, J., Stotler, H., Rubinstein, L., Hollingshead, M., Melillo, G., Pommier, Y., Bonner, W., Tomaszewski, JE., Doroshow, JH. Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas. Cancer Res. 71:5626-34; 2011.
 
82. Meng, J., Yang, X.D., Jia. L., Liang, X.J., Wang, C. Impact of nanoparticles on cardiovascular diseases: modulating metabolism and function of endothelial cells. Curr. Drug Metab. 13: 1123-29; 2012. IF5.113
 
83. Jia, X., Jia, L*. Nanomaterials improve biological functions of photosensitizers used for photodynamic therapy. Curr. Drug Metab. 13: 1119-22, 2012. IF5.113
 
84. Xue, X., You, S., Zhang, Q., Wu, Y., Zou, GZ., Wang, PC., Zhao, YL., Xu, Y., Jia, L.,  Zhang, X., Liang, XJ. Mitaplatin increases sensitivity of tumor cells to cisplatin by inducing
mitochondrial dysfunction. Mol. Pharmaceutics 9：634−644 ；2012. IF4.782
 
85. Shao, J., Xue, JP., Dai, YC., Liu, H, Jia*, L, Chen, NS., Huang, JL. Inhibition of human hepatocellular carcinoma HepG2 by phthalocyanine photosensitizer Photocyin: ROS production, apoptosis, and cell cycle arrest. Eur. J. Cancer. 48: 2086-96; 2012. ISSN:0959-8049; IF5.536
 
86. Meng, J., Xing, J., Wang, Y., Lu, Y., Zhao, YL., Gao, X., Wang, P.C., Jia, L. Liang, XJ. Epigenetic modulation of human breast cancer by metallofullerene nanoparticles: in vitro analysis and in vivo treatment. Nanoscale. 3: 4713-19; 2011. IF5.914
 
87. Zhang, F., Xie, JP., Shao, JW., Jia*, L. Compilation of 222 Drugs’ Plasma Protein Binding
Data and Guidance for Study Designs. Drug Discovery Today 17:475-495, 2012. IF6.828
 
88. Xu, Y., Jia, L. Nanoscaled Proteomic Analysis. 64-81, Chapter 4th In Nanopharmaceuticals Ed by Liang. World Scientific Publishing, Singapore. 2012.
 
89. Jia, L.* Lu, Y., Shao, J., Liang, XJ., Xu Y. Nanoproteomics: a new spin from emerging links between nanotechnology and proteomics. Trends Biotech. 31:99-107, 2013. 一区 IF11.96
 
90. Shao, JW., Dai, Y., Zou, WT., Xue, JP., Ye, J., Jia*, L. Intracellular distribution and mechanisms of actions of photosensitizer Zinc (II)-phthalocyanine solubilized in Cremophor EL against human hepatocellular carcinoma HepG2 cells. Cancer Lett. 330：49-56，2013. 二区 IF5.621
 
91. Xie, JJ., Shao, JW., Lu, Y., Chen, JZ., Wang, J., Yu SH., Jia, L*. Separation of ginseng active ingredients and their roles in cancer metastasis supplementary therapy. Curr. Drug Metabo. 14:614-621；2013. 二区 IF4.8
 
92. Jiang, Z., Shao, J., Chen, M, Hu, Y., Wang, J., Jia*, L. A novel SPE-HPLC method for simultaneous determination of selected sulfonated phthalocyanine zinc complexes in mouse plasma following cassette dosing. Analyst 138: 4385 – 4392, 2013. 二区IF4.2
 
93. Jia*, L. Science Requires Coexisting of Opposite Opinions: “One Country, Two Systems” Pharmaceutical Reg. Affairs: Open Access ISSN:2167-7689; 1(4):1000e114;2012
 
94. Shao, J., Jia*, L. Potential serious interactions between nutraceutical ginseng and warfarin in patients with ischemic stroke. Trends Pharmacol. Sci. 34(2):85-86, 2013. 一区IF11.54
 
95. Yin, J.J., Sharma, S., Shumyak, S.P., Wang, Z.X., Zhou, Z., Zhang, Y., Guo, P., Li, C.Z., Kanwar, J.R., Yang, T.X., Mohapatra, S.S., Liu, W., Duan, W., Wang, J., Li, Q., Zhang, X., Tan, J., Jia, L. Liang, J., Wei, M.Q., Li, X., Zhou, S.F. Synthesis and Biological Evaluation of a Novel Cancer Treatment Based on Folic Acid Receptor-Targeted, β-Cyclodextrin-Based Drug Complexes for Cancer Treatment. PLoS ONE 8(5): e62289; 2013. 二区 IF4.8
 
96. Gao, Y. Xie, J., Chen, H., Gu, S., Zhao, R., Shao, J., Jia*, L. Nanotechnology-based intelligent drug design for cancer metastasis treatment. Biotech Adv. 32:761-777, 2014. 一区 IF9.6 
 
97. Jiang, Z., Shao, J., Ting, Y., Wang, J., Jia*, L. Pharmaceutical development, composition and quantitative analysis of phthalocyanine as the photosensitizer for cancer photodynamic therapy. J. Pharm. Biomed. Anal. 78：98-104; 2014. 三区 IF 2.829
 
98. Gao, Y., Shao, J., Jiang, Z., Chen, J., Gu, S., Yu, S., Zheng, K., Jia, L.* Drug enterohepatic circulation and disposition: constituents of systems pharmacokinetics. Drug Disc. Today  19:326-340，2014. 一区 IF6.89
 
99. Wang, J., Jiang, Z., Shao*, J., Ou, M., Li, Y., Lu, Y., Xiang, L., Lin, L., Dai, Y., Jia, L*, Synergism of ursolic acid derivative with 2-deoxy-D-glucose to preferentially induce tumor cell death by dual targeting of apoptosis and glycolysis. Sci. Reports 2014, 4:5006; DOI: 10.1038/srep05006 二区 IF5.578
 
100. Chen, JZ., Wang, JC., Shao, JW., Gao, Y., Xu, JG, Yu, SH., Liu, ZH., Jia, L*. The Unique Pharmacological Characteristics of Mifepristone: from Terminating Pregnancy to Preventing Cancer Metastasis. Med. Res. Rev. 34：979–1000, 2014. 一区 IF 9.583
 
101. Wang, J., Chen, J., Wan, L., Shao*, JW., Lu, Y., Zhu, Y., Ou, M., Yu, SH., Chen, HJ., Jia*, L. Synthesis, spectral characterization and pharmacological evaluation of metapristone, a novel cancer metastatic chemopreventive derived from mifepristone (RU486). AAPS J. 16:289-298，2014. 二区 IF 4.905
 
102. Reid, JM., Buhrow, SA., Gilbert, JA., Jia, L., Shoji, M., Snyder, J., Ames. MM. Mouse pharmacokinetics and metabolism of the curcumin analog, 4-Piperidione,3,5-bis[(2-fluorophenyl)methylene]-acetate(3E,5E) (EF-24; NSC 716993) Cancer Chemother. Pharmacol. 73(6):1137-46, 2014.  IF3
 
103. Chen, JZ., Wang, JC., Gao, Y., Zeng, R., Jiang, Z., Zhu, YW., Shao, JW., Jia, L. A novel UPLC/MS/MS method for rapid determination of metapristone in rat plasma, a new cancer metastasis chemopreventive agent derived from mifepristone (RU486). J Pharm. Biomed. Anal, 95:158-63; 2014 三区 IF 2.829
 
104. Lu, Y., Yu, T., Liang, H., Wang, J., Xie, J., Shao*, J., Gao, Y., Yu, S., Chen, S., Wang, L., Jia, L.* Nitric oxide inhibits hetero-adhesion of cancer cells to endothelial cells: restraining circulating tumor cells from initial metastatic cascade.  Scientific reports DOI: 10.1038/srep04344，2014二区 IF5.578
 
105. Chen, P., Zhang, X., Jia, L., Prud'homme, RK., Szekely, Z., Sinko, PJ. Optimal structural design of mannosylated nanocarriers for macrophage targeting. J. Controlled Release 2014; 194:341-34. IF7.705
 
106. XIE, JJ., ZHAO R., CHEN, HN., XIE, XD., JIA,* L. Specificity of Capturing and Restraining Colon Cancer Cells in Vitro by Multifunctional Nanomaterial Conjugates 科技导报2014, 32(34):26-32. doi 10.3981/j.issn.1000-7857.2014.34.002
 
107. Xie, JJ, Zhao, R, Gu, S., Dong, H., Wang, J., Lu, Y., Sinko, PJ., Yu, T., Xie, FW., Wang, L., Shao*, J., Jia, L* The architecture and biological function of dual antibody-coated dendrimers: enhanced control of circulating tumor cells and their hetero-adhesion to endothelial cells for metastasis prevention. Theranostics 2014;4: 1250-63; 二区IF8.022
 
108. Xie, JJ., Lu, Y., Dong, HY., Zhao, RL., Chen, HN., Shen, WY., Sinko, PJ., Zhu, Y., Wang, JC., Shao, JW., Gao, Y., Xie, FW., Jia*, L. Enhanced specificity in capturing and restraining circulating tumour cells with dual antibody-dendrimer conjugates. Adv. Funct. Mater. 2015, 25, 1304–1313一区 IF11.805.
 
109. Yu, S., Yang, XT., Zhu, Y., Xie, FW., Lu, YS., Yu, T., Yan, CC., Shao, J., Gao, Y., Mo, F., Cai, GN., Sinko, PJ., Jia, L.* Systems biological pharmacology of mifepristone (RU486) reveals its 47 hub targets and network: comprehensive analysis and pharmacological focus on FAK-Src-Paxillin complex. Sci. Rep., 5: 7830, 2015 二区 IF5.578
 
110. Xie, J., Dong, HY., Chen, HN., Zhao, R., Sinko, JP., Shen, WY., Wang, JC., Lu, YS., Yang, XT., Xie, FW., Jia,* J. Exploring cancer metastasis prevention strategy: interrupting adhesion of cancer cells to vascular endothelia of potential metastatic tissues by antibody-coated nanomaterial J. Nanobiotechnology, 2015; 13:9,1-13. DOI 10.1186/s12951-015-0072-x  一区 IF4.115
 
111. Xie J, Wang, J., Chen H, Shen, WY., Sinko JP., Dong H., Zhao R., Lu Y., Zhu YW., Jia L*. Multivalent Conjugation of Antibody to Dendrimers for the Enhanced Capture and Regulation on Colon Cancer Cells. Sci. Reports 5: 9445, 2015；二区 IF5.578
 
112. Dong, HY., Yang, X., Xiang,L., Li, YF., Ou, M., Chi, T., Liu, ZH., Shao*, JW., Jia*, L. UP12, a novel ursolic acid derivative with potential for targeting multiple signaling pathways in hepatocellular carcinoma. Biochem. Pharmacol. 2015; 93:151-162二区 IF 5.009.
 
113. Xu, J., Dong, H., Shen, W., He, S., Li, H., Lu, Y., Wu, Z.-S*., Jia, L*., New molecular beacon for p53 gene point mutation and significant potential in serving as the polymerization primer. Biosensors Bioelectronics 2015; 66:504-511. IF 6.451.
 
114. Jiang, Z., Yang, J., Pang, YQ., Yang, XT., Yu*, SH., Jia*, L. Bioactivity-guided fast screen and identification of cancer metastasis chemopreventive components from raw extracts of Murraya exotica J. Pharm. Biomed. Anal. 107C:341-45, 2015. 三区 IF 2.98
 
115. Gao*, Y., Li, ZR., Xie, XD., Wang, CQ.,You, J., Mo, F., Jin, B., Chen, JZ., Shao, JW., Chen, HJ., Jia*, L. Dendrimeric anticancer prodrugs for targeted delivery of ursolic acid to folate receptor-expressing cancer cells: synthesis and biological evaluation. Eur. J. Pharm. Sci. 70:55-63, 2015. IF3.01.
 
116. Lu, Y., Liang, HY., Yu, T., Xie, JJ., Chen, SM., Dong, HY., Sinko, PJ., Lian, S., Xu, JG., Wang, JC., Yu, SH., Shao, JW., Yuan, B., Wang, L., Jia,* L. Isolation and Characterization of Alive Circulating Tumor Cells by Immunomagnetic Negative Enrichment Coupled with Flow Cytometry. Cancer 121(17):3036-45, 2015. IF4.901.
 
117. Wan#, LY, Dong#, HY, Xu, H., Zhu, YW., Lu, Y., Ma, J., Wang, JC., Xie, JJ., Xu, B., Gao, Y., Shao, JW., Jia, L* Aspirin, lysine, mifepristone and doxycycline combined can effectively and safely prevent and treat cancer metastasis: prevent seeds from gemmating on soil. Oncotarget. priority publication; 6(34):35157-72；2015. IF6.63. DOI: 10.18632/oncotarget.6038；
 
118. R.J. Zeng, Y. Li, J.Z. Chen*, G. X. Chou*, Y. Gao, J.W. Shao, L. Jia, and S.S. Wu, A novel UPLC-MS/MS method for sensitive quantitation of boldine in plasma, a potential anti-inflammatory agent: application to a pharmacokinetic study in rats. Biomed. Chromatogr. 29:459–464, 2015. (IF=1.95)
 
119. Xiang, LP., Chi, T., Tang, Q., Yang, X., Ou, M., Chen, X., Yu, XB., Chen, JZ., Shao*, JW.,  Jia, L.  A pentacyclic triterpene natural product, ursolic acid and its prodrug US597 inhibit targets within cell adhesion pathway and prevent cancer metastasis. Oncotarget  2015, 6(11):9295-312. IF6.63. 
 
120. Xie, J., Yu, G., Zhao, R., Sinko, P., Gu, S., Wang, J., Li, Y., Lu, Y., Yu, S., W, Lie., Chen, S., Shao, J., Jia, L*. Ex vivo and in vivo capture and deactivation of circulating tumor cells by dual-antibody-coated dendrimers. J. Control Release. 2015; 209:159-69. 一区IF7.705.
 
121. Dong, HY., Wu* ZS, Xu, JG., Ma, J., Zhang, HJ., Wang, J., Shen, WY., Xie, JJ., Jia,*L Novel multifunction-integrated molecular beacon for the amplification detection of DNA
hybridization based on primer/template-free isothermal polymerization. Biosensors Bioelectronics 72:182-190, 2015.
 
121. Xu JG., Wu* ZS., Shen, WY., Xu, H, Li, LH., Jia,* L. Cascade DNA nanomachine and exponential amplification biosensing. Biosensors and Bioelectronics. 73:19-25, 2015. IF 6.451.
 
122. Gao§,Y., Gu§, S., Zhang, Y., Xie, XD., Yu, T., Lu, Y., Zhu, Y., Chen, WG., Zhang, H., Dong, HY., Sinko, PJ., Jia,* L. The architecture and function of monoclonal antibody-functionalized mesoporous silica nanoparticles loaded with mifepristone: repurposing abortifacient for cancer metastatic chemoprevention. Small. 2016；12(19):2595-608   IF8.368.
 
123. Dong, HY#, Gao, Y#, Sinko, PJ., Wu, ZS., Xu, JG., Jia,*L. The nanotechnology race   between China and the United States. Nano Today. 11:7-12; 2016. IF18
 
124. Gao Y., Jin B., Shen WY., Sinko PJ., Xie XD., Zhang, HJ., Jia* L. China and the United States- global partners, competitors and collaborators in nanotechnology development. Nanomedicine: Nanotechnology, Biology, and Medicine. 12:13-19；2015. IF6.5
doi: 10.1016/j.nano.2015.09.007. 
 
125. Li, Y., Zeng, RJ., Chen*, JZ., Wu, BY., Chou, GX., Gao, Y., Shao, JW., Cai, HZ., Jia, L. Pharmacokinetics and metabolism study of isoboldine, a major bioactive component from Radix Linderae in male rats by UPLC-MS/MS. J. Ethnopharmacol. 2015, 171:154-60. IF3
 
126. Xu, JG., Qian, J., Li, H., Wu,* ZS., Shen, W., Jia,*L.  Intelligent DNA machine for the ultrasensitive colorimetric detection of nucleic acids. Biosensors and Bioelectronics, 2016,75:41-47
 
127. Xiao#, YY., Zhu#, YW., Yu#, SH., Ho, RJ., Yan, CC., Liu, J., L, T., Wang, J., Wan, LY., Yang, XT., Xu, H., Wang, JC., Jia,* L. Thirty-day rat toxicity study reveals reversible liver toxicity of mifepristone (RU486) and metapristone. Toxicol. Mech. & Methods 2016; 6: 36-45.
 
128. Xu, JG., Li, HN., Wu ZS*., Qian, J., Xue, C. Jia* L. Double-stem Hairpin Probe and Ultrasensitive Colorimetric Detection of Cancer-related Nucleic Acids. 2016; 6(3): 318-327. Theranostics. IF8.85
 
129. Xie, XD., Li, FQ., Zhang, HJ., Lu, YS., Lian, S., Lin, H., Gao*, Y., Jia* L. EpCAM aptamer- functionalized mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery. Eur. J. Pharm. Sci. 2016; 83:28-35. IF3.35
 
130. Dong, HY., Ma, J. Wang, J., Wu, ZS., Sinko, PJ.,  Jia*, L. A biofunctional molecular beacon for detecting single base mutations in cancer cells. Mol Ther Nucleic Acids. 2016 Apr 5;5:e302. doi: 10.1038/mtna.2016.18;   IF4.512
 
131. Jiang#, Z., Pang# Y, Yu#, XB., Zhou, SX., Qian, J., Zheng, N., Dong, HY., Shi, Q., Jia* L. The paradigm-shifting idea and its practice: from traditional abortion Chinese medicine Murraya paniculata to safe and effective cancer metastatic chemopreventives.  Oncotarget 2016; 7(16): 21699-712. Mar 5.
 
132. Yu,#SH*, Yan#, CC, Yang#, XT., He, SD., Liu, J., Qin, CT., Huang, CZ., Lu, YS., Tian, ZQ., Jia,* L. Pharmacoproteomic analysis reveals that metapristone (RU486 metabolite) intervenes E-cadherin and vimentin for cancer metastasis chemoprevention. Sci. Rep. 6, 22388; 2016. doi:10.1038/srep22388. IF5.578
 
133. Wang, JC.#, Chen, JZ.#, Zhu, YW., Zheng, N., Liu, J., Xiao, YY., Lu, YS., Dong, HY., Xie,JJ., Shao, JW., Yu, SH., Jia,*L. In vitro and in vivo efficacy and safety evaluation of metapristone and mifepristone as cancer metastatic chemopreventive agents. Biomed Pharmacother. 78 (2016) 291–300. IF2  
 
134. Dong HY.#, Wang#, J., Zhang, T., Ma, J., Han, LY., Tu, XH., Jia*L. Aptamers and their biological applications to bio-medicine and analytical diagnostics. Chinese J Pharm.  Anal. 2016 (3): In press.
 
135. Xu, JG., Wu*, ZS., Wang, ZM., Li, HN., Le, JQ.,  Jia* L. Two-wheel drive-based DNA nanomachine and its sensing potential for highly sensitive analysis of cancer-related gene. Biomaterials. 2016;100:110-117. IF8.557
 
136. Xu, JG., Wu*, JS., Shen, WY., Wang, ZM., Li, HN., Jia,*L Autonomous and orderly assembly of two DNA oligonucleotides into metastable nanoarchitecture: simplicity and great theranostics potential. 2016  Clinical Science
 
137. Xu, JG., Wu, *ZS., Li, HN., Wang, ZM., Le, JQ., Zheng, TT., Jia,*L. Dual-cyclical nucleic acid strand-displacement polymerization based signal amplification system for highly sensitive determination of p53 gene.  Biosensors and Bioelectronics doi:10.1016/j.bios.2016.07.029. available online: 9-JUL-2016
 
138. Li, HN. Xu, JG., Wang ZM., Wu,# ZS., Jia,# L. Increasingly branched rolling circle amplification for the cancer gene detection. Biosensors and Bioelectronics. doi.org/10.1016/j.bios.2016.07.095,  2016.
 
139. Shao, JW., Zhou, SX., Jiang Z., Chi, T., Ma, J., Guo, ML., Lee, A., Jia,*L Warfarin and coumarin-like Murraya paniculata extract down-regulate EpCAM-mediated cell adhesion: individual components versus mixture for studying botanical metastatic chemopreventives
Scientific Report (accepted) 2016
 
140. Lian, S., Lu., YS., Cheng YL., Yu, T., Xie, XD., Liang, HY., Jia, *L. S-nitrosocaptopril interrupts cancer cells adhesion to endothelium by suppressing cell adhesion molecules via inhibition of the NF-кB signal pathway in endothelial cells. Eur. J. Pharmacol. (accepted) IF2.53.
 
141. Xiao, YY., Chen, WG., Chen, JZ., Liu, J., Shao, JW., Li, T., Zhu, YW., Ma, J. Gao, Y., Wang JC., Xu, JG., Lu, YS., Yu, SH., Jia* L. Sex-related pharmacokinetic differences and mechanisms of metapristone derived from RU486. Sci. Rep. (under revision) 2016
 
142.     Lu, YS., Lian, Yu1, Cheng1, Liang1, Xie, JJ, Zhu, Y, Xu, H, Xie, XD, Yu, SH, Gao, Y, Jia,*L. Multifunctional nitric oxide prevents metastatic cascade spark by interrupting platelets-circulating tumor cell interplay.
 
143. Sudan He; Xingtian Yang; Cuicui Yan; Suhong Yu; Zhou Jiang; Lee Jia. A Novel Coumarin from Murraya Exotica and Its Potential Prevention of Cancer Metastasis Bioorganic & Medicinal Chemistry Letters 
 
144. Xiufen Chen1#,Jianzhong Chen3#, Bowen Li4, Xiang Yang1, Rongjie Zeng3, Yajun Liu1, Tao Li1, Jingwei Shao1, 2*, Lee Jia1, 2*, Rodney J.Y. Ho Oral PLGA-PEG-PLGA micelles nanoparticles of US597 (an ursolic acid derivative): preparation, biological activities and pharmacokinetics. J. Pharm. Sci.
 
145. Jun Qian1,#, Zhou Jiang1,#, Haiyan Dong1,2#, Jingyi Yang1, Xiaobo Yu1, Jianzhong Chen1, Hongning Chen1, Qing Shi1, Lee Jia1,*The 5000-year old traditional Chinese medicine Achyranthes bidentata and our de novo conception of its metastatic chemoprevention: from phytochemistry to pharmacology (submitted to Oncogene; cancer letter)
 
146. Ma, J. Dong, HY., Shao, JW., Gao Y., Jia* L Global deregulation of ginseng products may be life-threatening to warfarin takers for preventing stroke and thromboembolism: solid evidence of serious ginseng-warfarin interaction (submitted)
 
147. Shao#, JW., Chen#, HN., Liu, J., Zheng, GR., Li, T. Lu, Y., Xu, JG., Zheng, N., Jia*L.  Metapristone suppresses NSCLC by targeting EGFR and its PI3K/PTEN/AKT and ERK signaling pathways. Biochem Pharmacol. (submitted) (recomm cancer letter)
 
148. Xu, JG., Composite DNA nanomachine that functions with high cooperativity
MANUSCRIPT ID: NR-ART-04-2016-002997 Nanoscale IF7.39.
 
149. Xiaobo Yu1,*, Yusheng Lu1,*, Jingwei Shao1, Jian Liu1, Haiyan Dong1, 2, Ting Yu1, Haiyan Liang1, Qing Shi1, Lee Jia1Embedding similarities between blastocyst and cancer cells: fundamentals for abortifacients used for cancer metastatic chemoprevention 
 
150.    Jiang, Z., Rui Wang, Xiao Ma,Tingting Yang, Wang*, J., Jia*L, Conjugation of
           phthalocyanine photosensitizer with poly(amidoamine) dendrimer: improved solubility,
           aggregation and photocatalyzed bioactivity against cancer cells (in preparation), 2015
 
151.    Jia,*L. Three decades of transdisciplinary understanding and re-evaluating of the politics- and religion-involved abortion pill mifepristone and its niche in cancer metastasis chemoprevention. Cancer J. 2016.
         
 
*, principal or corresponding author;
 
ABSTRACTS:
 
1. Jia, L: Pharmacokinetic differentiation of six substituted phenylethylamines.   Chinese Pharmaceutics Press pp. 16, 1988.
 
2. Jia L, Bonaventura C, Bonaventura J, Stamler JS: S-nitrosohemoglobin: a new transport function of arterial erythrocytes involved in regulation of blood pressure.    Endothelium S6, 1995
 
3. Day, B. J, L, Jia, Arnelle D. R, Crapo, J. D, and Stamler, J. S.: Transduction of NOS activity from endothelium to vascular smooth muscle: involvement of S-nitrosothiols  In Biology of Nitric Oxide. Endothelium. S 72, 1995.
 
4. Day, B. J, Jia, L, Crapo, J. D. and Stamler, J. S.:  EDRF and mechanisms of nitric oxide protection..    Am. J. Respir. Crit. Care  Med.    A 627, 1995.
 
5. Jia L, Bonaventura C, Bonaventura J, Stamler JS: S-nitrosohemoglobin: a new synthetic activity of the lung involved in regulation of blood pressure.  Am.  J.  Respir.  Crit.  Med.  A 582, 1996.
 
6. Zhang, J., Saman, G., Jia, L., Stamler, J.S., Cobb, F.R.:  Effects of S-nitrosohemoglobin on the conductance and resistance coronary vasculature.    Circulation, 94:(Suppl 1-16), 1996.
 
7. Jia, L., Blantz, RC.  The effects of S-nitrosocaptopril on renal function and blood pressure in rats.   J. Am. Society   Nephrology.  8:317A, 1997.
 
8. Jia, L. Zhang, J.: Pharmacokinetics of S-nitrosohemoglobin in unanethetized dogs   J.  Artificial Cells, Blood  Substitutes, Immobilization  Biotechnology  21, 1997
 
9. Jia, L.: S-nitrosocaptopril crystals: physicochemical characterization and cardiovascular activities.  Am. J. Hypertension.  1998; 11(4): 105A.  
 
10. Jia, L: Simultaneous measurement of pharmacodynamics and pharmacokinetics of S-nitrosocaptopril in hypertensive rats.  AAPS Western Regional Meeting  1998; page.41.                         
 
11. Jia, L. Thomson, S. Blantz, R.  L-arginine increases GFR partially by nitric oxide independent mechanisms via activity of agmatine.    J.  Am. Society  Nephrology  1998; 308A.
 
12. Jia, L.: VIPGC-NO preserves intrinsic function of VIP but acquires NO-like activities.  Am. J. Hypertension. 1999;12(4): 54A.  
 
13. Lin, M., Yang, X, Wang.,  Jia, BJ., Jia, L.  S-nitrosocaptopril crystals preferentially decreases diastolic pressure in hypertensive rats.  Am. J. Hypertension.  1999; 12(4):114.
 
14. Jia, L. Linnik, D.M.  The Stability of the first domain of b2-glycoprotein I in rat serum and microsomes.  AAPS PharmSci. 1999; 1(S1): 524.
 
15. Jia, L., Yu, l., Linnik, D.M., Jack, R.M.  Stability and Pharmacokinetics of LJP 920, an octameric Gal (a1-3) Gal conjugate for inhibition of xenotransplantation rejection.    AAPS PharmSci. 1999; 1(S1): 11
 
16. Jia, L., Pei, R. Acute and subacute toxicity and efficacy of S-nitrosylated captopril, an ACE inhibitor possessing nitric oxide activities. AAPS PharmSci. 2000; 2(S1):726.
 
17. Jia, L. Wong, H. Garza, M. Weitman, S. Pharmacokinetic Comparison of intravenous carbendazim and its liposome and emulsion forms in nude mice. Proc. Am. Assoc. Cancer Res. 42: 381, 2001.
 
18. Jia, L. Garza, M. Wong, H. Wang, Y. Weitman, S. Paclitaxel Tumor cellular Permeability: Influence of plasma binding, P-glycoprotein and nitric oxide. Proc. Am. Assoc. Cancer Res. 42: 951, 2001.
 
19. Wang, Y., Wong, H., Weitman, S. Jia, L. LC/MS/MS assay of a novel anti-virus drug 301029: application to cellular permeability studies. AAPS PharmSci. 2001; 3(S1): 861.
 
20. Wong, H. Wang, Y. Weitman, S. Jia, L. Carcinoma cell permeability, tissue distribution and disposition of carbendazim, a novel anti-cancer drug.  Proc. Am. Assoc. Cancer Res. 43: 430, 2002.
 
21. Wang, Y. Wong, H. Jia, L. Effect of S-nitrosocaptopril on Taxol permeability and cytotoxicity against carcinoma cells. Proc. Am. Assoc. Cancer Res. 43: 431, 2002.  
 
22. Wong, H., Wang, Y., Garza, M. Weitman, S. Jia, L.  Carbendazim and its nanoparticle formulation: Pharmacokinetic comparison and metabolite identification.  AAPS PharmSci. 2001; 3(S1): 609.
 
23. Wang, Y. Jia, L. Wong, H. Endothelial permeability to captopril and S-nitrosocaptopril and in vivo bioactivity thereof. AAPS PharmSci. 2001; 3(S1): 493.
 
24. Jia, L. Wong, H. Cerna, C. Piazza, G. LC/MS/MS-based proteomic analysis of the membrane proteins of human prostate carcinoma LNCaP Cells. Proc. Am. Assoc. Cancer Res. 43: 34, 2002.
 
25. Cerna, C. Wang, Y. Schweizer, J. Revilla, M. Wong, H. Jia, L. Effects of S-nitrosocaptopril on cytotoxicity and permeability of paclitaxel in human carcinoma cell lines. Proc. Am. Assoc. Cancer Res. 43: 585, 2002.
 
26. Jia, L. Wong, H. Cerna, C. Weitman, SD. Size-dependent absorption of micro- and nanoparticle 301029: ex vivo and in vivo pharmacokinetic correlations determined by LC/MS.  AAPS PharmSci. 2002; 4(S1): 1569.
 
27. Jia, L. Tomaszewski, J. Jothianandan, D. Furchgott, R.F. Keefer, L. Shami, P. EDRF-like activity and anticancer spectrum of JS-K, a novel diazeniumdiolate nitric oxide donor.  Proc. Am. Assoc. Cancer Res. 44: 1059, 2003.
 
28. Bolterman, S.A., Reid, J.M., Jia, L. Shami, P.J., Ames, M.M.  HPLC analysis of the NO-donating prodrug JS-K: inhibition of sulfhydryl-catalyzed degradation in plasma and whole blood lysates by thiol depletion with diamide. Proc. Am. Assoc. Cancer Res. 44: 387, 2003.
 
29. Jia, L., Tomaszewski, J., Noker, P., Norman, G., Protopopova, M. Ethambutol Analogs. I. LC/MS/MS analysis and cassette dosing for pharmacokinetic screening of candidate drugs. AAPS PharmSci. 2003; 5(S1): 716.
 
30. Jia, L., Tomaszewski, J., Noker, P., Norman, G., Protopopova, M. Ethambutol analogs. II. Pharmacokinetic characterization of SQ109. AAPS PharmSci. 2003; 5(S1): 724.
 
31. Jia, L., Tomaszewski, J., Noker, P., Norman, G., Protopopova, M. Ethambutol analogs. Assessment of pharmacokinetic drug-drug interaction after cassette dosing. AAPS PharmSci. 2003; 5(S1): 719.
 
32. Jia, L., Tomaszewski, J., Noker, P., Norman, G., Yang, D. Pharmacokinetic profiling of (-)Gossypol (NSC 726190), a novel anticancer agent. Molecular Targets & Cancer Ther. p241, 2003  (AACR-NCI-EORTC international conference).
 
33. Reid, J., Buhrow, S.A., Kuffel, M., Jia, L., Covey, J., Ames, M.M. LC-MS/MS assay and rat pharmacokinetics and metabolism of the dimeric pyrrolobenzodiazepine SJG-136. Proc. Am. Assoc. Cancer Res. 45:1248, 2004.
 
34. Jia, L., Spanswick, VJ., Reid, JM., Kuffel, M. Buhrow, SA., Ames, MM., Hartley, JA., Thurston, DE., Tomaszewski, JE. Use of the Comet assay as a surrogate biomarker for the in vivo measurement of DNA damage to Lymphocytes. Proc. Am. Assoc. Cancer Res. 45: 452, 2004.
 
35. Jia, L. Peggins, J., Reid, JM., Buhrow, SA., Ames, MM., Kobs, DJ., Grossi, IM., Thurston, DE., Tomaszewski, JE. Interspecies differences in pharmacokinetcs and time-dissociated toxicokinetics of SJG-136. Proc. Am. Assoc. Cancer Res. 45:487 2004.
 
36. Coward, L, Cook, L. Kerstner-Wood, C. Noker, P. Page, J. Jia, L. Schweikart, K. Gorman, G. Simultaneous Determination of a Novel Synthetic Triterpenoid Derivative(CDDO-Im) and its Metabolites using LC/MS/MS. American Society of Mass Spectrometry(ASMS). May, 2004.
 
37. Jia, L. Noker, P.E. Gorman, G. Coward, L. Protopopova, M. Tomaszewski, J.E. In vitro metabolic profiling of SQ109 and identification of main CYP isoforms catalyzing the metabolism. The AAPS Journal. 2004; 6(S1): 969.
 
38. Jia, L. Noker, P.E. Gorman, G. Coward, L. Protopopova, M. Tomaszewski, J.E. Interspecies similarities and differences in pharmacokinetics of SQ109 (NSC722041), an anti-tuberculosis drug. The AAPS Journal. 2004; 6(S1): 1092.
 
39. Shami, P.J., Kaur, G., Jia, L., Saavedra, J.E., Keefer, L.K. JS-K, a novel nitric oxide (NO) generator, shows potent anti-angiogenic activity.  Am. Society Hematology. Dec. 2004.   
 
40. Glaze, E., Chen, Y., Lyubimov, A., Jia, L., Noker, P., Morrissey, R., Tomaszewski, J. Range-finding toxicity studies with SQ109, an anti-tuberculosis agent, in rats and dogs. 2005 Annual Society of Toxicology Conference.
 
41. Jia, L., Coward, L., Gorman, G. Noker, P.E., Hanrahan, C., Protopopova, M. Tomaszewski, J.E.  Fingerprinting of pharmacoproteomic changes of mycobacterium tuberculosis H37Rv induced by anti-tuberculosis drugs.  2005 Annual Am. Thoracic Soc. San Diego, May.
 
42. Jia, L., Gorman, G.S., Noker, P.E., Coward, L., Tomaszewski, J.E. In Vitro Metabolism Analysis of CDDO-Imidazolide. Proc. Am. Assoc. Cancer Res. 46: 779, 2005.
 
43. Jia, L., Kuffel, M.J., Buhrow,S.A., Reid, J.M., Ames, M.M. Pharmacokinetic profile 1-methyl-[d]-tryptophan, an orally-bioavailable immune modulator.  Proc. Am. Assoc. Cancer Res. 46: 987, 2005.
 
44. Coward, L.C. Kerstner-Wood, Noker, P., Gorman, G., Becattini, B., Pellecchia, M., Reed, J.C., Jia, L. Analysis of bioconversion from apogossypol hexaacetate to apogossypol, a novel proapoptotic compound. Proc. Am. Assoc. Cancer Res. 46: 530, 2005.
 
45. Noker, P.E., Gorman, G.S., Coward, L., Hansel, W., Jia. L. Lytic Peptide Phor21-bCG(ala) I: Pharmacokinetic Profile in Mice and Rats. Proc. Am. Assoc. Cancer Res. 46: 982, 2005.
 
46. Piazza, G., Jones, Noker, P.E., Hansel, W., Leuschner, C., Jia, L. Lytic Peptide Phor21-βCG(ala) II: Selective Cytotoxicity and Its Effects on Membrane Integrity as Measured by Permeability to Mannitol. Proc. Am. Assoc. Cancer Res. 46: 1395, 2005.
 
47. Kuffel, M.J., Buhrow, S.A., Reid, J.M., Jia, L., Ames, M.M. Kynurenine: a biomarker for in vitro and in vivo modulation of indoleamine 2,3-dioxygenase by 1-Methyl-[d]-tryptophan (NSC 721782)  Proc. Am. Assoc. Cancer Res. 46: 982, 2005.
 
48. Sarah A. Buhrow, Joel M. Reid, Lee Jia, Mamoru Shoji, James P. Snyder, Dennis C. Liotta, Matthew M.  LC/MS/MS assay and mouse pharmacokinetics and metabolism of the novel curcumin analog EF-24 (NSC 716993).  Proc. Am. Assoc. Cancer Res. 46: 984, 2005.
 
49. Jia, L., Noker, P., Coward, L., Gorman, G., Reed, J.C.  Quantitative determination of formulation and biomatrix stability of Apogossypol, a novel proapoptotic compound. The AAPS Journal 7(S2): T2307; 2005.
 
50. Jia, L., Noker, P., Coward, L., Gorman, G., Reed, J.C. In vitro and in vivo bioconversion of apogossypol hexaacetate to apogossypol: implication for chemotherapy development.  Clin. Cancer Res. 11(24 Suppl):9072s, 2005.
 
51. Jia, L. Tomaszewski, J. Toxicokinetic profile of Batracylin in beagle dogs. The Toxicologist 90(1):122, 2006. (Abstract # 596)
 
52. Kuffel, MJ., Buhrow, SA., Myers, RM., Greiner, SM., Harvey, ME., Reid, JM., Peng, KW., Jia, L., Russell, SJ., Ames, MM. Tissue distribution of viral gene expression after intravenous administration of an oncolytic measles virus encoding the sodium-iodide symporter (MV-NIS) in transgenic IfnarKO x CD46 Ge mice. Proc. Am. Assoc. Cancer Res. 47: 494, 2006.
 
53. Coward, L., Gorman, G., Noker, P., Hamilton, A. Sebti, S., Jia, L. A rapid and selective method for the analysis of GGTI-2418 in mouse plasma by HPLC/MS/MS. American Society of Mass Spectrometry (ASMS). May, 2006.
 
54. Coward, L., Kerstner-Wood, C., Cork, L., Noker, P., Jia, L., Hamilton, A., Sebti, S., Gorman. G.  Analysis of GGTI-2418 in Plasma and its Pharmacokinetics by HPLC/MS/MS.  The AAPS Journal 2006; 8(S2): T2024
 
55. Kitada S, Jia L, Coward LC, Gorman GS, Noker P, Pellecchia M, and Reed JC .  Bcl-2 antagonist ApoGossypol (NSC736630) displays single-agent activity in Bcl-2 transgenic mice and has superior efficacy and pharmacology with less toxicity compared to Gossypol (NSC19048). Am. Hematology Soc. 2006.
 
56. P. Noker, R., Fulton, J. Heath, L. Jia, J.M. Reid, M.M. Ames, K.M. Schweikart, and J.E., Tomaszewski. Toxicity and Pharmacokinetics of 1-Methyl-D-Tryptophan in Rats and Dogs. Proc. Am. Assoc. Cancer Res. 48: 366, 2007.
 
57. J.M., Reid, R.M. McGovern, S.A. Buhrow, L. Jia, J., Tomaszewski, B.J. Jean-Claude, M.M. Ames.  Lead compound selection in a series of combi-molecules with dual EGFR inhibitory and DNA alkyating activity.  Proc. Am. Assoc. Cancer Res. 48: 937, 2007.
 
58. Roberts, M.J., Coward, L., Noker, P. Jia, L. In Vitro Bioavailability Testing of GGTI-2418 Using the Caco-2 Model. Proc. 2007 EORTC-ASCO, Belgium.  
 
59. Greg Gorman, Lori Coward, Corenna Kerstner-Wood, Lea Freeman, Patricia E. Noker, Craig Beattie, Tapas K. Das Gupta, Lee Jia.  Quantitative analysis of Azurin p28, an anti-tumor peptide: Serum stability and mouse pharmacokinetics. Proc. Am. Assoc. Cancer Res. 49: 1138, 2008.
  
60. Noker, P., Coward, L., Gorman, G., Jia, L. Pharmacokinetics, Tissue Distribution, and Excretion of GGTI-2418, an Inhibitor of Geranylgeranyl Transferase I, in Mice. Proc. Am. Assoc. Cancer Res. 49: 785, 2008.
 
61. Kitada, S., Wei, J., Kress, C.L. Zhai, C. Krajewska, M., Jia, L., Pellecchia, M., Reed, J.C.  In vitro and in vivo efficacy and toxicity comparison between ApoGossypol and Gossypol, Bcl-2 Antagonists. Proc. Am. Assoc. Cancer Res. 49: 1044, 2008
 
62. Reid, J.M., McGovern, R.M. Kuffel, M.J., Jia, L., Ames, MM. Species comparison of 1-Methyl-D-tryptophan metabolism by cryopreserved hepatocytes from beagle dog, Fisher rat, CD2F1 mouse and pooled human. Proc. Am. Assoc. Cancer Res. 49: 1137, 2008
 
63. Malhotra, SV., Kumar, V., Parchment, RE., Jia, L., Noker, PE., Misra, RN., Narayanan VL., Tomaszewski, JE. Ionic Liquid ‘Therapeutic Agents’- New Paradigm in Drug Development.  Am. Chem. Soc. Philadelphia, August 17-21, 2008.
 
64. Gorman, G., Coward, L., Kerstner-Wood, C., Noker, P., Beattie, C.W., Jia, L. Metabolic Characterization of Azurin p28 in Human, Mouse and Monkey Liver Microsomes.  The AAPS Journal 2008;10(S2): M2230
 
65. Kumar, V., Parchment, R.E., Jia, L. Noker, P.E., Misra, R.N., Narayanan, V.L., Tomaszewski, J.E., Malhotra, S.V. Cytotoxicity studies of ionic liquids for potential anticancer drug therapy. 2009, 48th annual meeting of Society of Toxicology. Abs# 2067
 
66. Reid, J.M., McGovern, R.M., Buhrow, S.A., Jia, L., Ames, M.M. LC/MS/MS assay and mouse pharmacokinetics and metabolism of the eukaryotic elongation factor-2 kinase inhibitor NSC 745343. Proc. Am. Assoc. Cancer Res. 50: 709, 2009.
 
67. Gorman, G., Coward, L., Kerstner-Wood, C., Freeman, L., Noker, P.E., Sharifi, N., Figg, W., Jia, L. Pharmacokinetic, Metabolic and Stability Investigations of CCN, a Conjugate of Colchicine and Cyanonilutamide. The AAPS Journal 2009;11(S2): T2234.
 
68. Rayburn, E., Wang, W., Grau, S., Li, H., Xu, H., Zhang, X., Li, M., Sommers, C., Jia, L., Lee, M. Zhang, R., Enterohepatic circulation of indolecarboxamide ML-970 (NSC 716970), an investigative anticancer agent. Proc. Am. Assoc. Cancer Res. 51: 875, 2010.
 
69. Reid, JM., Buhrow, SA., Safgren, SL., Jia, L., Schweikart, K., Noker, P., Davis, M., Collins, J., Goetz, MP., Ames. MM. Endoxifen pharmacokinetics and bioavailability in female rats and dogs. Proc. Am. Assoc. Cancer Res. 51: 632, 2010.
 
70. Buhrow, S.A., Reid, J.M., Walden, C.A., Jia, L., Davis, M., Keefer, L., Barazi, H., Ames, MM. Pharmacokinetics, metabolism and tissue distribution of the nitric oxide-donating prodrug JS-K following administration in liposomes. Proc. Am. Assoc. Cancer Res. 51: 646, 2010.
 
71. Gorman, G.S., Noker, P.E., Coward, L.U., Ross, D, Guertin, P.A., Jia, L. In-vitro and In-vivo Drug-Drug Interaction Studies with SPINALON, a combination of buspirone and levodopa/ carbidopa for spinal cord injury. The AAPS Journal 2010; 12(S2):T2405.
 
72. J. Meng, Y. Wang, L. Jia, X-J. Liang. Epigenetic Characteristics of Endohedral Metallofullerene Nanoparticles with anti-tumor activity and low toxicity The AAPS Journal 2010; 12(S2): W4444.
 
73. M. Song, S. Zhang, T. Hang, L. Jia. Panax notoginseng saponins in dogs determined by LC/MS/MS following oral administration of Danshen Tablets. The AAPS Journal 2010; 12(S2): W4477.
 
74. Malhotra, S.V., Kumar, V., Parchment, R.E., Jia, L. Noker, P.E., Kumar, K., Misra, R.N., Narayanan, V.L., Tomaszewski, J.E., Cytotoxicity studies of ionic liquids for potential anticancer drug therapy. The AAPS Journal 2010; 12(S2): T3010.
 
75. Xue, J., Shao, J, Dai, Y, Liu, H., Chen, NS., Huang, JL., Jia,* L Overview of Global Development of Photodynamic Therapy for Cancer and China’s First Generation of Photosensitizer ZnPcS2P2 in Clinical Trials. 17th International Biophysics Congress (IUPAB), Beijing. 10/30 -11/3, 2011.
 
76. Shao, JW., Dai, YC., Xue, JP., Jia, L. Anticancer activity and mechanism of ZnPc in human hepatocellular carcinoma cell line HepG2. The AAPS Journal 2011; 12(S2): W4057; Submission ID: AM-11-00707; Wed. Oct. 26; 8:00-12:00 pm.
 
77. Xue, JP., Fang, Y., Jia, L. Liu, H., Chen, N., Hang, J. Preparation and in vitro photodynamic activities of a novel mono(8-quinolinoxy) phthalocyanato zinc(II). The AAPS Journal 2011; 12(S2): W4078; Submission ID: AM-11-01735; Wed. Oct. 26; 8:00-12:00 pm
 
78. Shao, JW., Du, H., Bai, Z., Xie, J., Cheng, X., Jia, L. Effects of fermentation conditions on the growth of Cordyceps kyushuensis in submerged culture and its antioxidative and anticancer activity in vitro. The AAPS Journal 2011; 12(S2): T2015; Submission ID: AM-11-01127; Tuesday, October 25, 8:00-12:00 pm
 
79. Gao, Y., Wang, A., Jia, L. (invited presentation) A urgent need for bilateral acceptability of GLP inspections and regulations between USA and China (制药业的全球化趋势急待中美GLP互认的双边协定). 高银燕,王爱平,贾力，制药业的全球化趋势急待中美GLP互认的双边协定，2011年中国药学大会暨第11届中国药师周论文集, pp 1017-1025, 2011. Nov. 6, 2011. 8:30-12:00 am.
 
80. Wang, J., Shao, J., Zhang, F., Jia, L. Design, synthesis and anticancer activity of a series of ursolic acid derivatives conjugated to folate: targeting folate receptors on cancer cells. October 14–17, 2012; Chicago. Poster T3023.
 
81. Fang, Y., Song, J., Wang, M., Zhang, J., Wang, X., Sun, JJ., Jia, L. A novel analytical method for detection of H2O2 by using electrogenerated chemiluminescence of cadmium germanate nanomaterials to overcome interferences from other coreactants: long-term stability and quality analysis. Abstract # 2605.
 
82. Xie, J., Zhao, R., Lu, Y., Wang, J., Gu, S., Jia, L. Re-engineering PAMAM dendrimer for its multivalent binding specifically to colon cancer cells HT29. XianShan Science Conference. Forum on Cancer Nanotechnology and Nanomedicine. 3rd US-China Symposium on Cancer Nanotech & NanoMed. Beijing, Dec., 5-7, 2012.
 
83. Lu, Y., Yu, T., Liang, H., Xie, J., Wang, J., Xu, J., Shao, J., Jia, L. S-nitrosocaptopril interferes hetero-adhesion between human colon cancer cells HT-29 and vascular endothelial cells. 2013 AAPS annual meeting; AM-13-0574
 
84. Xie, J., Zhao, R., Gu, S., Shao, J., Lu, Y., Wang, J., Jia, L. Surface-functionalizing modification of nanomaterial dendrimer PAMAM with anti-epithelial cell adhesion molecule antibody for its binding to colon cancer cells HT29. 2013 National Biotechnology Conference, San Diego, USA
 
85. J. C. Wang, Y. L. Wan, Y. W. Zhu, Y. S. Lu, J. J. Xie, T. Yu, J. Z. Chen, L. Jia. Synthesis, characterization and anti-adhesion effect of metapristone, a novel cancer metastasis chemopreventive agent derived from RU486 (mifepristone) 2013 AAPS annual meeting，AM-13-0927; San Antonio, USA
 
86. Jingjing Xie, Rongli Zhao, Songen Gu, Jichuang Wang, Yuanfang Li, Haiyan Liang, Ting Yu, Lee Jia Capture behaviors of PAMAM dendrimers functionalized with anti-Sialyl Lewis X antibody in vitro。AM-13-2174, 2013 AAPS annual meeting, San Antonio, USA
 
87. Y. Zhu, J. Wang, L. Wan, Y. Li, J. Xie, J. Chen, Y. Pang, L. Jia. Effects of Metapristone on Smooth Muscle Contraction in Isolated Rat Organs. Abstract AM-13-1771, 2013 AAPS Annual Meeting, San Antonio,USA.
 
88. Chen, J., Wang, J. Jia L. A novel UPLC/MS/MS method and its application to pharmacokinetic determination of metapristone, a novel cancer metastasis chemopreventive agent derived from RU486: pharmacokinetic difference between genders. Abstract AM-13-1044, 2013 AAPS annual meeting, San Antonio, USA
 
89. Wan, LY, Xu, H, Ma, J., Zhu, Y, Wang, JC, Xiao, YY, Shao, JW, Jia L.  HAMPT, a specific combination designed to control key cancer metastatic pathways: in vitro and in vivo evidences for its cancer metastasis chemoprevention. 2014, AAPS
 
90. Xie, JJ, Zhao, R, Shao, JJ, Sinko, PJ, Lu, YS, Gao, Y, Wang, JC, Dong, HY, Jia, L.
Increased capture and restraint of Hepatocellular circulating tumor cells in blood by  aEpCAM- and aSlex-coated dendrimer conjugates. 2014 AAPS.
 
91. Xie, JJ, Dong, HY, Zhao, R, Gu,S., Wang,JC., Lu,YS., Ting Yu, Xie, FW., Wang, L., Shao, JW., Jia, L*Enhanced Restraining Circulating Colorectal Cancer Cells in Blood and Their Hetero-Adhesion to Endothelial Cells with Dual Antibody-coated Dendrimer Conjugates. 2014; Nov. 5-7; SiChun Changdu, Nanotechnology meeting.
 
92. J. Xie, H. Chen, W. Shen, R. Zhao, Y. Lu, J. Wang, Y. Zhu, X. Xie, L. Jia. Targeting Antibody-Coated Dendrimers for Biological Functions in Cancer Metastasis Prevention. Abstract AM-14-1402, 2014 AAPS annual meeting, San Diego, USA.
 
93. Y. Zhu, Y. Xiao, J. Wang, L. Wan, T. Yu, J. Ma, J. Liu, S. Yu, L. Jia. Effects of Metapristone and Mifepristone (RU486) on Murine B16-F10 Melanoma Cancer Metastasis. Abstract AM-14-1786, 2014 AAPS annual meeting, San Diego, USA.
 
94. L. Wan, H. Xu, J. Ma, Y. Zhu, J. Wang, Y. Xiao, J. Shao, L. Jia. HAMPT, a Specific Combination Designed to Control Key Cancer Metastatic Pathways: In Vitro and In Vivo Evidences for Its Cancer Metastasis Chemoprevention. Abstract AM-14-2258, 2014 AAPS annual meeting, San Diego, USA.
 
95. Y. Lu, T. Yu, H. Liang, H. Xu, Y. Zhu, Y. Pang, J. Wang, J. Xie, L. Wan, L. Jia. S-nitrosocaptopril Prevents Cancer Metastasis by Inhibiting Adhesion of Circulating Tumor Cells to Endothelial Cells. Abstract AM-14-2797, 2014 AAPS annual meeting, San Diego, USA.
 
96. J. Xie, R. Zhao, J. Shao, P. Sinko, Y. Lu, Y. Gao, J. Wang, H. Dong, L. Jia. Increased Capture and Restraint of Hepatocellular Circulating Tumor Cells in Blood by aEpCAM- and aSlex-Coated Dendrimer Conjugates. Abstract AM-14-2260, 2014 AAPS annual meeting, San Diego, USA.
 
97. J. Wang, N. Zheng, Y. Zhu, L. Wan, J. Xie, L. Jia. Metapristone Exhibits Anti-metastatic Melanoma B16F10 Activity via Inhibiting the Expression of Integrin &[alpha]4 and Inducing Apoptosis. Abstract AM-14-1672, 2014 AAPS annual meeting, San Diego, USA.
 
98. Jingjing Xie1, Haiyan Dong1, Rongli Zhao1, Songen Gu1, Jichuang Wang1, Yusheng Lu1, Patrick J. Sinko2, Ting Yu1, Fangwei Xie3, Lie Wang3，Jingwei, Shao1,4, Lee Jia1,4* Enhanced sensitivity and specificity of capturing and restraining circulating tumour cells in blood with dual antibody-coated nanomaterials2014全国纳米生物与医学学术会议-四川成都2014-11-05
 
99. Huo Xu, Yu Gao, Yewei Zhu, Jia Lee*, Formulation, Transdermal Absorption and Penis Relaxation of An Nitric Oxide Donor Drug for its Coating on Condom, 2014,NOV; International Chinese Symposium on free radical research, Hong Kong.
 
100. Haiyan Liang, Yusheng Lu, Ting Yu, Shu Lian, Haiyan Dong, Lee Jia*. Enumeration, Characterization and Proliferation of Circulating Tumor Cells for Clinical Application Potential by Flow Cytometry. The 8th Pong Ding Yuen International Symposium on Traditional Chinese Medicine cum, The 2nd International Chinese Symposium on Free Radical Research & The 6th Symposium for Three Districts of Cross-straits on Free Radical Research. November 15-16, 2014, Hong Kong.
 
101. Jian Liu, Hongning Chen, Xiaobo Yu, Liping Xiang, Qiao Tang, Ting Chi , Jinwei Shao*, and Lee Jia* Functionalized PLGA-PEG nanoparticles conjugated with aptamer for targeting circulating tumor cells for drug delivery 2015, April; China Nanomedicine杭州
 
102. Yingying Xiao, Yewei Zhu, Jianzhong chen, Tao li , Lee Jia* Bioavailability and Pharmacokinetics of Nanometer Drug of Metapristone in Different Genders, A New Cancer Metastasis Chemopreventive Agent Derived From Mifepristone (RU486) 2015, April; China Nanomedicine杭州
 
103. Jingjing Xie1, Hongning Chen1, Yewei Zhu1, Weiyu Shen1, Rongli Zhao1, Lie Wang2, Fangwei Xie2, Lee Jia1,* Dual antibody-functionalized dendrimers for the specific capture of colorectal circulating tumor cells in vitro and in vivo. 2015, April, 9; China Nanomedicine杭州
 
104. Xiao-Dong Xie , Feng-Qiao Li, Yu Gao* , Lee Jia* DUAL-APTAMER-MODIFIED-MESOPOROUS SILICA NANOPARTICLES LOADING DOXORUBICIN FOR HIGH EFFICIENT RESTRAINING CANCER METASTASIS. 2015, April 9; China Nanomedicine杭州
 
105. Haiyan Dong, Yu Gao, Jingjing Xie, Jingwei Shao, Rodney Ho, Lee Jia  From Imitation to Innovation: the Ten-year Chinese Bionanotechnology Development. 2015, April 9 China Nanomedicine April; China Nanomedicine杭州
 
106. Jianguo Xu, Haiyan Dong, Weiyu Shen, Sudan He, Hongling Li,Yusheng Lu,Zaisheng Wu*, Lee Jia*. New molecular beacon for detection of p53 gene point mutation and its potential as a primer for polymerization. 2014; Nov. 5-7; SiChuan Chengdu, Nanotechnology meeting.
 
107. Ting Chi, Liping Xiang, Xiang Yang, Qiao Tang, Xiaobo Yu, Jian Liu, Yajun Liu,Jingjing Xie, Jingwei Shao*, Lee Jia*.Preparation and Anti-Tumor Activity of mesoporous silica nanoparticles (MSN) containing both free and conjugated ursolic acid (UA@MSN-UA). 2014全国纳米生物与医学学术会议-四川成都2014-11-05
 
108. Ting Yu, Yusheng Lu, Haiyan Liang, Yaqiong Pang, Jianguo Xu, Haiyan Dong, Songen Gu, Suhong Yu, Jingwei Shao and Lee Jia*. Nitric Oxide Inhibits Adhesion of Circulating Tumor Cells to Endothelial Cells. 2014 Chemical Biology-Nitric Oxide Shanghai International Conference, Shanghai, July 4-6, 2014.
 
109. Dong, H., Lu, Y., Xu, JG., Zheng, N., Liu, J., Jia. L. Bionanotechnology used for capturing and restraining circulating tumor cells: eliminating the suffering and death from cancer metastasis. Beijing, 2015 ChinaNano, Sept. 3-5., 2015.
 
110. Jingjing Xie#, Weiyu Shen#, Rongli Zhao, Lee Jia* Enhanced binding and restraint of hepatocellular carcinoma cells by multiple antibodies-conjugated dendrimers. Beijing, 2015 ChinaNano, Sept. 3-5., 2015.
 
111. Dong, H., Ma, J., Wang, J., Zhang, T., Wu, ZS., Lu, YS., Han, LY., Jia, L. The novel aptamer cyclization technology: resistant to exonuclease degradation, good biostability and enhanced specificity in binding target cancer cells. AAPS-AM-15-2352
 
97. Y. Lu, S. Lian, T. Yu, H. Liang, Y. Zhu, H. Xu, Y. Cheng, H. Dong, L. Jia*. S-nitrosocaptopril as a Potential Cancer Metastatic Chemopreventive Agent: A Promising Molecule for Preventing Cancer Metastasis. AAPS AM-15-1598.
 
98. N. Zheng, J. Wang, H. Chen, J. Liu, Y. Lu, H. Dong, L. Jia*. Metapristone Inhibits Cell Mobility and Adhesion of Ovarian Cancer.AAPS AM-15-1737.
 
99. Y. Xiao, Y. Zhu, T. Li, Y. Lu, J. Liu, X. Yu, X. Xie, H. Dong, S. Lian, W. Chen, L. Jia*. Metapristone, an active metabolite of mifepristone (RU486), prevent Lewis lung carcinoma cell metastasis. AAPS AM-15-886.
 
100. C.Yan , S.He , X.Yang , J.Liu , J.Ma , S.Yu* , L.Jia* Functions and Mechanisms of Metapristone in Triple-negative breast cancer cells. 2015, Nov.  AACR Shanghai
 
101. H. Chen, G. Zhen, J. Liu , J. Wang , Y. Lu, N. Zhen, C. Ting, Y. Xiao, J. Shao*, L. *Jia Metapristone Reduces Cell Proliferation and Induces Apoptosis of Non-Small-Cell Lung Cancer Cells A549 in vitro. 2015, Nov.  AACR Shanghai
 
102. Jun Qian, Xiaobo Yu, Xingtian Yang, Hongning Chen, Ting Zhang, Zhou Jiang*, Suhong Yu, Lee Jia** Achyranthes bidentata saponion: a promising cancer metastatic prevention agent. 2015, Nov.  AACR Shanghai
 
103. N. Zheng, J. C. Wang, J. H. Chen, J. Liu, X. B. YU, Y. S. Lu, X. D. Xie, and L. Jia
Metapristone exhibits anti-adhesive activity via down-regulating the expression of multiple adhesion molecules in ovarian cancer SKOV3 cells. A0065 2015, Nov.  AACR Shanghai
 
104. Xiaobo Yu, Qing Shi, Jian Liu, Yusheng Lu, Ting Chi, Yajun Liu, Jingwei Shao, Lee Jia . Similarities between embryo implantation and circulating tumor cells adhesion to human umbilical vein endothelial cells. 2015, Nov.  AACR Shanghai
 
105. Ji Ma, Tao Li, Hongning Chen, Cuicui Yan, Yingying Xiao, Lee Jia* The effect of ginseng on the pharmacological function of warfarin in rats.
 
106. Yingying Xiao, Yewei Zhu, Yusheng Lu, Wenge Chen, Xiaobo Yu, Hongning Chen, Ting Chi, Jian Liu, Lee Jia* A Novel Anti-metastatic Metapristone Inhibits MCF-7 Adhesion via Down-regulating Expression of MUC-1 Pathway in Vitro and Inhibits Lung Metastasis in Vivo. 2015, Nov.  AACR Shanghai
 
107. XT. Y, SD.H, CC.Y, SH.Y, L.JIA* Metapristone inhibits cell adhesion with reversal of epithelial-mesenchymal transition in MDA-MB-231 breast cancer cells. 2015, Nov.  AACR Shanghai
 
108. S.He , C.Yan , X.Yang , S.Yu , L.Jia  A pharmacoproteomic study of metapristone: a potential cancer metastatic chemopreventive agent. 2015, Nov.  AACR Shanghai
 
109. Yusheng Lu, 1Shu Lian, 1Yunlong Cheng, 2Min-Liang Kuo, 1Haiyan Liang, 1Lee Jia*
Bioenergetic Adaptation by Metastatic Cancer Cells to Reduce the Unrequired Bioenergy in Emergencies
 
110. Shu Lian, 1Yusheng Lu, 2Min-Liang Kuo, 3Alan Yueh-Luen Lee, 1Ting Yu, 1Haiyang Liang, 1Yunlong Cheng, 1Lee Jia S-nitrosocaptopril inhibits expression of cell adhesion molecules via regulating NF-кB signal pathway  AAPS abstract poster 2098.
 
111. H. Dong1,2, T. Zhang1, L. Han1, J. Ma1, J. Wang1, J. Xie3, Z. Wu1, P.J. Sinko2, Lee Jia*In vivo specifically capturing circulating tumor cells by dual ds-aptamer ring-coated dendrimers,1  2016 AAPS  abstract poster 1882
 
112. Yunlong Cheng, Yusheng Lu, Shu Lian, Lee Jia. TGF-β Can Enhance the Invasive Ability and the Rate of Metabolism and Proliferation of Cancer Cells. 2016 AAPS abstract poster 1200
 
113. Le, JQ, Zheng, TT. Xu, JG, Jia, L. Rapid and Reliable Construction of Aptamer-tethered DNA Nanoarchitecture for Targeted Cancer Therapy. 2016 AAPS poster abstract 1156
 
114. Wang, J. Dong, HY., Jia, L. Petitive Pseudo-DNA Nanocatenane for Ultrasensitive CTCs Detection in Peripheral Blood. 2016 AAPS poster Abstract 2111.

 

贾力 博士生导师、博士后导师；福州大学肿瘤转移的预警和预防研究所所长。福州大学能源与环境光催化国家重点实验室生物医药光催化课题组长。福建省药学重点学科福州大学负责人、福建省肿瘤转移药物干预重点实验室主任
学术兼职 他曾兼职担任美国药学会（American Association of Pharmaceutical Scientists, AAPS）药物设计和开发专业委员会（drug design and development, DDD）的副主席、主席（2009-2012）、世界中医药学联合会/ 植物药代谢与临床监测专业委员会委员（2016-）。他是福建药理学会理事，江苏省和福建省“创新创业人才”综合评审员、教育部博士学科点专项科研基金评审员、国家自然科学基金函评和会评评审员、江西省科技厅评审员、科技部创新人才推进计划评审员、参与中国工程院与国家自然科学基金委联合开展的《中国工程科技2035发展战略研究》的咨询工作。2002年4月- 2011年12月，担任美国国立卫生研究院国家癌症研究所（NIH/NCI）的高级项目主管（级别GS14/step9）和高级药理研究员，负责新药研发（主要是抗癌药），指导药理毒理工作和参与新药申报。他参与过美国国立卫生研究院（NIH/ NCI）的12项新药申报，领导或参与过35项新药开发项目，获得和主持过17项新药研究课题。他设计、主持和主讲过50次国际药学学术会议。2008年至今，为中国科学院纳米材料和纳米安全生物效应重点实验室客座教授、中国药科大学讲课教授。先后在加利福尼亚州立大学、圣地亚哥医学院和La Jolla Pharmaceuticals任高级研究员。2000-2002年担任美国德州圣安东尼奥药物开发研究所/癌症治疗和研究中心副主任和Associate Member。受聘为12家专业期刊任副主编、或编委。
论著成果 他在美国纽约州立大学，师从1998年诺贝尔奖获得者、著名药理学教授Robert Furchgott博士获得药理学博士学位。他发表论文和论著>140篇(大多数为一作或通讯作者)，会议文摘110篇。 论文发表在国际自然科学顶尖学术杂志（Nature、Science、PNAS）及专业主流高影响因子学术刊物（Nano Today、Adv. Funct. Mater、Theranostics、Trends Pharm Sci、Trends Biotech、Biotech Adv、Cancer Res、J. Control Release、Blood、Drug Disc Today、Eur.J. Cancer、Oncotarget等）。论文总引用次数>5,000，h-index 28, i10-index 50; 总影响因子IF>750。
获得的重要奖项有：
•  1997年获得全军科技进步一等奖（第一名）；
• 1999年11月，经中国教育部批准，入选为中国医学科学院国家第二批长江学者奖励计划教授（后因故未赴任）；
•  2004年,获得美国国立卫生研究院(NIH)颁发的NIH荣誉奖；
• 2011年荣获美国药学会（AAPS）会士（Fellow）称号,以认可他对国际药学研究的重要影响。
• 2011年福建省引进高层次创业创新“百人计划”人才；
• 2012年福建省高校100领军人物入选者；
•  2014年由福州市第十四届人大常委会第十七次会议审议通过，授予他“福州市荣誉市民”称号，以表彰其“在促进福州市经济社会发展和扩大对外交流合作等方面做出的突出贡献”；
• 2014-2015年二度入选为“2014年、2015年中国高被引学者榜单”。中国高被引学者榜单的研究数据来自Scopus数据库。Scopus是全球最大的同行评议学术论文索引摘要数据库。

Curriculum Vitae
 
Name: Lee Jia
 
Business Address: 523 Industry Road, Science Building, 3FL., Cancer Metastasis Alert and Prevention Center, College of Chemistry, Fuzhou University, Fuzhou, Fujian 350002, China;
 
Business Email and Phone: pharmlink@gmail.com; cmapcjia1234@163.com Phone: 0591-83576912 (China);
 
EDUCATION:
 
1994-1996 Post-Doctoral Fellow, Department of Medicine, Divisions of Respiratory & Cardiovascular Medicine, Duke University Medical Center, Durham, NC, USA
 
1990-1994 Ph.D. (Pharmacology), State University of New York, NY, USA: Mentor Dr. Robert F. Furchgott, the 1998 Nobel Laureate.
 
1984-1987 M.S. (Pharmaceutical Science), China Pharmaceutical University, China
 
1978-1982 B.S.  (Pharmacy), Fudan University, College of Pharmacy, China.
 
PROFESSIONAL & ADMINISTRATIVE Appointments 
  
01/2012-present Distinguished Professor, “The China Recruitment Program of Global Experts” (1000-talent plan); Founding Director, Cancer Metastasis Prevention & Alert Center, Fuzhou University, China.
 
09/2014-present Director, Biopharmaceutical Photocatalysis of State Key Laboratory of Photocatalysis on Energy and Environment, Fuzhou University
 
12/2015-present Director, Fujian Provincial Key Laboratory of Cancer Metastasis Chemoprevention and Chemotherapy (Fuzhou University）
 
4/2005-4/2012 Senior Pharmacologist; Senior Project Officer (Permanent Tenure, GS14/Step 9), Toxicology and Pharmacology Branch, Developmental Therapeutics Program (DTP), Division of Cancer Treatment & Diagnosis, National Cancer Institute/ NIH; Rockville, MD.

4/2002-2005 Senior Pharmacologist; Project Officer (Conditional Tenure, GS14/
Step 6), Developmental Therapeutics Program (DTP), Division of Cancer Treatment & Diagnosis, National Cancer Institute/ NIH; Rockville, MD.
 
2008-Present Visiting Professor, Chinese Academy of Science Key Laboratory for Biomedical Effects of Nanomaterials and Nano-safety, Beijing, China.  
 
2/2000-3/2002 Associate Director, Department of Translational Research; Head, PK/PD Laboratory. Institute for Drug Development/ Cancer Therapy & Research Center, San Antonio, TX;
 
5/2000-3/2002 Associate Member (equivalent to Associate Professor), San Antonio Cancer Institute, San Antonio, TX.
 
1998-1999 Group Leader and Member of IACUC (Institutional Animal Care and Use Committee), La Jolla Pharmaceutical Company, San Diego, CA.
 
1996-1998 Senior Researcher, Dept. of Medicine, Uni. California San Diego, CA.   
            Visiting Scholar, Chinese Academy of Medical Sciences, Beijing, China.
 
1994-1996 Post-doctor, NitroMed Inc. / Department of Medicine, Divisions of Respiratory & Cardiovascular Medicine, Duke University Medical Center, Durham, NC.
 
1990-1994 PhD. Research supervised by Dr. Robert F. Furchgott, the 1998 Nobel Laureate, SUNY, NY.
 
1987-1989  Project Leader, Clinical Pharmacy and Pharmacology, East Hospital, China
 
PROFESSIONAL MEMBERSHIPS, ACTIVITIES AND AWARDS:

· 2015 Most Cited Chinese Researchers selected by Scopus/ Elsevier Research Intelligence 
· 2014 Most Cited Chinese Researchers selected by Scopus/ Elsevier Research Intelligence 
· Committee of Botanic Drug Metabolism and Clinical Monitoring Society/ World Federation of Chinese Medicine Societies 世界中医药学联合会/ 植物药代谢与临床监测专业委员会委员 (2016-present)
· Commission Member of Free Radical Biology and Medicine, The Biophysical Society of China (中國生物物理學會自由基生物學與自由基醫學專業委員會, 2014-president) 
· “Honorable Fuzhou Citizen” (2014) awarded by the Fuzhou City Standing Committee for his outstanding contributions to the promotion of the development and expansion of international exchanges and cooperation to make the economic and social prosper of Fuzhou   
· The China Recruitment Program of Global Experts Award (2011)
· The Fujian Science & Technology Innovation Leadership Award (2011).
· Member, American Association of Pharmaceutical Scientists (AAPS, 135447)
· Committee, Fujian Pharmacological Society, China (2012-present)
· Vice-Chair, Chair-elect, Chair and Past Chair (2009-2013), AAPS Drug Design & Discovery Section
· 2012 AAPS Program Coordination Committee, Award Committee 
· 2011 AAPS annual meeting programming committee
· Chair-elected (2007-2009), and Chair (2009-2010), AAPS CRO Focus Group (600+ members) 
· AAPS Nanotechnology Focus Group Steering Committee
· AAPS Fellow (2011) 
· Member, American Association for Cancer Research (AACR, 75164)
· Member, American Society of Gene & Cell Therapy (ASGCT; 2016- present; Member ID25579; account/code: LeeJia541123)
· Member, American Heart Association (1997-2000)
· Executive Board Member, State University of New York Alumni Association (2004-2010)
· 2004 National Cancer Institute Merit Awards
· 1998 American Heart Society Travelship Award 
· Yangtze River (Changjiang) Scholar Distinguished Professor (1999);
· First-class Army Science and Technology Progress Award: S-nitrosohemoglobin,1997
· Vice Chair, Graduate Student Association, China Pharmaceutical University (1985-1987)  
 
EDITORIAL SERVICES
 
Organize review processes for submitted manuscripts, including identifying and inviting qualified reviewers, analyzing reviewers’ critiques, comments, and overall scores to make final fair justifications, setting criteria for acceptance, rejection, and revision.    
 
1. Associate Editor, Current Drug Metabolism (2005-present);
2. Editorial Advisory Board Member, Current NanoSciences (2005-present); 
3. International Editorial Advisory Board, Therapeutic Delivery (2010-present);
4. Editorial Board Member, Pharmaceutica Analytica Acta (2010-present)
5. Editorial Board Member, Pharmaceutical Regulatory Affairs (OMICS Publishing Group; 2011-pesent)
6. Editorial Board Member, International J. Tumor Therapy; Scientific & Academic Publishing (2011-Present)
7. Associate Editor, Drug Metabolism Letter (2007-present);
8. Editorial Advisory Board Member, Current Bioactive Compounds (2007-present);
9. Editorial Board Member, The Open Drug Metabolism Journal (2008-present);
10. Editorial Advisory Board Member, The Open Drug Delivery Journal (2008-present);
11. 《药物分析杂志》特邀编委(Editor, Pharmaceutical analysis Journal)（2012年--）
12. 《贵阳医学院学报》特邀编委(Editor, Guiyang Medicinal College J.)（2013年--）
13. Advisor to the Science and Technology Group Publishers (2008-present);
  
Invited  or ad hoc Reviewers for the Following 40 Journals:
 
1. Cell Biology & Toxicology; 
2. J. Pharm. Sci; 
3. Brain Research; 
4. Biochem Pharmacol; 
5. Letters in Drug Design & Discovery; 
6. Rapid Communications in Mass Spectrometry; 
7. Biopharmaceutics & Drug Disposition; 
8. J. Pharm. BioMed. Anal; 
9. Clinica Chimica Acta; 
10. NeuroScience Letters; 
11. J. Pharmacol. Exp. Ther; 
12. Molecular Pharmacology; 
13. Anti-Cancer Agents in Medicinal Chemistry; 
14. Current Drug Metabolism; 
15. Bioorganic & Medicinal Chemistry Letters; 
16. Biomedical Chromatography; 
17. J. Chromatography; 
18. Planta Medica; 
19. Xenobiotics; 
20. Molecular Pharmaceutics; 
21. Acta Pharmacol Sin.; 
22. Drug Metabolism Letter; 
23. Curr. NanoScience; 
24. Arch Pharmacol.; 
25. Drug Metabolism and Disposition (ASPET); 
26. Toxicology Letter;
27. Biomaterials
28. Chinese Medicine
29. Current HIV Research
30. J. NanoSci. NanoTech.
31. Therapeutic Delivery
32. Journal of Medicinal Plant Research
33. Drug Discovery Today
34. Biomaterials (IF8.557)
35. Current Medicinal Chemistry
36. Toxicological Sciences
37. Journal of Acquired Immune Deficiency Syndromes (JAIDS)
38. The AAPS J
39. Oncotarget (IF6.63)
40. Science Translational Med (IF 15.8)
41. Chemical Science (IF9.21)
 
Abstracts Reviewer for Annual AAPS Conferences (2008-2010).
 
CONSULTANTSHIPS AND COMMITTEE SERVICES (selected):
 
2005 Reviewer for 5-year NIH/NCI pharmacology/ toxicology contract research applications
 
2009-2010 Peer-reviewer invited by the Medical Research Council (MRC) of South Africa (a statutory science council that is responsible for managing and funding research in South Africa) to evaluate the merit of research proposals submitted for funding.
 
2012-2014 Invited grant reviewer for National Natural Science Foundation of China (NSFC)
 
2011 Invited reviewer for the young 1000-plan award
 
2013 Invited reviewer for Jiangxi Province Science and Technology Innovative Project applications
 
2014-2015   Invited Oncology Study Section Review Site Panel of the National Natural Science Foundation of China (NSFC)
 
2013-2016   Invited Oncology or Pharmacology Study Section Grant Application Reviewer of the National Natural Science Foundation of China (NSFC)
 
10/2014 Committee of the innovative pharmaceutical research of outstanding scientist award
 
2011-2014 Committee of the AAPS annual meeting abstract Award/ travelship
 
2013-2014 Reviewer for 2014 AAPS Research Achievement Award in Drug Discovery and Development Interface (DDDI)
 
 
Invited Speaker, Conference MODerate and ORGANIZER: 
 
1. Presentation entitled “Discovery of nitric oxide/ EDRF and its pharmacological effects” in East Hospital, Fuzhou, China, June, 1997.
 
2. Invited speaker, “S-nitrosylation and related drug discovery and development”, Nov. 1997, in Shenyang PHARON Health Products Co. LTD.
  
3. Invited speaker, presentation title “L-Arginine increases GFR partially by nitric oxide independent mechanism via activity of agmatine”.1998 American Society of Nephrology Annual Conference, Philadelphia, Oct. 25, 1998.
 
4. Invited speaker, presentation title “Nitric Oxide Research: From Hypothesis to Drug Development” State University of New York at Buffalo, Nov., 2001.  
 
5. Speaker, presentation title “EDRF Activity, Anticancer Spectrum and Pharmacokinetics of JS-K” NCI-SAIC Frederick, MD. Oct. 18, 2002.
 
6. Invited speaker, presentation title “Nitric Oxide Research: From Hypothesis to Drug Development” Johnson & Johnson Pharmaceuticals, San Diego, CA. Feb. 2002.  
 
7. Speaker, presentation title ‘Stability of JS-K in Biomatrices’ at NCI-SAIC Frederick, MD. Oct. 16, 2003.
 
8. Speaker, presentation title ‘Public-private partnerships for development of 2nd generation of ethambutol analogs for tuberculosis treatment’. Sequella, Inc. Rockville, MD, Dec. 2, 2003.
 
9. Invited speaker, presentation title “Nitric Oxide Research: From Hypothesis to Drug Development” in Division of Applied Pharmacology Research, OTR/OPS/CDER/FDA, April, 2004.  
 
10. Speaker, presentation title ‘Interspecies pharmacokinetics of SQ109 and its metabolism profile’ Sequella, Inc. Rockville, MD. Aug. 3, 2004.
 
11. Speaker, presentation title “In vitro and in vivo testing of JSK”. NCI-Frederick, MD 10/26/2006
 
12. Speaker, Moderator and Organizer, presentation title “GLP-Regulations and Inspections in USA and China: Differences, Similarities and Case Analysis” in the two-day conference “Pharmaceutical Outsourcing: Regulations, IP, Technology, Capabilities, and Partnership” Shanghai, China, April 2-4, 2007, co-sponsored by Fudan University (SPFDU) and AAPS.
 
13. Speaker, Moderator and Organizer, presentation title “New Drug Applications in USA and China: Acceptability, Data Requirements and Benefit/Risk Analyses” in the two-day conference “Pharmaceutical Outsourcing: Regulations, IP, Technology, Capabilities, and Partnership” Shanghai, China, April 2-4, 2007. I designed topics and agenda, invited prominent experts for presentations.
 
14. Moderator and Organizer of the symposium entitled “Exploratory IND (phase 0 trial) and its practices” at the 2007 annual National Biotechnology Conference. San Diego, CA June, 26. 2007. I designed topics and agenda, invited leaders from the FDA, NIH, and Pharmaceutics who drafted or implemented the Phase 0 trials for presentations.
 
15. Speaker, presented “Differences and similarities between USA and China in new drug application procedures and regulations”. Global R&D Congress, May 29-30, 2008, in Washington, DC,
 
16. Moderator: 2008 AAPS, November 19, 2008. Georgia World Congress Center, Atlanta, Georgia, USA. “Outsourcing Drug Product Development to India and China” (Roundtable).
 
17. Session Chair and Speaker, presented ‘Sino-USA collaboration: challenges and opportunities for advancing nanomedicine’, moderated a brainstorm panel session at The 1st Joint US-China Symposium on Nanobiology and NanoMedicine, Oct. 21-23, 2008; Fragrant Hill, Beijing, China;
 
18. Moderator and Speaker: “Celebrating the Nanotechnology R&D Act: Then, Now and the Future” (Symposium), 2008 AAPS, November, 20, 2008. Georgia World Congress Center, Atlanta, Georgia, USA.
 
19. Interviewed by Pharmaceutical Technology’s Live Vidcast, Nov. 18, 2008, on “Nanotechnology in Pharmaceutical Applications”. 
 
20. Speaker: “From Hypothesis to Discovery: Untold Stories about the 1998 Nobel Prize In Medicine─Maximize Your Research Achievements By Publications And Networking” to the School of Pharmacy, Fujian Medical University, April 2, 2009.
 
21. Invited Speaker: “From Hypothesis to Discovery: Untold Stories about the 1998 Nobel Prize In Medicine─Maximize Your Research Achievements By Publications And Networking” to the Nanobiological Center of Shanghai University, April 6, 2009.
 
22. Invited speaker: “Differences and similarities in GLP-regulations and inspections between USA and China”, presented at Medicilon, Inc. April, 7. 2009.
 
23. Invited Speaker: “Comparison of new drug application procedures and regulations between USA and China” at “China 2009 Pharmaceutical R&D Summit” 4th International Conference & Exhibition, April 7-9, 2009 • Grand Hyatt Hotel • Shanghai, China.
 
24. Invited Speaker: “From Hypothesis to Discovery: Untold Stories about the 1998 Nobel Prize in Medicine─Maximize Your Research Achievements by Publications and Networking” to the School of Pharmacy Fudan University, April 9, 2009.
 
25. Invited Speaker: “From Hypothesis to Discovery: Untold Stories about the 1998 Nobel Prize in Medicine─Maximize Your Research Achievements By Publications And Networking” to the China Pharmaceutical University, April 10, 2009.
 
26. Seminar entitled “The Four-decade War on Cancer: Are We Winning???” presented to South China Center for Innovative Pharmaceuticals, Nov. 18, 2009.
 
27. Speaker, presentation title “Anti-HIV drug development involved in ADME and nanotechnology”, and moderator at International Symposium of NanoMedicine on AIDS/HIV sponsored by Beijing University of Technology, the National Center for Nanosciences and Technology of China, AAPS, Chinese Academy of Sciences and Chinese Ministry of Science and Technology (MOST), Beijing, China; Nov.19-20, 2009.
 
28. “Why we are not winning the war on cancer and how to lead the war to win: my view, my dreams and my strategies” presented at Graduate School of Pharmacy, Shanghai Jiao Tong University. Nov. 20. 2009.
 
29. Invited Speaker, “Contemporary understanding of the Millennium Phytomedicine― Ginseng” in Symposium: The Appalachian Center for Ethnobotanical Studies (ACES) in Tai Sophia Institute in Laurel, MD, on Saturday 26 June 2010. 
 
30. Invited Speaker, “The four-decade war on cancer: are we winning?” in Capital Medical University, Beijing, China. 10/25/2010, afternoon  
 
31. Invited Speaker, “The four-decade war on cancer: are we winning?” in Symposium 6: Advances of Drug Discover against cancers, The 8th Annual Congress of International Drug Discovery Science and Technology. 10/26/2010, 9:45-10:10 am  
 
32. Invited Speaker, “Current understanding of cancer metastasis requires changes in strategies of anticancer drug development”, in symposium 5 of annual Chinese Pharmaceutical Association Conference; Beijing, China, 11/7/2010, 9:15-9:35 am
 
33. Symposium: “Re-Engineering Nanomaterials with Biomolecules: Strategies, In Vivo Stability and Specificity, and Drugability", as both the moderator and speaker for the 2011 National Biotechnology Conference, Wednesday, May 18, 2011, from 1:30 pm - 4:00 pm, at the Hilton San Francisco, CA.
 
34. Invited Speaker, “From understanding the complex of cancer metastasis to designing cancer nanomedicine: what nanomedicines can and can’t succeed” and moderator of Nano-pharmaceutics Session at the International conference of 2011 China Nano, at the National Convention Center, Beijing. Sept.7-9, 2011.
 
35. Designed and Chaired the Hot topic: “The heating-up of pharmaceutical globalization:  current mergers and acquisitions by Chinese Pharma in the USA and basic knowledge of laws about drug importation to China”. October 24, 2011 12:15 PM – 1:30 PM, at the Walter E. Washington Convention Center, Washington, DC. USA (attendees 500)
  
36. Session Chair, Symposium: “Global Competition and Geopolitical Priorities for Bionanotechnology R&D”. 9:00-11:00 am, Oct 25, 2011. Convention Center, Washington DC, USA. The 2011 AAPS.
 
37. Speaker, Jia: “The market and contemporary understanding of the millennium phytomedicine-ginseng” and Session Chair “Evaluating Drug Development Opportunities in Botanical Polymolecular Therapeutics”. Time: Wed. 8:30-11:00 am, 10/26/2011; Place: Washington DC convention CTR.
 
38. Speaker, Jia: “Overview of Global Development of Photodynamic Therapy for Cancer and   China’s First Generation of Photosensitizer ZnPcS2P2” and co-Chaired the session “Nanobiotechnology” with Dr. Chen Wang, Director, National CTR for Nanoscience & Technology; 19:20-22:00, Oct. 31, 2011. 17th International Biophysics Congress, Beijing.
 
39. Invited speaker “Contemporary understanding of the nutraceutical ginseng: its anti-diabetic and cancer preventive effects and possible interaction with Warfarin”, and Session Chair “2012 International Conference on Ginseng”, Jilin, Chair; Sept. 4-7, 2012. (260 Attendees)
 
40. Invited speaker and organizer “The 40-year war on cancer: are we winning or Losing, and our strategies” at Fujian Pharmacological Society Conference (150 attendees), Fuzhou, Nov. 17th, 2012. Fujian Pharmacology Society, China.
 
41. Invited speaker “Re-engineering PAMAM dendrimer for its multivalent binding to colon cancer cells HT29” at The 3rd Joint US-China Symposium on Nanobiology and NanoMedicine, Dec. 5-7, 2012; Fragrant Hill, Beijing, China; 第449次北京香山科学会议、即第3次中美癌症纳米技术和纳米医学研讨会（2012年12月5-7日）
 
42. Invited speaker “Restrain activity of circulating tumor cells: the new strategy for preventing cancer from metastasis” at the China-US translational medicine international forum (250 attendees), 中国科协15届年会 (Chinese Association of Scientists)；Guiyan medical university, May 25, 2013.
 
43. Invited speaker “The new strategy to prevent cancer from metastasis: restrain circulating tumor cells” at the 2013 AAPS@ China Symposium, the Chinese University of Hong Kong, August 17-18, 2013.
 
44. Invited speaker and organizer “From endothelium-derived relaxing factor (EDRF)
to intervention of adhesion-invasion of circulating tumor cells (CTCs) to endothelium: a new horizon in biomedical nitric oxide research” at the 2014 International Nitric Oxide Conference, Shanghai Jiaotong University. July 5-6th, 2014.
 
45. Invited speaker and Section Chair: “Enhanced sensitivity and specificity of capturing and restraining circulating tumour cells in blood with dual antibody-coated nanomaterials” China Nanobiomedicine conference, Chenddu, 2014-11-05 China nanobiology and nanomedicine conference (全国纳米生物与医学学术会议-成都)
 
46. Invited speaker and Section Chair: “Nitric oxide prevents cancer metastasis by interrupting adhesion-invasion of circulating tumor cells to endothelium” in the 8th Pong Ding Yuen International Symposium on Traditional Chinese Medicine cum The 2nd International Chinese Symposium on Free Radical Research & The 6th Symposium for Three Districts of Cross-straits on Free Radical Research; University of Hong Kong, November 14-16, 2014.
 
47. Invited speaker “From endothelium-derived relaxing factor (EDRF) to intervention of adhesion-invasion of circulating tumor cells (CTCs) to endothelium: a new horizon in biomedical nitric oxide research” Chinese Pharm. University. Nov. 17, 2014.
 
48. Invited speaker: “Nitric oxide prevents cancer metastasis by interrupting adhesion-invasion of circulating tumor cells to endothelium” Fujian Chinese Medicine University. Nov. 20, 2014.
 
49. Invited speaker: “From Imitation to Innovation: the Ten-year Chinese Bionanotechnology Development” China Nanomedicine Conference, Hangzhou, April 7-9, 2015
 
50. Invited speaker: “The unique bionanotechnology conception focuses on cancer pre-metastatic prevention for tens of millions of survivorship" Nature Nanotechnology Forum at Fudan University, May 25th, 2015.
 
51. Invited speaker: “Separation, detection, capture and restraining of circulating tumor cells for cancer metastasis prevention for the increasing cancer survivors”BD Shanghai July 2015
 
52. Invited speaker: “Bionanotechnology used for capturing and restraining circulating tumor cells: eliminating the suffering and death from cancer metastasis” Dong, HY., Lu, Y., Xu, JG., Zheng, N., Liu, J. Jia,*L. ChinaNano 2015 meeting; Sept. 3-5, Beijing
 
53. Invited speaker: “Development of theranostical nanomedicine to specifically target circulating tumor cells (CTCs)” Jianguo Xu, Haiyan Dong, Yusheng Lu, Ning Zheng, Jian Liu, Lee Jia* 2015年中华放射学会年会，哈尔滨，9月17-20日“精准与可视化”专题
 
54. Invited speaker: “避孕药美她司酮用于二性预防肿瘤手术后的再转移：研究背景、现状、及其药代动力学的性别特征”. 中国药理学会全国药代动力学会议；济南，2015-10-10/12.分会场主持。
 
55. Invited speaker: “Novel strategy: shifting from traditional anticancer drugs and nanomedicines to circulating-tumor-cell-based metastasis chemoprevention (创新研发战略：从传统的抗癌药和纳米药物向基于循环肿瘤细胞的肿瘤转移的化学预防转变”。Suzhou Institute of Nano-Tech and Nano-Bionics Chinese Academy of Sciences, Oct., 13th, 2015.
 
56. Invited speaker: “Overview of Global Development of Photodynamic Therapy for Cancer and Our Contribution to Biopharmaceutical Photocatalysis” at the 2nd Fuzhou University-Osaka Prefecture Uni. Joint International Symposium. Oct., 30th 2015；Fuzhou Uni.
 
57. Invited speaker: “from the 1971 Cancer Act and NCI founded to today’s global cancer therapy: cancer metastatic alert and chemoprevention”. Aug. 6-7th 2016; Beijing; PLA 302 Hospital. The first NIH/USA overseas returnee scholar forum.
 
58. Organizer and Invited speaker: “Global deregulation of ginseng products may be life-threatening to warfarin takers: solid evidence of serious ginseng-warfarin interaction” International Conference on Ginseng 2016 Jilin, China; Sept. 6-9, 2016; Changchun.     
 
PRE-IND Packages and Meetings with FDA and IND APPLICATIONS: 
 
1. Pyrrolobenzodiazepine (SJG-136), Preclinical pharmacology summary prepared by Jia. (Date filed: July 14, 2004; FDA IND# 70218; FDA approved August 13, 2004)
 
2. Pre-IND packages and meetings with FDA and Sponsors: LIV-1, a novel drug delivery system to deliver 5-FU to hepatocytes and hepatoma cells to treat hepatocellular carcinoma (HCC). Cell-Works, Inc. Feb, 2003.
 
3. R(-)Gossypol (AT-101), FDA IND# 68255: Pharmacology Summary prepared partially by Jia; Sponsor: Ascenta Therapeutics, 2005.
 
4. SQ109, FDA IND# 69597: Pharmacology Summary prepared by Jia; Sponsor: Sequella, Inc. Filed in Sept. 2006.
 
5. MV-NIS virus, a live tissue culture adapted measles virus selectively targeting human myeloma cells. FDA IND# 13023. May 3rd, 2006.
 
6. Batracylin (NSC 320846): Pharmacology and Toxicology Summary prepared by Jia for IND filing; IND# 76254; Sponsor: National Cancer Institute. Completed in March, 2006.
 
7. 1-methyl-[D]-tryptophan (NSC721782; IND#78060): Pharmacology and Toxicology Summary prepared by Jia for IND filing; Sponsors: NCI and NewLink Co. Completed Aug., 2006. IND meeting: July 19, 2007.
 
8. P-28 peptide (IND# 77754) Pre-IND meeting with FDA July, 12, 2007; IND submitted July 8, 2008.
 
9. Development of allopregnanolone in Neiman-Pick type C disease (NP-C) PIND-74900 for treatment of inherited mitochondrial respiratory chain diseases; Pre-IND on Oct 17, 2006; White oak, Building 22/FDA; Sponsor: Edison Pharm.
 
10. Pre-IND meeting with FDA for single chain urokinase plasminogen activator (ScuPA) (PIND 106014) development; Oct. 27, 2009.
 
11. Pre-IND meeting with FDA for SPINALON designed to prevent or reverse chronic immobility-related health problems typically found in spinal cord-injured patients; Jan. 14, 2010.
 
12. Pre-IND meeting with FDA for development of PEG-hemoglobin-based oxygen carriers (HBOC) for AfterShock treatment; Feb., 23, 2010, at FDA Woodmont Office Building, Rockville, MD.
 
PATENTS:
 
1. Jia, L.: Method of synthesis of S-nitrosocaptopril crystals and the use thereof (issued as both the inventor and owner: CO7D207/16).
 
2. Jia, L. Garza, M, Wong, H, Redelmeier, T.E.: Intravenous carbendazim compositions (filed as inventor).
 
3. Jia, L: Method and compounds that prevent circulating tumor cells from adhesion and extravasations to distant organs (filed as the inventor and owner: file # 201110338508.9) 专利授权号：ZL 2011 10338508.9 干预循环肿瘤细胞粘附和浸润到外周组织的药物和新方法。
 
4. Jia, L.: Medicinal combination that prevent cancer metastasis after surgical removal of primary tumors (filed as the inventor and owner: file # 201210379714.9) 专利申请号201210379714.9   预防原发性肿瘤在手术切除后再转移的药用组合物
 
5. 陈海军，贾力(Lee Jia)，刘剑，俞雪梅， 陈晓云，黄惠龄、王继闯，高瑜。一种合成美她司酮的方法专利授权号（patent issued#：ZL 2013 1 0510394.0.‍ (Method of synthesis metapristone;
 
6. 高瑜，李志洪，王超群，陈海军，贾力。具有肿瘤靶向的叶酸-PAMAM-熊果酸纳米药物及其制备方法。专利授权号：ZL201410271351.6。
 
7. 高瑜，吴福强，顾颂恩，李志洪，解晓东，陈海军，贾力。一种米非司酮脂质体制剂及其制备方法。申请号：201410219537.7。
 
8. 高瑜，贾力，顾颂恩。一种抗体偶联的介孔二氧化硅/米非司酮纳米制剂。申请号：201510635471.4.
 
9. 江舟，杨纪娜， 庞雅琼， 王建， 贾力(Lee Jia). “一种九里香香豆素及其提取方法”中国专利授权号(patent issued#：201510003203.0; Method of extracting coumarins from Murraya exotica).
 
10. 贾力(Lee Jia)，卢余盛，于婷，梁海燕。斯诺普利在制备预防肿瘤转移或肿瘤治疗药物中的应用。专利申请号(patent file#：201410609416.3‍; Method of using S-nitrosocaptopril for  cancer metastasis prevention or cancer treatment)
 
11. 贾力(Lee Jia)、谢静静、陈红宁; 专利名称：识别、捕获和抑制循环肿瘤细胞的功能纳米材料载药系统;专利申请号(patent file#：201410639414.9; Functionalized nanomaterial carrier for recognizing, capturing and inhibiting circulating tumor cells)
 
12. 江舟，庞雅琼，周素霞，王建，贾力(Lee Jia); 专利名称：六甲氧基二氢黄酮-鼠李糖基-鼠李糖苷在肿瘤转移预防中的应用（patent file#:201510596604.1）
 
13. 江舟，马骁，张俨君，王锐，王建，余素红，贾力..怀牛膝和川牛膝中的牛膝皂苷 (已公示)。
 
 
Managed and directed NIH Contract research Funding 
 
1. Southern Research Institute (NO1-CM-52203) Total budget $ 2,774,595 from 2005-2011 for preclinical pharmacological studies of antitumor and other therapeutic agents.
 
2. Mayo Clinic (NO1-CM-52206) Total budge $1,828,875 from 2005-2011 for preclinical pharmacological studies of antitumor and other therapeutic agents.
 
3. University of Alabama at Birmingham (NO1-CM-52207) Total budget $ 1,714,794 from 2005-2011 for preclinical pharmacological studies of antitumor and other therapeutic agents.
  
FundingS 
 
1. Title: Nitric Oxide in Apoptosis: S-nitrosocaspases and Cytochrome C (Jan. 1998) PI: Jia, L.
CA-98-003, Outstanding Scholars Program (K22), Supported by NCI. $150,000/year for 4 yr.
 
2. Title: Development of a proteomic database for cancer prevention and treatment (Feb. 2001) PI: Jia, L. 5% effort, Supported by SACI. $21,500 for one year.
 
3. Title: Pharmaceutical development of 301029, an antiviral drug (March, 2000-June, 2001) PI: Jia, L., Supported by The Procter and Gamble Co. P&G 250-259. $350,000
 
4. Title: Pharmaceutical development of FB642 (Carbendazim) as an anticancer drug (May, 2000- Sept. 2001) PI: Jia, L., Supported by The Procter and Gamble Co. P&G 210-233. $ 550,000.
 
5. Title: Dynamic analysis of pharmacoproteomic effects of docetaxel and nitric oxide on prostate cancer cells (March 21, 2001) PI: Jia, L. 25% effort, PC010169; Submitted to Department of Defense, Prostate Cancer Research Program. $326,085 for 3 yrs.
 
6. Title: Urinary proteomic analysis of normal and prostate cancer patients using LC/MS/MS (Nov. 2, 2001) PI: Jia, L. Submitted to SA Area Foundation $34,700 for one year.
 
7. Title: Discovery of novel prostate cancer biomarkers from patient’s specimens by LC/MS/MS-based proteomics (January 30, 2002) PI: Jia, L. Cancer Center Council $46,050/year.
 
8. Title: Anti-tuberculosis SQ109 development (Sept. 2003-Feb. 2005); co-PI: Jia, L 15% effort; $211,900, NO1-CM-07710, NO1-CM-52203;
 
9. Title: PK/PD study with GGTI inhibitor GGTI-2418 (10/2005-1/2007); PI $87,387; NO1-CM-52203;
 
10. Title: Development of Phor21-BCG(ala), a lytic peptide conjugate (04/2004- 10/2004); PI $112,000, NO1-CM-07110.
 
11. Title: Development of pro-apoptotic Apogossypol, a Gossypol metabolite (08/2004- 11/2005); PI $190,000; NO1-CM-52203; NO1-CM-52205; NO1-CM-07110.  
 
12. Title: Anticancer drug 1-methyl-D-trytophan development (02/2004-04/2007); PI, $180,000, NO1-CM42201; NO1-CM52206; NO1-CM-07105.
 
13. Title: Anticancer dimeric pyrrolobenzodiazepine SJG-136 PK/PD characterization (12/2002-06/2003); PI, $183,740; NO1-CM-07105.
 
14. Title: Nitric oxide prodrug JS-K pharmacology and formulation development (08/2002-06/2009); PI, $237,000; NO1-CM-52206; NO1-CM-07105.
 
15. Title: Azurim p-28 toxicology, pharmacology and metabolism (06/2007-05/2008); PI, $92,790; NO1-CM-52203.
 
16. Title: Pharmacology of the novel investigative anti-cancer indolecarboxamide ML-970 (03/2008- 09/2009); co-PI, $363,000; NO1-CM-52207.
 
17. Title: Safety evaluation of new formulations (11/2007-05/2008); PI. $346,560; NO1-CM-52203.
 
18. Title: Patient pharmacokinetics of Topotecan and PARP inhibitor ABT888 (05/2007-12/2009); co-PI. $173,500; NO1-CM-52206.
 
19. Fuzhou University Start-up fund ￥10 millions (01/2012-present)   
 
20. Title：Interference by nitric oxide with adhesion of circulating tumor cells to vascular endothelium (01/2013-12/2016). PI. Natural Science Foundation of China NSFC81273548. ￥650,000.
 
21. Title: Innovative research team start-up fund; PI￥1.5M, 2013-2014; from the China Finance Department of Central Government.   
 
22. 973 program: 项目编号：Ministry of Science and Technology of China (2015CB931804); Project title: Basic research for novel nanomaterial image probes for in vivo lung cancer classification 2015/01—2019/12; Sub-project title: Lung cancer personal treatment and resultant evaluation based on in vivo lung carcinoma classification. 项目名称：肺癌在体分子分型的新型纳米分子成像探针基础研究; 课题组: 基于在体分子分型的肺癌个体化治疗及评价; 项目起止时间：2015年1月-2019年12月; ￥5.25 millions.
 
23. Fujian Development and Reform Commission project# 829054(2014;168); ￥500,000; Development of novel cancer metastasis chemopreventive agent Metapristone; period, 2014-2016.
 
24. NSFC program: Frontier researches on bioactive materials extracted from Murraya paniculata widely-grown in Fujian and Taiwan, their mechanism of actions and drugability used for cancer metastasis chemoprevention after operation(闽台盛产九里香用于预防肿瘤手术后再转移的药效物质基础、作用机制及其成药性的前沿研究) U1505225; ￥2.58M, 2016.01 to 2019.12
 
 
BIBLIOGRAPHY
 
PUBLICATIONS:
 
1. Jia, L*. Chemistry, pharmacology, toxicity and clinical uses of Tripterygium Wilfordii.    J.  Chinese  Pharmaceutical  20: 101-106, 1985
               
2. Jia, L*. Studies on physicochemical stability of triptolide injection.  J. Chinese  Pharmaceutical  20: 629, 1985.                     
 
3 Jia, L* Probit analysis of LD50 of triptolide and its cytotoxicity.  Chinese J. Pharmacol Toxical.  1: 78-80, 1986.
 
4. Jia, L* Studies on angiotensin converting enzyme inhibitors. Prog. Physiol. Sci. 6:229-234, 1985.         
 
5. Jia, L* Hoe, D. H.: Negative chronotropic effects of meglumine cyclic adenylate on cardiac pacemaker in vitro and in vivo.   Acta  Pharmacol  Sin   9: 421-426, 1988.
 
6. Jia, L*, Hoe, D. H.: Antiarrhythmic effects of meglumine cyclic adenylate. Chinese J. Pharmacol. Toxical.  3: 251-255,1989.
 
7. Jia, L*,  Hoe, D. H.: Effects of meglumine cyclic adenylate on contractility, oxygen consumption and excitability of Langendorff heart and cardiac cells.  Chinese J. Pharmacol. Toxicol. 2:16-19,1988.
 
8. Jia, L*. Hoe, D. H.: Effects of meglumine cyclic adenylate on drug-induced positive chronotropic action in rabbit right atria.  Chinese J. Pharmacol  Toxicol.  2: 235-238, 1988.
 
9 Jia, L.: Adenosine Receptors and adenosine pharmacology.    Chinese  Pharmacol.  Bull. 5: 129-133, 1989.
 
11. Jia, L and Furchgott R.F.: Inhibition by sulfhydryl compounds of vascular  relaxation induced by nitric oxide and endothelium-derived relaxing factor  J. Pharmacol. Exp. Ther. 267:371-378, 1993    
 
12. Jia, L* Liu, X., Furchgott R. F.:  Blockade of nitric oxide-induced relaxation of rabbit aorta by cysteine and homocysteine. Acta.  Pharmacol.  Sin. 18(1):11-20, 1997.
 
13. Jia L, Bonaventura, C., Bonaventura, J. and Stamler, J. S.: S-nitrosohemoglobin:  a dynamic activity of blood involved in vascular control.    Nature    380: 221-226, 1996                 
 
14. Simon, D.I., Mullins, M.E., Jia, L., Gaston, B., Singel, D. J., Stamler, J.S.: Polynitrosylated Proteins: Characterization, bioactivity and functional consequences.  Proc. Natl. Acad. Sci. U.S.A.  93: 4736-4741, 1996.
 
15. Day, B J, Jia L, Arnelle DR, Crapo, JD, and Stamler, JS.: Transduction of  NOS activity from endothelium to vascular smooth muscle: involvement of S-nitrosothiols  In  Biology of NO, ed. by Moncada, Stamler, Gross and Higgs, pp. 202-4  Portland Press, London, 1996.
 
16. Jia, L* Clinical trials and therapeutic implications of nitric oxide and its donors.  Pharmaceutical Commun Sin. (Review).     13: (3) 204-206, 1997,  
 
17. Stamler, J.S., Jia, L., Eu, J.P., McMahon, T.J., Demchenko, I.T., Bonaventura, J., Piantadosi, C.A.: Blood flow regulation by S-nitrosohemoglobin in the physiological oxygen gradient.    Science. 276: 2034-2037, 1997.
 
18. Lin, M, Yang X, Wang, J., Jia, B.J., Jia, L*.    Inhibitory effects of S-nitrosocaptopril on vasomotor tone.  Acta Pharmacol  Sin.    1998, 19 (5): 485-488.
 
19. Jia, L* and Stamler, J. S.: Dual actions of S-nitrosylated derivative of vasoactive intestinal peptide as a vasoactive intestinal peptide-like mediator and a nitric oxide carrier.  Eur.  J.  Pharmacol   1999, 366: 79-96.
 
20. Lin, M, Yang X, Wang, J., Jia, B.J., Jia, L. S-nitrosocaptopril preferentially decreases diastolic pressure in hypertensive models. Chinese Pharm. Bulletin  1999, 15(1) 73-76.  
 
21. Jia,L*., Blantz, RC. The effects of S-nitrosocaptopril on renal filtration and blood pressure in rats  Eur  J. Pharmacol. 1998, 354: 33-41.
 
22. Jia, L*. Young, X, Guo, W:  Physicochemistry, pharmacokinetics and pharmacodynamics of S-nitrosocaptopril crystals, a new nitric oxide donor    J.  Pharm.  Sci.  1999, 88: 981-986.
 
23 Jia, L* A design of a novel compound S-nitrosocaptopril possessing the capacities of both angiotensin converting enzyme inhibitors and nitric oxide donors. Prog. Physiol. Sci. 1999, 29: 12-15.
 
24. Jia, L* Nitric oxide research and new drugs: Challenges and success. Commentary on the 1998 Nobel Prize in Medicine.   Science (in Chinese) 1999, 51(2): 49-52.
 
25. Lin, M., Jia, L*. International principles of nomenclature and abbreviations of nitric oxide research. Prog. Physiol. Sci. 1999, 30(4): 376-78.  
 
 26. Jia, L*, Yu, L. Linnik, D.M., Jack, R.M.  Stability and Pharmacokinetics of LJP 920, an octameric Gal (a1-3) Gal conjugate for the inhibition of xenotransplantation rejection.   J. Pharm. Pharmacol. 53: 999-1005, 2001.
 
27. Jia, L*. Wu, C. Young, X: Anti-angiogenetic effects of S-nitrosocaptopril crystals as a nitric oxide donor.  Eur.  J.  Pharmacol.  391: 137-144, 2000.
 
28. Jia, L*. Pei, R. Lin, M. Young, X. Acute and subacute toxicity and efficacy of S- nitrosylated captopril, an ACE inhibitor possessing nitric oxide activities.  Food & Chem.  Toxicol. 39: 1135-1143, 2001.
 
29 Jia, L*. Garza, M. Wong, H. Camden, J. Redelmeier, T. Weitman, S. Pharmacokinetic comparison of intravenous carbendazim and remote loaded carbendazim liposomes in nude mice.  J. Pharm. Biomed Anal. 28(1): 65-72, 2002.
 
30. Wong, H. Jia, L*. Camden, J. Weitman, S. Liquid chromatography-mass spectrometry assay of a thiodiazole derivative in mice: application to pharmacokinetic studies.  J. Chromatogr. 765:55-62, 2001.
 
31. Jia, L*. Wong, H. In vitro and in vivo assessment of cellular permeability and pharmacodynamics of S-nitrosylated captopril, a nitric oxide donor. Br. J. Pharmacol. 134: 1697-1704, 2001
 
32. Jia, L*. Wong, H. Cerna, C. Weitman, S. Effect of nanonization on absorption of 301029: Ex vivo and in vivo pharmacokinetic correlations determined by LC/MS. Pharm. Res. 19:1091-1096, 2002.
 
33. Jia, L*. Wong, H. Wang, Y. Garza, M. Weitman, S. Carbendazim: Disposition, cellular permeability, metabolite identification and pharmacokinetic comparison with its nanoparticle. J. Pharm. Sci. 92:161-172, 2003.
 
34. Jia, L*. Schweizer, J. Cerna, C. Wong, H. Revilla, M. Effect of Nitric Oxide on Cytotoxicity of Taxol: enhanced Taxol transcellular permeability. Biochem Pharmacol. 66:2193-2199, 2003.
 
35. Jia, L*. Tomaszewski, J.E., Noker, P.E., Gorman, G.S., Glaze, E., Protopopova,M. Simultaneous determination of pharmacokinetic properties of three anti-tubercular ethambutol analogs resulting from combinatorial lead optimization. J. Pharm. Biomed Anal. 37(2), 23-33, 2005.
 
36. Jia, L*. Tomaszewski,J., Hanrahan, C. Coward, L. Noker, P. Gorman, L. Nikonenko, B. Protopopova, M. Pharmacodynamic and pharmacokinetic characteristics of SQ109, a new diamine-based antitubercular drug. Br. J. Pharmacol. 144, 80-87, 2005.
 
37. Jia, L*. Coward, L. Gorman, L. Noker, P. Tomaszewski, J. Pharmacoproteomic effects of isoniazid, ethambutol, and N-Geranyl-N'-(2-adamantyl)ethane-1,2-diamine (SQ109) on Mycobacterium tuberculosis H37Rv.  J. Pharmacol. Exp. Ther. 315, 905-911, 2005.
 
38. Saavedra, J.E., Srinivasan, A., Buzard, G.S., Davies, K.M., Waterhouse, D., Inami, K., Wilde, T.C., Citro, L.M., Cuellar, M., Deschamps, J.R., Parrish, D. Shami, P.J., Findlay, V.J. Jia, L., Ji, X., Keefer, L.K., PABA/NO as an anticancer lead: analogue synthesis, structure revision, solution chemistry, reactivity toward glutathione, and in vitro activity.  J. Med. Chem.  49, 1157-1164, 2006.
 
39. Jia, L*. Global governmental investment in nanotechnologies. Curr. NanoScience (Review) 1:(3) 263-266, 2005.
 
40. Jia, L*. Nanoparticle formulation Increases oral bioavailability of poorly soluble drugs: experimental evidences, theory, and approaches. Curr. NanoScience (Review) 1:(3) 237-243, 2005.
 
41. Coward, L.C. Kerstner-Wood, Noker, P., Gorman, G., Pellecchia, M., Reed, J.C., Jia, L*. Quantitative determination of Apogossypol, a pro-apoptotic analog of gossypol, in mouse plasma using LC/MS/MS. J. Pharm. Biomed. Anal. 42: 581-586, 2006.
 
42. Jia, L.*, Noker, P.E., Coward, L. Gorman, G. Protopopova, M., Tomaszewski, J.E. Interspecies pharmacokinetics and in vitro metabolism of SQ109   Br. J. Pharmacol. 147(5):476-85, 2006.
 
43. Buhrow, S.A., Reid, J.M., Jia, L., Covey, J., Kobs, D.J., Grossi, I. M., Ames, M.M. LC/MS/MS assay and dog pharmacokinetics of the dimeric pyrrolobenzodiazepine SJG-136 (NSC 694501).  J. Chromatogr.  2006; 840: 56-62.
 
44. Shami, PJ., Saavedra, J. E., Bonifant, C. L., Chu, J.; Udupi, V.; Malaviya, S.; Carr, B. I.; Kar, S.; Wang, M.; Jia, L.; Ji, X.; Keefer, L. K. Antitumor Activity of JS-K [O2-(2,4-Dinitrophenyl) 1-[(4-Ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate] and Related O2-Aryl Diazeniumdiolates in Vitro and in Vivo.  J. Med. Chem. 2006; 49(14); 4356-4366. 
 
45. Jia, L. Pharmaceutical Globalization: First International CRO/CMO Conference sponsored by the AAPS in China.  AAPS NewsMagazine 7(3): 67, 2007.
 
46. Jia, L*, Wang, Y., Zhu, YZ.  Pharmaceutical globalization urges cooperation between China and USA on GLP regulations. Chinese Medicine & Drugs Newspaper, March 22, 2007
 
47. Jia, L*., Zhu, Y., Wang, Y., Wu, W., Dong, Y.C., Zhang, R., Fu, L., Bi, H., Tam, J. Harmonising GLP rules in the US and China: The globalisation of the pharma industry means China and the US need bilateral agreements on GLP regulations. The Regulatory Affairs Journal  18(3):147-152, 2007.
 
48. Liu, X.D., Jia*, L. The conduct of drug metabolism studies considered good practice (I): analytical systems and in vivo studies. Curr. Drug Metab.  8: 815-821, 2007.
 
49. Jia, L*., Liu, X.D. The conduct of drug metabolism studies considered good practice (II): in vitro experiments. Curr. Drug Metab.  8: 822-829, 2007. 
 
50. Jia, L.*, Schweikart, K., Tomaszewski, J., Reed, J., Ames, M, Page, J., Noker, P., Munn, D. Toxicology and pharmacokinetics of 1-methyl-D-tryptophan: absence of toxicity due to saturating absorption.   Food Chem. Toxicol. 46: 203-211, 2008.
 
51. Jia, L.* Coward, L.C. Kerstner-Wood, Gorman, G., Noker, Kitada S, Pellecchia M P., Reed, J.C., Comparison of pharmacokinetic and metabolic profiling among gossypol, apogossypol and apogossypol hexaacetate.  Cancer Chemotherapy Pharmacol. 61: 63-73, 2008.
 
52. Liu, H.Y., Liu, X.D., Jia, L., Liu, Y.C., Yang, H.W., Wang, G.J., Xie, L.  Insulin therapy restores impaired function and expression of P-glycoprotein in blood–brain barrier of experimental diabetes.  Biochem. Pharmacol. 75: 1649-1658, 2008.
 
53. Jia*, L., Noker, P.E., Piazza, G.A., Leuschner, C., Hansel, W., Gorman, G.S., Coward, L.U., Tomaszewski, J. Pharmacokinetics and Pharmacodynamics of Phor21-βCG(ala), a lytic peptide conjugate. J. Pharm. Pharmacol. 60:1441-48, 2008.
 
54. Liang, X.J., Chen, C.Y., Zhao, Y.L., Jia, L., Wang, P.C. Biopharmaceutics and Therapeutic Potential of Engineered Nanomaterials.  Curr. Drug Metab. 9(8): 697-709, 2008.
 
55. Jia, L*. Drug discovery and development operations in emerging regions: global R&D congress. Thomson-Pharma, June, 2008 (invited conference proceedings)
 
56. Song, M., Wang, L., Hang, T., Wen, A., Yang, L., Jia, L. Rapid and sensitive liquid chromatography-tandem mass spectrometry for rasagiline: assay development, validation and application to a human pharmacokinetic study.  J. Chromatogr. 875:515-521, 2008.
 
57. Jia, L. The Great Meeting Held in the Bitter Cold Economic Climate: 2008 AAPS Annual Meeting and Exposition. Thomson-Pharma, December, 2008 (invited conference proceedings)
 
58. Kitada, S., Kress, C.L., Krajewska, M., Jia, L., Pellecchia, M., Reed, J.C. Bcl-2 antagonist ApoGossypol (NSC736630) displays single-agent activity in Bcl-2 transgenic mice and has superior efficacy with less toxicity compared to Gossypol (NSC19048).  Blood, 2008; 111: 3211 - 3219.
 
59. Zhang, TT., Song, M., Hang, HJ., Xu, XF., Wen, A.D.,Yang, L., Jia, L*. Pharmacokinetic profile of talipexole in healthy volunteers is not altered when it is co-administered with Madopar (co-beneldopa). J. Clin. Pharm. Ther.  33, 1-10, 2009.
 
60. Jia* L. Zhao, YQ. Current Evaluation of Ginseng (I): Etymology, Pharmacognosy, Phytochemistry, Market and Regulations. Curr. Med. Chem. 16: 2475-2484, 2009.
 
61. Jia*, L, Zhao, YQ. Liang, X.J. Current Evaluation of the Millennium Phytomedicine― Ginseng (II): Collected Chemical Entities, Modern Pharmacology, and Clinical Applications Emanated from Traditional Chinese Medicine.  Curr. Med. Chem. 16: 2924-2942, 2009.
 
62. Ni. L., Yu, X.,Yu, Q.，Chen, X., Jia, L*. Effects of cyclosporine A and itraconazole on permeability, biliary excretion and pharmacokinetics of amlodipine.  Drug Metab. Lett. 2(3): 163-168, 2008.
 
63. Meng, J., Wang, D.L., Wang, P.C., Jia, L., Chen, C., Liang, XJ. Biomedical Activities of Endohedral Metallofullerene Optimized for Nanopharmaceutics. J. NanoSci NanoTech., 10: 8610-7, 2010.
 
64. Jia*, L. Soldati, F. Ginseng, Asian (Panax ginseng); In Encyclopedia of Dietary Supplements. Ed by Coates PM. 2nd edition, pp.352-366, 2010; Informa Healthcare, New York, London. (Invited review).
 
65. Jia* L, Gu Y., Zeng E, Linnik, MD, Jones, DS. Biostability, Tissue Distribution and Disposition of LJP 993, a Tetrameric Conjugate of Domain 1 of b2-glycoprotein I for antiphospholipid syndrome. Lupus. 19: 130-137, 2010.
 
66. Kiziltepe, T., Anderson, K.C., Kutok, J.L., Jia, L., Saavedra, J.E., Keefer, L.K., Shami, P.J. JS-K has potent anti-angiogenic activity in vitro and inhibits tumor angiogenesis in a multiple myeloma model in vivo. J. Pharm. Pharmacol 62: 145-151, 2010.
 
67. Liang, XJ., Meng, H., Wang, Y., He, H., Meng, J., Lu, J., Wang, P., Zhao, YL., Gao, X., Sun, B., Chen, CY., Xing, GM., Shen, DW., Yin, JJ., Gottesman M., Jia, L.  Metallofullerene Nanoparticles Overcome Tumor Resistance to Cisplatin by Reactivating Endocytosis. Proc. Natl. Acad. Sci. U.S.A. 107: 7449-7454, 2010.
 
68. Tan, J.J., Cong, X.J., Hu, L.M., Wang, C.X., Jia, L, Liang, X.J. Therapeutic strategies underpinning the development of novel techniques for the treatment of HIV infection. Drug Discovery Today  15: 186-197; 2010.
 
69. Ma, X.W., Wang, D.L., Wu. Y., Ho, R.J.Y., Jia, L., Guo, P., Hu, L., Xing, G.M., Zeng, Y., Liang, X.J., AIDS Treatment with Novel Anti-HIV Compounds Improved by Nanotechnology. The AAPS Journal 12, 272-278, 2010.
 
70. Gorman, G., Coward, L., Kerstner-Wood, C., Noker, P., Beattie, C.W., *Jia, L. A novel and rapid LC/MS/MS assay for bioanalysis of Azurin p28 in serum and its pharmacokinetics in mice J. Pharm. BioMed. Anal. 53: 991-996, 2010.
 
71. Wang, YZ., Ma, XW., Ma, HL, Wang DL., Lu, J., Jia, L., Duan, XL., Liang, XJ. Specific hemosiderin deposition in spleen induced by a low dose of cisplatin: altered iron metabolism and its implication as an acute hemosiderin model. Curr. Drug Metabo. 11, 507-515, 2010.
 
72. Tang, W., Jia, L., Zhao, Y. The newly-found bioactivities and clinical uses of ginseng and ginsenosides. Ginseng Res. 22(2): 32-38, 2010.
 
73. *Jia, L. Qian K. An Evidence-based Perspective of Ginseng as a Preventing or Supplementary Therapy for Cancer Patients. In Evidence-based Anticancer Herbal Medicine., Ed., by W. Cho, Springer Science. 85-95, 2011.
 
74. Jia, L*, Zhao, YL, Liang, XJ. Fast Evolving Nanotechnology and Relevant Programs and Entities in China. Nano Today 6: 6-11, 2011.
 
75. Reid, J.M., Buhrow, S.A., Kuffel, M.J., Jia, L.  Spanswick, V.J., Thurston, D.E., Tomaszewski, J.E., Ames, M.M. Pharmacokinetics, Pharmacodynamics and Metabolism of the Dimeric Pyrrolobenzodiazepine SJG-136 in Rats. Cancer Chemother. Pharmacol. 68: 777-786, 2011.
 
76. Jia, L., Gorman, G., Coward, L., Noker, P., McCormick, D.L., Horn, H.L., Harder, J.B., Muzzio, M., Prabhakar, B., Balaji, G., Gupta, T.K.D., Beattie, C.W. Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination Cancer Chemother. Pharmacol. 68: 513-24, 2011.
 
77. Xu Z., Jia L., Zhao, YQ. Ginseng etymology, pharmacognosy, and the evaluation of its current products and markets. Modern drugs & Clin. 2:1-6, 2011.
 
78. Xu, Z. Jia, L., Zhao, YQ. Constituents of ginseng and quality evaluation of ginseng products.  Drug evaluation research 2011; 34(3),1-5.
 
79. Song M., Zhang, S., Xu, X., Hang, T., Jia, L. Simultaneous determination of three Panax notoginseng saponins by LC-MS/MS at sub-nanograms in dog plasma for pharmacokinetics of compound Danshen Tablets. J. Chromatogr. 878: 3331-7, 2010.
 
80. Rayburn, E., Wang, W., Li, M., Zhang, X., Xu, H., Li, H., Qin, JJ., Jia, L., Covey, J., Lee, M., Zhang, R. Preclinical pharmacology of novel indolecarboxamide ML-970, an investigative anticancer agent. Cancer Chemother. Pharmacol. 69:1423-31; 2012.
 
81. Kummar, S., Chen, A., Ji, J., Zhang, Y., Reid, JM., Ames, M., Jia, L., Weil, M., Speranza, G., Murgo, A.J., Kinders, R., Wang, L., Parchment, R.E., Carter, J., Stotler, H., Rubinstein, L., Hollingshead, M., Melillo, G., Pommier, Y., Bonner, W., Tomaszewski, JE., Doroshow, JH. Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas. Cancer Res. 71:5626-34; 2011.
 
82. Meng, J., Yang, X.D., Jia. L., Liang, X.J., Wang, C. Impact of nanoparticles on cardiovascular diseases: modulating metabolism and function of endothelial cells. Curr. Drug Metab. 13: 1123-29; 2012. IF5.113
 
83. Jia, X., Jia, L*. Nanomaterials improve biological functions of photosensitizers used for photodynamic therapy. Curr. Drug Metab. 13: 1119-22, 2012. IF5.113
 
84. Xue, X., You, S., Zhang, Q., Wu, Y., Zou, GZ., Wang, PC., Zhao, YL., Xu, Y., Jia, L.,  Zhang, X., Liang, XJ. Mitaplatin increases sensitivity of tumor cells to cisplatin by inducing
mitochondrial dysfunction. Mol. Pharmaceutics 9：634−644 ；2012. IF4.782
 
85. Shao, J., Xue, JP., Dai, YC., Liu, H, Jia*, L, Chen, NS., Huang, JL. Inhibition of human hepatocellular carcinoma HepG2 by phthalocyanine photosensitizer Photocyin: ROS production, apoptosis, and cell cycle arrest. Eur. J. Cancer. 48: 2086-96; 2012. ISSN:0959-8049; IF5.536
 
86. Meng, J., Xing, J., Wang, Y., Lu, Y., Zhao, YL., Gao, X., Wang, P.C., Jia, L. Liang, XJ. Epigenetic modulation of human breast cancer by metallofullerene nanoparticles: in vitro analysis and in vivo treatment. Nanoscale. 3: 4713-19; 2011. IF5.914
 
87. Zhang, F., Xie, JP., Shao, JW., Jia*, L. Compilation of 222 Drugs’ Plasma Protein Binding
Data and Guidance for Study Designs. Drug Discovery Today 17:475-495, 2012. IF6.828
 
88. Xu, Y., Jia, L. Nanoscaled Proteomic Analysis. 64-81, Chapter 4th In Nanopharmaceuticals Ed by Liang. World Scientific Publishing, Singapore. 2012.
 
89. Jia, L.* Lu, Y., Shao, J., Liang, XJ., Xu Y. Nanoproteomics: a new spin from emerging links between nanotechnology and proteomics. Trends Biotech. 31:99-107, 2013. 一区 IF11.96
 
90. Shao, JW., Dai, Y., Zou, WT., Xue, JP., Ye, J., Jia*, L. Intracellular distribution and mechanisms of actions of photosensitizer Zinc (II)-phthalocyanine solubilized in Cremophor EL against human hepatocellular carcinoma HepG2 cells. Cancer Lett. 330：49-56，2013. 二区 IF5.621
 
91. Xie, JJ., Shao, JW., Lu, Y., Chen, JZ., Wang, J., Yu SH., Jia, L*. Separation of ginseng active ingredients and their roles in cancer metastasis supplementary therapy. Curr. Drug Metabo. 14:614-621；2013. 二区 IF4.8
 
92. Jiang, Z., Shao, J., Chen, M, Hu, Y., Wang, J., Jia*, L. A novel SPE-HPLC method for simultaneous determination of selected sulfonated phthalocyanine zinc complexes in mouse plasma following cassette dosing. Analyst 138: 4385 – 4392, 2013. 二区IF4.2
 
93. Jia*, L. Science Requires Coexisting of Opposite Opinions: “One Country, Two Systems” Pharmaceutical Reg. Affairs: Open Access ISSN:2167-7689; 1(4):1000e114;2012
 
94. Shao, J., Jia*, L. Potential serious interactions between nutraceutical ginseng and warfarin in patients with ischemic stroke. Trends Pharmacol. Sci. 34(2):85-86, 2013. 一区IF11.54
 
95. Yin, J.J., Sharma, S., Shumyak, S.P., Wang, Z.X., Zhou, Z., Zhang, Y., Guo, P., Li, C.Z., Kanwar, J.R., Yang, T.X., Mohapatra, S.S., Liu, W., Duan, W., Wang, J., Li, Q., Zhang, X., Tan, J., Jia, L. Liang, J., Wei, M.Q., Li, X., Zhou, S.F. Synthesis and Biological Evaluation of a Novel Cancer Treatment Based on Folic Acid Receptor-Targeted, β-Cyclodextrin-Based Drug Complexes for Cancer Treatment. PLoS ONE 8(5): e62289; 2013. 二区 IF4.8
 
96. Gao, Y. Xie, J., Chen, H., Gu, S., Zhao, R., Shao, J., Jia*, L. Nanotechnology-based intelligent drug design for cancer metastasis treatment. Biotech Adv. 32:761-777, 2014. 一区 IF9.6 
 
97. Jiang, Z., Shao, J., Ting, Y., Wang, J., Jia*, L. Pharmaceutical development, composition and quantitative analysis of phthalocyanine as the photosensitizer for cancer photodynamic therapy. J. Pharm. Biomed. Anal. 78：98-104; 2014. 三区 IF 2.829
 
98. Gao, Y., Shao, J., Jiang, Z., Chen, J., Gu, S., Yu, S., Zheng, K., Jia, L.* Drug enterohepatic circulation and disposition: constituents of systems pharmacokinetics. Drug Disc. Today  19:326-340，2014. 一区 IF6.89
 
99. Wang, J., Jiang, Z., Shao*, J., Ou, M., Li, Y., Lu, Y., Xiang, L., Lin, L., Dai, Y., Jia, L*, Synergism of ursolic acid derivative with 2-deoxy-D-glucose to preferentially induce tumor cell death by dual targeting of apoptosis and glycolysis. Sci. Reports 2014, 4:5006; DOI: 10.1038/srep05006 二区 IF5.578
 
100. Chen, JZ., Wang, JC., Shao, JW., Gao, Y., Xu, JG, Yu, SH., Liu, ZH., Jia, L*. The Unique Pharmacological Characteristics of Mifepristone: from Terminating Pregnancy to Preventing Cancer Metastasis. Med. Res. Rev. 34：979–1000, 2014. 一区 IF 9.583
 
101. Wang, J., Chen, J., Wan, L., Shao*, JW., Lu, Y., Zhu, Y., Ou, M., Yu, SH., Chen, HJ., Jia*, L. Synthesis, spectral characterization and pharmacological evaluation of metapristone, a novel cancer metastatic chemopreventive derived from mifepristone (RU486). AAPS J. 16:289-298，2014. 二区 IF 4.905
 
102. Reid, JM., Buhrow, SA., Gilbert, JA., Jia, L., Shoji, M., Snyder, J., Ames. MM. Mouse pharmacokinetics and metabolism of the curcumin analog, 4-Piperidione,3,5-bis[(2-fluorophenyl)methylene]-acetate(3E,5E) (EF-24; NSC 716993) Cancer Chemother. Pharmacol. 73(6):1137-46, 2014.  IF3
 
103. Chen, JZ., Wang, JC., Gao, Y., Zeng, R., Jiang, Z., Zhu, YW., Shao, JW., Jia, L. A novel UPLC/MS/MS method for rapid determination of metapristone in rat plasma, a new cancer metastasis chemopreventive agent derived from mifepristone (RU486). J Pharm. Biomed. Anal, 95:158-63; 2014 三区 IF 2.829
 
104. Lu, Y., Yu, T., Liang, H., Wang, J., Xie, J., Shao*, J., Gao, Y., Yu, S., Chen, S., Wang, L., Jia, L.* Nitric oxide inhibits hetero-adhesion of cancer cells to endothelial cells: restraining circulating tumor cells from initial metastatic cascade.  Scientific reports DOI: 10.1038/srep04344，2014二区 IF5.578
 
105. Chen, P., Zhang, X., Jia, L., Prud'homme, RK., Szekely, Z., Sinko, PJ. Optimal structural design of mannosylated nanocarriers for macrophage targeting. J. Controlled Release 2014; 194:341-34. IF7.705
 
106. XIE, JJ., ZHAO R., CHEN, HN., XIE, XD., JIA,* L. Specificity of Capturing and Restraining Colon Cancer Cells in Vitro by Multifunctional Nanomaterial Conjugates 科技导报2014, 32(34):26-32. doi 10.3981/j.issn.1000-7857.2014.34.002
 
107. Xie, JJ, Zhao, R, Gu, S., Dong, H., Wang, J., Lu, Y., Sinko, PJ., Yu, T., Xie, FW., Wang, L., Shao*, J., Jia, L* The architecture and biological function of dual antibody-coated dendrimers: enhanced control of circulating tumor cells and their hetero-adhesion to endothelial cells for metastasis prevention. Theranostics 2014;4: 1250-63; 二区IF8.022
 
108. Xie, JJ., Lu, Y., Dong, HY., Zhao, RL., Chen, HN., Shen, WY., Sinko, PJ., Zhu, Y., Wang, JC., Shao, JW., Gao, Y., Xie, FW., Jia*, L. Enhanced specificity in capturing and restraining circulating tumour cells with dual antibody-dendrimer conjugates. Adv. Funct. Mater. 2015, 25, 1304–1313一区 IF11.805.
 
109. Yu, S., Yang, XT., Zhu, Y., Xie, FW., Lu, YS., Yu, T., Yan, CC., Shao, J., Gao, Y., Mo, F., Cai, GN., Sinko, PJ., Jia, L.* Systems biological pharmacology of mifepristone (RU486) reveals its 47 hub targets and network: comprehensive analysis and pharmacological focus on FAK-Src-Paxillin complex. Sci. Rep., 5: 7830, 2015 二区 IF5.578
 
110. Xie, J., Dong, HY., Chen, HN., Zhao, R., Sinko, JP., Shen, WY., Wang, JC., Lu, YS., Yang, XT., Xie, FW., Jia,* J. Exploring cancer metastasis prevention strategy: interrupting adhesion of cancer cells to vascular endothelia of potential metastatic tissues by antibody-coated nanomaterial J. Nanobiotechnology, 2015; 13:9,1-13. DOI 10.1186/s12951-015-0072-x  一区 IF4.115
 
111. Xie J, Wang, J., Chen H, Shen, WY., Sinko JP., Dong H., Zhao R., Lu Y., Zhu YW., Jia L*. Multivalent Conjugation of Antibody to Dendrimers for the Enhanced Capture and Regulation on Colon Cancer Cells. Sci. Reports 5: 9445, 2015；二区 IF5.578
 
112. Dong, HY., Yang, X., Xiang,L., Li, YF., Ou, M., Chi, T., Liu, ZH., Shao*, JW., Jia*, L. UP12, a novel ursolic acid derivative with potential for targeting multiple signaling pathways in hepatocellular carcinoma. Biochem. Pharmacol. 2015; 93:151-162二区 IF 5.009.
 
113. Xu, J., Dong, H., Shen, W., He, S., Li, H., Lu, Y., Wu, Z.-S*., Jia, L*., New molecular beacon for p53 gene point mutation and significant potential in serving as the polymerization primer. Biosensors Bioelectronics 2015; 66:504-511. IF 6.451.
 
114. Jiang, Z., Yang, J., Pang, YQ., Yang, XT., Yu*, SH., Jia*, L. Bioactivity-guided fast screen and identification of cancer metastasis chemopreventive components from raw extracts of Murraya exotica J. Pharm. Biomed. Anal. 107C:341-45, 2015. 三区 IF 2.98
 
115. Gao*, Y., Li, ZR., Xie, XD., Wang, CQ.,You, J., Mo, F., Jin, B., Chen, JZ., Shao, JW., Chen, HJ., Jia*, L. Dendrimeric anticancer prodrugs for targeted delivery of ursolic acid to folate receptor-expressing cancer cells: synthesis and biological evaluation. Eur. J. Pharm. Sci. 70:55-63, 2015. IF3.01.
 
116. Lu, Y., Liang, HY., Yu, T., Xie, JJ., Chen, SM., Dong, HY., Sinko, PJ., Lian, S., Xu, JG., Wang, JC., Yu, SH., Shao, JW., Yuan, B., Wang, L., Jia,* L. Isolation and Characterization of Alive Circulating Tumor Cells by Immunomagnetic Negative Enrichment Coupled with Flow Cytometry. Cancer 121(17):3036-45, 2015. IF4.901.
 
117. Wan#, LY, Dong#, HY, Xu, H., Zhu, YW., Lu, Y., Ma, J., Wang, JC., Xie, JJ., Xu, B., Gao, Y., Shao, JW., Jia, L* Aspirin, lysine, mifepristone and doxycycline combined can effectively and safely prevent and treat cancer metastasis: prevent seeds from gemmating on soil. Oncotarget. priority publication; 6(34):35157-72；2015. IF6.63. DOI: 10.18632/oncotarget.6038；
 
118. R.J. Zeng, Y. Li, J.Z. Chen*, G. X. Chou*, Y. Gao, J.W. Shao, L. Jia, and S.S. Wu, A novel UPLC-MS/MS method for sensitive quantitation of boldine in plasma, a potential anti-inflammatory agent: application to a pharmacokinetic study in rats. Biomed. Chromatogr. 29:459–464, 2015. (IF=1.95)
 
119. Xiang, LP., Chi, T., Tang, Q., Yang, X., Ou, M., Chen, X., Yu, XB., Chen, JZ., Shao*, JW.,  Jia, L.  A pentacyclic triterpene natural product, ursolic acid and its prodrug US597 inhibit targets within cell adhesion pathway and prevent cancer metastasis. Oncotarget  2015, 6(11):9295-312. IF6.63. 
 
120. Xie, J., Yu, G., Zhao, R., Sinko, P., Gu, S., Wang, J., Li, Y., Lu, Y., Yu, S., W, Lie., Chen, S., Shao, J., Jia, L*. Ex vivo and in vivo capture and deactivation of circulating tumor cells by dual-antibody-coated dendrimers. J. Control Release. 2015; 209:159-69. 一区IF7.705.
 
121. Dong, HY., Wu* ZS, Xu, JG., Ma, J., Zhang, HJ., Wang, J., Shen, WY., Xie, JJ., Jia,*L Novel multifunction-integrated molecular beacon for the amplification detection of DNA
hybridization based on primer/template-free isothermal polymerization. Biosensors Bioelectronics 72:182-190, 2015.
 
121. Xu JG., Wu* ZS., Shen, WY., Xu, H, Li, LH., Jia,* L. Cascade DNA nanomachine and exponential amplification biosensing. Biosensors and Bioelectronics. 73:19-25, 2015. IF 6.451.
 
122. Gao§,Y., Gu§, S., Zhang, Y., Xie, XD., Yu, T., Lu, Y., Zhu, Y., Chen, WG., Zhang, H., Dong, HY., Sinko, PJ., Jia,* L. The architecture and function of monoclonal antibody-functionalized mesoporous silica nanoparticles loaded with mifepristone: repurposing abortifacient for cancer metastatic chemoprevention. Small. 2016；12(19):2595-608   IF8.368.
 
123. Dong, HY#, Gao, Y#, Sinko, PJ., Wu, ZS., Xu, JG., Jia,*L. The nanotechnology race   between China and the United States. Nano Today. 11:7-12; 2016. IF18
 
124. Gao Y., Jin B., Shen WY., Sinko PJ., Xie XD., Zhang, HJ., Jia* L. China and the United States- global partners, competitors and collaborators in nanotechnology development. Nanomedicine: Nanotechnology, Biology, and Medicine. 12:13-19；2015. IF6.5
doi: 10.1016/j.nano.2015.09.007. 
 
125. Li, Y., Zeng, RJ., Chen*, JZ., Wu, BY., Chou, GX., Gao, Y., Shao, JW., Cai, HZ., Jia, L. Pharmacokinetics and metabolism study of isoboldine, a major bioactive component from Radix Linderae in male rats by UPLC-MS/MS. J. Ethnopharmacol. 2015, 171:154-60. IF3
 
126. Xu, JG., Qian, J., Li, H., Wu,* ZS., Shen, W., Jia,*L.  Intelligent DNA machine for the ultrasensitive colorimetric detection of nucleic acids. Biosensors and Bioelectronics, 2016,75:41-47
 
127. Xiao#, YY., Zhu#, YW., Yu#, SH., Ho, RJ., Yan, CC., Liu, J., L, T., Wang, J., Wan, LY., Yang, XT., Xu, H., Wang, JC., Jia,* L. Thirty-day rat toxicity study reveals reversible liver toxicity of mifepristone (RU486) and metapristone. Toxicol. Mech. & Methods 2016; 6: 36-45.
 
128. Xu, JG., Li, HN., Wu ZS*., Qian, J., Xue, C. Jia* L. Double-stem Hairpin Probe and Ultrasensitive Colorimetric Detection of Cancer-related Nucleic Acids. 2016; 6(3): 318-327. Theranostics. IF8.85
 
129. Xie, XD., Li, FQ., Zhang, HJ., Lu, YS., Lian, S., Lin, H., Gao*, Y., Jia* L. EpCAM aptamer- functionalized mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery. Eur. J. Pharm. Sci. 2016; 83:28-35. IF3.35
 
130. Dong, HY., Ma, J. Wang, J., Wu, ZS., Sinko, PJ.,  Jia*, L. A biofunctional molecular beacon for detecting single base mutations in cancer cells. Mol Ther Nucleic Acids. 2016 Apr 5;5:e302. doi: 10.1038/mtna.2016.18;   IF4.512
 
131. Jiang#, Z., Pang# Y, Yu#, XB., Zhou, SX., Qian, J., Zheng, N., Dong, HY., Shi, Q., Jia* L. The paradigm-shifting idea and its practice: from traditional abortion Chinese medicine Murraya paniculata to safe and effective cancer metastatic chemopreventives.  Oncotarget 2016; 7(16): 21699-712. Mar 5.
 
132. Yu,#SH*, Yan#, CC, Yang#, XT., He, SD., Liu, J., Qin, CT., Huang, CZ., Lu, YS., Tian, ZQ., Jia,* L. Pharmacoproteomic analysis reveals that metapristone (RU486 metabolite) intervenes E-cadherin and vimentin for cancer metastasis chemoprevention. Sci. Rep. 6, 22388; 2016. doi:10.1038/srep22388. IF5.578
 
133. Wang, JC.#, Chen, JZ.#, Zhu, YW., Zheng, N., Liu, J., Xiao, YY., Lu, YS., Dong, HY., Xie,JJ., Shao, JW., Yu, SH., Jia,*L. In vitro and in vivo efficacy and safety evaluation of metapristone and mifepristone as cancer metastatic chemopreventive agents. Biomed Pharmacother. 78 (2016) 291–300. IF2  
 
134. Dong HY.#, Wang#, J., Zhang, T., Ma, J., Han, LY., Tu, XH., Jia*L. Aptamers and their biological applications to bio-medicine and analytical diagnostics. Chinese J Pharm.  Anal. 2016 (3): In press.
 
135. Xu, JG., Wu*, ZS., Wang, ZM., Li, HN., Le, JQ.,  Jia* L. Two-wheel drive-based DNA nanomachine and its sensing potential for highly sensitive analysis of cancer-related gene. Biomaterials. 2016;100:110-117. IF8.557
 
136. Xu, JG., Wu*, JS., Shen, WY., Wang, ZM., Li, HN., Jia,*L Autonomous and orderly assembly of two DNA oligonucleotides into metastable nanoarchitecture: simplicity and great theranostics potential. 2016  Clinical Science
 
137. Xu, JG., Wu, *ZS., Li, HN., Wang, ZM., Le, JQ., Zheng, TT., Jia,*L. Dual-cyclical nucleic acid strand-displacement polymerization based signal amplification system for highly sensitive determination of p53 gene.  Biosensors and Bioelectronics doi:10.1016/j.bios.2016.07.029. available online: 9-JUL-2016
 
138. Li, HN. Xu, JG., Wang ZM., Wu,# ZS., Jia,# L. Increasingly branched rolling circle amplification for the cancer gene detection. Biosensors and Bioelectronics. doi.org/10.1016/j.bios.2016.07.095,  2016.
 
139. Shao, JW., Zhou, SX., Jiang Z., Chi, T., Ma, J., Guo, ML., Lee, A., Jia,*L Warfarin and coumarin-like Murraya paniculata extract down-regulate EpCAM-mediated cell adhesion: individual components versus mixture for studying botanical metastatic chemopreventives
Scientific Report (accepted) 2016
 
140. Lian, S., Lu., YS., Cheng YL., Yu, T., Xie, XD., Liang, HY., Jia, *L. S-nitrosocaptopril interrupts cancer cells adhesion to endothelium by suppressing cell adhesion molecules via inhibition of the NF-кB signal pathway in endothelial cells. Eur. J. Pharmacol. (accepted) IF2.53.
 
141. Xiao, YY., Chen, WG., Chen, JZ., Liu, J., Shao, JW., Li, T., Zhu, YW., Ma, J. Gao, Y., Wang JC., Xu, JG., Lu, YS., Yu, SH., Jia* L. Sex-related pharmacokinetic differences and mechanisms of metapristone derived from RU486. Sci. Rep. (under revision) 2016
 
142.     Lu, YS., Lian, Yu1, Cheng1, Liang1, Xie, JJ, Zhu, Y, Xu, H, Xie, XD, Yu, SH, Gao, Y, Jia,*L. Multifunctional nitric oxide prevents metastatic cascade spark by interrupting platelets-circulating tumor cell interplay.
 
143. Sudan He; Xingtian Yang; Cuicui Yan; Suhong Yu; Zhou Jiang; Lee Jia. A Novel Coumarin from Murraya Exotica and Its Potential Prevention of Cancer Metastasis Bioorganic & Medicinal Chemistry Letters 
 
144. Xiufen Chen1#,Jianzhong Chen3#, Bowen Li4, Xiang Yang1, Rongjie Zeng3, Yajun Liu1, Tao Li1, Jingwei Shao1, 2*, Lee Jia1, 2*, Rodney J.Y. Ho Oral PLGA-PEG-PLGA micelles nanoparticles of US597 (an ursolic acid derivative): preparation, biological activities and pharmacokinetics. J. Pharm. Sci.
 
145. Jun Qian1,#, Zhou Jiang1,#, Haiyan Dong1,2#, Jingyi Yang1, Xiaobo Yu1, Jianzhong Chen1, Hongning Chen1, Qing Shi1, Lee Jia1,*The 5000-year old traditional Chinese medicine Achyranthes bidentata and our de novo conception of its metastatic chemoprevention: from phytochemistry to pharmacology (submitted to Oncogene; cancer letter)
 
146. Ma, J. Dong, HY., Shao, JW., Gao Y., Jia* L Global deregulation of ginseng products may be life-threatening to warfarin takers for preventing stroke and thromboembolism: solid evidence of serious ginseng-warfarin interaction (submitted)
 
147. Shao#, JW., Chen#, HN., Liu, J., Zheng, GR., Li, T. Lu, Y., Xu, JG., Zheng, N., Jia*L.  Metapristone suppresses NSCLC by targeting EGFR and its PI3K/PTEN/AKT and ERK signaling pathways. Biochem Pharmacol. (submitted) (recomm cancer letter)
 
148. Xu, JG., Composite DNA nanomachine that functions with high cooperativity
MANUSCRIPT ID: NR-ART-04-2016-002997 Nanoscale IF7.39.
 
149. Xiaobo Yu1,*, Yusheng Lu1,*, Jingwei Shao1, Jian Liu1, Haiyan Dong1, 2, Ting Yu1, Haiyan Liang1, Qing Shi1, Lee Jia1Embedding similarities between blastocyst and cancer cells: fundamentals for abortifacients used for cancer metastatic chemoprevention 
 
150.    Jiang, Z., Rui Wang, Xiao Ma,Tingting Yang, Wang*, J., Jia*L, Conjugation of
           phthalocyanine photosensitizer with poly(amidoamine) dendrimer: improved solubility,
           aggregation and photocatalyzed bioactivity against cancer cells (in preparation), 2015
 
151.    Jia,*L. Three decades of transdisciplinary understanding and re-evaluating of the politics- and religion-involved abortion pill mifepristone and its niche in cancer metastasis chemoprevention. Cancer J. 2016.
         
 
*, principal or corresponding author;
 
ABSTRACTS:
 
1. Jia, L: Pharmacokinetic differentiation of six substituted phenylethylamines.   Chinese Pharmaceutics Press pp. 16, 1988.
 
2. Jia L, Bonaventura C, Bonaventura J, Stamler JS: S-nitrosohemoglobin: a new transport function of arterial erythrocytes involved in regulation of blood pressure.    Endothelium S6, 1995
 
3. Day, B. J, L, Jia, Arnelle D. R, Crapo, J. D, and Stamler, J. S.: Transduction of NOS activity from endothelium to vascular smooth muscle: involvement of S-nitrosothiols  In Biology of Nitric Oxide. Endothelium. S 72, 1995.
 
4. Day, B. J, Jia, L, Crapo, J. D. and Stamler, J. S.:  EDRF and mechanisms of nitric oxide protection..    Am. J. Respir. Crit. Care  Med.    A 627, 1995.
 
5. Jia L, Bonaventura C, Bonaventura J, Stamler JS: S-nitrosohemoglobin: a new synthetic activity of the lung involved in regulation of blood pressure.  Am.  J.  Respir.  Crit.  Med.  A 582, 1996.
 
6. Zhang, J., Saman, G., Jia, L., Stamler, J.S., Cobb, F.R.:  Effects of S-nitrosohemoglobin on the conductance and resistance coronary vasculature.    Circulation, 94:(Suppl 1-16), 1996.
 
7. Jia, L., Blantz, RC.  The effects of S-nitrosocaptopril on renal function and blood pressure in rats.   J. Am. Society   Nephrology.  8:317A, 1997.
 
8. Jia, L. Zhang, J.: Pharmacokinetics of S-nitrosohemoglobin in unanethetized dogs   J.  Artificial Cells, Blood  Substitutes, Immobilization  Biotechnology  21, 1997
 
9. Jia, L.: S-nitrosocaptopril crystals: physicochemical characterization and cardiovascular activities.  Am. J. Hypertension.  1998; 11(4): 105A.  
 
10. Jia, L: Simultaneous measurement of pharmacodynamics and pharmacokinetics of S-nitrosocaptopril in hypertensive rats.  AAPS Western Regional Meeting  1998; page.41.                         
 
11. Jia, L. Thomson, S. Blantz, R.  L-arginine increases GFR partially by nitric oxide independent mechanisms via activity of agmatine.    J.  Am. Society  Nephrology  1998; 308A.
 
12. Jia, L.: VIPGC-NO preserves intrinsic function of VIP but acquires NO-like activities.  Am. J. Hypertension. 1999;12(4): 54A.  
 
13. Lin, M., Yang, X, Wang.,  Jia, BJ., Jia, L.  S-nitrosocaptopril crystals preferentially decreases diastolic pressure in hypertensive rats.  Am. J. Hypertension.  1999; 12(4):114.
 
14. Jia, L. Linnik, D.M.  The Stability of the first domain of b2-glycoprotein I in rat serum and microsomes.  AAPS PharmSci. 1999; 1(S1): 524.
 
15. Jia, L., Yu, l., Linnik, D.M., Jack, R.M.  Stability and Pharmacokinetics of LJP 920, an octameric Gal (a1-3) Gal conjugate for inhibition of xenotransplantation rejection.    AAPS PharmSci. 1999; 1(S1): 11
 
16. Jia, L., Pei, R. Acute and subacute toxicity and efficacy of S-nitrosylated captopril, an ACE inhibitor possessing nitric oxide activities. AAPS PharmSci. 2000; 2(S1):726.
 
17. Jia, L. Wong, H. Garza, M. Weitman, S. Pharmacokinetic Comparison of intravenous carbendazim and its liposome and emulsion forms in nude mice. Proc. Am. Assoc. Cancer Res. 42: 381, 2001.
 
18. Jia, L. Garza, M. Wong, H. Wang, Y. Weitman, S. Paclitaxel Tumor cellular Permeability: Influence of plasma binding, P-glycoprotein and nitric oxide. Proc. Am. Assoc. Cancer Res. 42: 951, 2001.
 
19. Wang, Y., Wong, H., Weitman, S. Jia, L. LC/MS/MS assay of a novel anti-virus drug 301029: application to cellular permeability studies. AAPS PharmSci. 2001; 3(S1): 861.
 
20. Wong, H. Wang, Y. Weitman, S. Jia, L. Carcinoma cell permeability, tissue distribution and disposition of carbendazim, a novel anti-cancer drug.  Proc. Am. Assoc. Cancer Res. 43: 430, 2002.
 
21. Wang, Y. Wong, H. Jia, L. Effect of S-nitrosocaptopril on Taxol permeability and cytotoxicity against carcinoma cells. Proc. Am. Assoc. Cancer Res. 43: 431, 2002.  
 
22. Wong, H., Wang, Y., Garza, M. Weitman, S. Jia, L.  Carbendazim and its nanoparticle formulation: Pharmacokinetic comparison and metabolite identification.  AAPS PharmSci. 2001; 3(S1): 609.
 
23. Wang, Y. Jia, L. Wong, H. Endothelial permeability to captopril and S-nitrosocaptopril and in vivo bioactivity thereof. AAPS PharmSci. 2001; 3(S1): 493.
 
24. Jia, L. Wong, H. Cerna, C. Piazza, G. LC/MS/MS-based proteomic analysis of the membrane proteins of human prostate carcinoma LNCaP Cells. Proc. Am. Assoc. Cancer Res. 43: 34, 2002.
 
25. Cerna, C. Wang, Y. Schweizer, J. Revilla, M. Wong, H. Jia, L. Effects of S-nitrosocaptopril on cytotoxicity and permeability of paclitaxel in human carcinoma cell lines. Proc. Am. Assoc. Cancer Res. 43: 585, 2002.
 
26. Jia, L. Wong, H. Cerna, C. Weitman, SD. Size-dependent absorption of micro- and nanoparticle 301029: ex vivo and in vivo pharmacokinetic correlations determined by LC/MS.  AAPS PharmSci. 2002; 4(S1): 1569.
 
27. Jia, L. Tomaszewski, J. Jothianandan, D. Furchgott, R.F. Keefer, L. Shami, P. EDRF-like activity and anticancer spectrum of JS-K, a novel diazeniumdiolate nitric oxide donor.  Proc. Am. Assoc. Cancer Res. 44: 1059, 2003.
 
28. Bolterman, S.A., Reid, J.M., Jia, L. Shami, P.J., Ames, M.M.  HPLC analysis of the NO-donating prodrug JS-K: inhibition of sulfhydryl-catalyzed degradation in plasma and whole blood lysates by thiol depletion with diamide. Proc. Am. Assoc. Cancer Res. 44: 387, 2003.
 
29. Jia, L., Tomaszewski, J., Noker, P., Norman, G., Protopopova, M. Ethambutol Analogs. I. LC/MS/MS analysis and cassette dosing for pharmacokinetic screening of candidate drugs. AAPS PharmSci. 2003; 5(S1): 716.
 
30. Jia, L., Tomaszewski, J., Noker, P., Norman, G., Protopopova, M. Ethambutol analogs. II. Pharmacokinetic characterization of SQ109. AAPS PharmSci. 2003; 5(S1): 724.
 
31. Jia, L., Tomaszewski, J., Noker, P., Norman, G., Protopopova, M. Ethambutol analogs. Assessment of pharmacokinetic drug-drug interaction after cassette dosing. AAPS PharmSci. 2003; 5(S1): 719.
 
32. Jia, L., Tomaszewski, J., Noker, P., Norman, G., Yang, D. Pharmacokinetic profiling of (-)Gossypol (NSC 726190), a novel anticancer agent. Molecular Targets & Cancer Ther. p241, 2003  (AACR-NCI-EORTC international conference).
 
33. Reid, J., Buhrow, S.A., Kuffel, M., Jia, L., Covey, J., Ames, M.M. LC-MS/MS assay and rat pharmacokinetics and metabolism of the dimeric pyrrolobenzodiazepine SJG-136. Proc. Am. Assoc. Cancer Res. 45:1248, 2004.
 
34. Jia, L., Spanswick, VJ., Reid, JM., Kuffel, M. Buhrow, SA., Ames, MM., Hartley, JA., Thurston, DE., Tomaszewski, JE. Use of the Comet assay as a surrogate biomarker for the in vivo measurement of DNA damage to Lymphocytes. Proc. Am. Assoc. Cancer Res. 45: 452, 2004.
 
35. Jia, L. Peggins, J., Reid, JM., Buhrow, SA., Ames, MM., Kobs, DJ., Grossi, IM., Thurston, DE., Tomaszewski, JE. Interspecies differences in pharmacokinetcs and time-dissociated toxicokinetics of SJG-136. Proc. Am. Assoc. Cancer Res. 45:487 2004.
 
36. Coward, L, Cook, L. Kerstner-Wood, C. Noker, P. Page, J. Jia, L. Schweikart, K. Gorman, G. Simultaneous Determination of a Novel Synthetic Triterpenoid Derivative(CDDO-Im) and its Metabolites using LC/MS/MS. American Society of Mass Spectrometry(ASMS). May, 2004.
 
37. Jia, L. Noker, P.E. Gorman, G. Coward, L. Protopopova, M. Tomaszewski, J.E. In vitro metabolic profiling of SQ109 and identification of main CYP isoforms catalyzing the metabolism. The AAPS Journal. 2004; 6(S1): 969.
 
38. Jia, L. Noker, P.E. Gorman, G. Coward, L. Protopopova, M. Tomaszewski, J.E. Interspecies similarities and differences in pharmacokinetics of SQ109 (NSC722041), an anti-tuberculosis drug. The AAPS Journal. 2004; 6(S1): 1092.
 
39. Shami, P.J., Kaur, G., Jia, L., Saavedra, J.E., Keefer, L.K. JS-K, a novel nitric oxide (NO) generator, shows potent anti-angiogenic activity.  Am. Society Hematology. Dec. 2004.   
 
40. Glaze, E., Chen, Y., Lyubimov, A., Jia, L., Noker, P., Morrissey, R., Tomaszewski, J. Range-finding toxicity studies with SQ109, an anti-tuberculosis agent, in rats and dogs. 2005 Annual Society of Toxicology Conference.
 
41. Jia, L., Coward, L., Gorman, G. Noker, P.E., Hanrahan, C., Protopopova, M. Tomaszewski, J.E.  Fingerprinting of pharmacoproteomic changes of mycobacterium tuberculosis H37Rv induced by anti-tuberculosis drugs.  2005 Annual Am. Thoracic Soc. San Diego, May.
 
42. Jia, L., Gorman, G.S., Noker, P.E., Coward, L., Tomaszewski, J.E. In Vitro Metabolism Analysis of CDDO-Imidazolide. Proc. Am. Assoc. Cancer Res. 46: 779, 2005.
 
43. Jia, L., Kuffel, M.J., Buhrow,S.A., Reid, J.M., Ames, M.M. Pharmacokinetic profile 1-methyl-[d]-tryptophan, an orally-bioavailable immune modulator.  Proc. Am. Assoc. Cancer Res. 46: 987, 2005.
 
44. Coward, L.C. Kerstner-Wood, Noker, P., Gorman, G., Becattini, B., Pellecchia, M., Reed, J.C., Jia, L. Analysis of bioconversion from apogossypol hexaacetate to apogossypol, a novel proapoptotic compound. Proc. Am. Assoc. Cancer Res. 46: 530, 2005.
 
45. Noker, P.E., Gorman, G.S., Coward, L., Hansel, W., Jia. L. Lytic Peptide Phor21-bCG(ala) I: Pharmacokinetic Profile in Mice and Rats. Proc. Am. Assoc. Cancer Res. 46: 982, 2005.
 
46. Piazza, G., Jones, Noker, P.E., Hansel, W., Leuschner, C., Jia, L. Lytic Peptide Phor21-βCG(ala) II: Selective Cytotoxicity and Its Effects on Membrane Integrity as Measured by Permeability to Mannitol. Proc. Am. Assoc. Cancer Res. 46: 1395, 2005.
 
47. Kuffel, M.J., Buhrow, S.A., Reid, J.M., Jia, L., Ames, M.M. Kynurenine: a biomarker for in vitro and in vivo modulation of indoleamine 2,3-dioxygenase by 1-Methyl-[d]-tryptophan (NSC 721782)  Proc. Am. Assoc. Cancer Res. 46: 982, 2005.
 
48. Sarah A. Buhrow, Joel M. Reid, Lee Jia, Mamoru Shoji, James P. Snyder, Dennis C. Liotta, Matthew M.  LC/MS/MS assay and mouse pharmacokinetics and metabolism of the novel curcumin analog EF-24 (NSC 716993).  Proc. Am. Assoc. Cancer Res. 46: 984, 2005.
 
49. Jia, L., Noker, P., Coward, L., Gorman, G., Reed, J.C.  Quantitative determination of formulation and biomatrix stability of Apogossypol, a novel proapoptotic compound. The AAPS Journal 7(S2): T2307; 2005.
 
50. Jia, L., Noker, P., Coward, L., Gorman, G., Reed, J.C. In vitro and in vivo bioconversion of apogossypol hexaacetate to apogossypol: implication for chemotherapy development.  Clin. Cancer Res. 11(24 Suppl):9072s, 2005.
 
51. Jia, L. Tomaszewski, J. Toxicokinetic profile of Batracylin in beagle dogs. The Toxicologist 90(1):122, 2006. (Abstract # 596)
 
52. Kuffel, MJ., Buhrow, SA., Myers, RM., Greiner, SM., Harvey, ME., Reid, JM., Peng, KW., Jia, L., Russell, SJ., Ames, MM. Tissue distribution of viral gene expression after intravenous administration of an oncolytic measles virus encoding the sodium-iodide symporter (MV-NIS) in transgenic IfnarKO x CD46 Ge mice. Proc. Am. Assoc. Cancer Res. 47: 494, 2006.
 
53. Coward, L., Gorman, G., Noker, P., Hamilton, A. Sebti, S., Jia, L. A rapid and selective method for the analysis of GGTI-2418 in mouse plasma by HPLC/MS/MS. American Society of Mass Spectrometry (ASMS). May, 2006.
 
54. Coward, L., Kerstner-Wood, C., Cork, L., Noker, P., Jia, L., Hamilton, A., Sebti, S., Gorman. G.  Analysis of GGTI-2418 in Plasma and its Pharmacokinetics by HPLC/MS/MS.  The AAPS Journal 2006; 8(S2): T2024
 
55. Kitada S, Jia L, Coward LC, Gorman GS, Noker P, Pellecchia M, and Reed JC .  Bcl-2 antagonist ApoGossypol (NSC736630) displays single-agent activity in Bcl-2 transgenic mice and has superior efficacy and pharmacology with less toxicity compared to Gossypol (NSC19048). Am. Hematology Soc. 2006.
 
56. P. Noker, R., Fulton, J. Heath, L. Jia, J.M. Reid, M.M. Ames, K.M. Schweikart, and J.E., Tomaszewski. Toxicity and Pharmacokinetics of 1-Methyl-D-Tryptophan in Rats and Dogs. Proc. Am. Assoc. Cancer Res. 48: 366, 2007.
 
57. J.M., Reid, R.M. McGovern, S.A. Buhrow, L. Jia, J., Tomaszewski, B.J. Jean-Claude, M.M. Ames.  Lead compound selection in a series of combi-molecules with dual EGFR inhibitory and DNA alkyating activity.  Proc. Am. Assoc. Cancer Res. 48: 937, 2007.
 
58. Roberts, M.J., Coward, L., Noker, P. Jia, L. In Vitro Bioavailability Testing of GGTI-2418 Using the Caco-2 Model. Proc. 2007 EORTC-ASCO, Belgium.  
 
59. Greg Gorman, Lori Coward, Corenna Kerstner-Wood, Lea Freeman, Patricia E. Noker, Craig Beattie, Tapas K. Das Gupta, Lee Jia.  Quantitative analysis of Azurin p28, an anti-tumor peptide: Serum stability and mouse pharmacokinetics. Proc. Am. Assoc. Cancer Res. 49: 1138, 2008.
  
60. Noker, P., Coward, L., Gorman, G., Jia, L. Pharmacokinetics, Tissue Distribution, and Excretion of GGTI-2418, an Inhibitor of Geranylgeranyl Transferase I, in Mice. Proc. Am. Assoc. Cancer Res. 49: 785, 2008.
 
61. Kitada, S., Wei, J., Kress, C.L. Zhai, C. Krajewska, M., Jia, L., Pellecchia, M., Reed, J.C.  In vitro and in vivo efficacy and toxicity comparison between ApoGossypol and Gossypol, Bcl-2 Antagonists. Proc. Am. Assoc. Cancer Res. 49: 1044, 2008
 
62. Reid, J.M., McGovern, R.M. Kuffel, M.J., Jia, L., Ames, MM. Species comparison of 1-Methyl-D-tryptophan metabolism by cryopreserved hepatocytes from beagle dog, Fisher rat, CD2F1 mouse and pooled human. Proc. Am. Assoc. Cancer Res. 49: 1137, 2008
 
63. Malhotra, SV., Kumar, V., Parchment, RE., Jia, L., Noker, PE., Misra, RN., Narayanan VL., Tomaszewski, JE. Ionic Liquid ‘Therapeutic Agents’- New Paradigm in Drug Development.  Am. Chem. Soc. Philadelphia, August 17-21, 2008.
 
64. Gorman, G., Coward, L., Kerstner-Wood, C., Noker, P., Beattie, C.W., Jia, L. Metabolic Characterization of Azurin p28 in Human, Mouse and Monkey Liver Microsomes.  The AAPS Journal 2008;10(S2): M2230
 
65. Kumar, V., Parchment, R.E., Jia, L. Noker, P.E., Misra, R.N., Narayanan, V.L., Tomaszewski, J.E., Malhotra, S.V. Cytotoxicity studies of ionic liquids for potential anticancer drug therapy. 2009, 48th annual meeting of Society of Toxicology. Abs# 2067
 
66. Reid, J.M., McGovern, R.M., Buhrow, S.A., Jia, L., Ames, M.M. LC/MS/MS assay and mouse pharmacokinetics and metabolism of the eukaryotic elongation factor-2 kinase inhibitor NSC 745343. Proc. Am. Assoc. Cancer Res. 50: 709, 2009.
 
67. Gorman, G., Coward, L., Kerstner-Wood, C., Freeman, L., Noker, P.E., Sharifi, N., Figg, W., Jia, L. Pharmacokinetic, Metabolic and Stability Investigations of CCN, a Conjugate of Colchicine and Cyanonilutamide. The AAPS Journal 2009;11(S2): T2234.
 
68. Rayburn, E., Wang, W., Grau, S., Li, H., Xu, H., Zhang, X., Li, M., Sommers, C., Jia, L., Lee, M. Zhang, R., Enterohepatic circulation of indolecarboxamide ML-970 (NSC 716970), an investigative anticancer agent. Proc. Am. Assoc. Cancer Res. 51: 875, 2010.
 
69. Reid, JM., Buhrow, SA., Safgren, SL., Jia, L., Schweikart, K., Noker, P., Davis, M., Collins, J., Goetz, MP., Ames. MM. Endoxifen pharmacokinetics and bioavailability in female rats and dogs. Proc. Am. Assoc. Cancer Res. 51: 632, 2010.
 
70. Buhrow, S.A., Reid, J.M., Walden, C.A., Jia, L., Davis, M., Keefer, L., Barazi, H., Ames, MM. Pharmacokinetics, metabolism and tissue distribution of the nitric oxide-donating prodrug JS-K following administration in liposomes. Proc. Am. Assoc. Cancer Res. 51: 646, 2010.
 
71. Gorman, G.S., Noker, P.E., Coward, L.U., Ross, D, Guertin, P.A., Jia, L. In-vitro and In-vivo Drug-Drug Interaction Studies with SPINALON, a combination of buspirone and levodopa/ carbidopa for spinal cord injury. The AAPS Journal 2010; 12(S2):T2405.
 
72. J. Meng, Y. Wang, L. Jia, X-J. Liang. Epigenetic Characteristics of Endohedral Metallofullerene Nanoparticles with anti-tumor activity and low toxicity The AAPS Journal 2010; 12(S2): W4444.
 
73. M. Song, S. Zhang, T. Hang, L. Jia. Panax notoginseng saponins in dogs determined by LC/MS/MS following oral administration of Danshen Tablets. The AAPS Journal 2010; 12(S2): W4477.
 
74. Malhotra, S.V., Kumar, V., Parchment, R.E., Jia, L. Noker, P.E., Kumar, K., Misra, R.N., Narayanan, V.L., Tomaszewski, J.E., Cytotoxicity studies of ionic liquids for potential anticancer drug therapy. The AAPS Journal 2010; 12(S2): T3010.
 
75. Xue, J., Shao, J, Dai, Y, Liu, H., Chen, NS., Huang, JL., Jia,* L Overview of Global Development of Photodynamic Therapy for Cancer and China’s First Generation of Photosensitizer ZnPcS2P2 in Clinical Trials. 17th International Biophysics Congress (IUPAB), Beijing. 10/30 -11/3, 2011.
 
76. Shao, JW., Dai, YC., Xue, JP., Jia, L. Anticancer activity and mechanism of ZnPc in human hepatocellular carcinoma cell line HepG2. The AAPS Journal 2011; 12(S2): W4057; Submission ID: AM-11-00707; Wed. Oct. 26; 8:00-12:00 pm.
 
77. Xue, JP., Fang, Y., Jia, L. Liu, H., Chen, N., Hang, J. Preparation and in vitro photodynamic activities of a novel mono(8-quinolinoxy) phthalocyanato zinc(II). The AAPS Journal 2011; 12(S2): W4078; Submission ID: AM-11-01735; Wed. Oct. 26; 8:00-12:00 pm
 
78. Shao, JW., Du, H., Bai, Z., Xie, J., Cheng, X., Jia, L. Effects of fermentation conditions on the growth of Cordyceps kyushuensis in submerged culture and its antioxidative and anticancer activity in vitro. The AAPS Journal 2011; 12(S2): T2015; Submission ID: AM-11-01127; Tuesday, October 25, 8:00-12:00 pm
 
79. Gao, Y., Wang, A., Jia, L. (invited presentation) A urgent need for bilateral acceptability of GLP inspections and regulations between USA and China (制药业的全球化趋势急待中美GLP互认的双边协定). 高银燕,王爱平,贾力，制药业的全球化趋势急待中美GLP互认的双边协定，2011年中国药学大会暨第11届中国药师周论文集, pp 1017-1025, 2011. Nov. 6, 2011. 8:30-12:00 am.
 
80. Wang, J., Shao, J., Zhang, F., Jia, L. Design, synthesis and anticancer activity of a series of ursolic acid derivatives conjugated to folate: targeting folate receptors on cancer cells. October 14–17, 2012; Chicago. Poster T3023.
 
81. Fang, Y., Song, J., Wang, M., Zhang, J., Wang, X., Sun, JJ., Jia, L. A novel analytical method for detection of H2O2 by using electrogenerated chemiluminescence of cadmium germanate nanomaterials to overcome interferences from other coreactants: long-term stability and quality analysis. Abstract # 2605.
 
82. Xie, J., Zhao, R., Lu, Y., Wang, J., Gu, S., Jia, L. Re-engineering PAMAM dendrimer for its multivalent binding specifically to colon cancer cells HT29. XianShan Science Conference. Forum on Cancer Nanotechnology and Nanomedicine. 3rd US-China Symposium on Cancer Nanotech & NanoMed. Beijing, Dec., 5-7, 2012.
 
83. Lu, Y., Yu, T., Liang, H., Xie, J., Wang, J., Xu, J., Shao, J., Jia, L. S-nitrosocaptopril interferes hetero-adhesion between human colon cancer cells HT-29 and vascular endothelial cells. 2013 AAPS annual meeting; AM-13-0574
 
84. Xie, J., Zhao, R., Gu, S., Shao, J., Lu, Y., Wang, J., Jia, L. Surface-functionalizing modification of nanomaterial dendrimer PAMAM with anti-epithelial cell adhesion molecule antibody for its binding to colon cancer cells HT29. 2013 National Biotechnology Conference, San Diego, USA
 
85. J. C. Wang, Y. L. Wan, Y. W. Zhu, Y. S. Lu, J. J. Xie, T. Yu, J. Z. Chen, L. Jia. Synthesis, characterization and anti-adhesion effect of metapristone, a novel cancer metastasis chemopreventive agent derived from RU486 (mifepristone) 2013 AAPS annual meeting，AM-13-0927; San Antonio, USA
 
86. Jingjing Xie, Rongli Zhao, Songen Gu, Jichuang Wang, Yuanfang Li, Haiyan Liang, Ting Yu, Lee Jia Capture behaviors of PAMAM dendrimers functionalized with anti-Sialyl Lewis X antibody in vitro。AM-13-2174, 2013 AAPS annual meeting, San Antonio, USA
 
87. Y. Zhu, J. Wang, L. Wan, Y. Li, J. Xie, J. Chen, Y. Pang, L. Jia. Effects of Metapristone on Smooth Muscle Contraction in Isolated Rat Organs. Abstract AM-13-1771, 2013 AAPS Annual Meeting, San Antonio,USA.
 
88. Chen, J., Wang, J. Jia L. A novel UPLC/MS/MS method and its application to pharmacokinetic determination of metapristone, a novel cancer metastasis chemopreventive agent derived from RU486: pharmacokinetic difference between genders. Abstract AM-13-1044, 2013 AAPS annual meeting, San Antonio, USA
 
89. Wan, LY, Xu, H, Ma, J., Zhu, Y, Wang, JC, Xiao, YY, Shao, JW, Jia L.  HAMPT, a specific combination designed to control key cancer metastatic pathways: in vitro and in vivo evidences for its cancer metastasis chemoprevention. 2014, AAPS
 
90. Xie, JJ, Zhao, R, Shao, JJ, Sinko, PJ, Lu, YS, Gao, Y, Wang, JC, Dong, HY, Jia, L.
Increased capture and restraint of Hepatocellular circulating tumor cells in blood by  aEpCAM- and aSlex-coated dendrimer conjugates. 2014 AAPS.
 
91. Xie, JJ, Dong, HY, Zhao, R, Gu,S., Wang,JC., Lu,YS., Ting Yu, Xie, FW., Wang, L., Shao, JW., Jia, L*Enhanced Restraining Circulating Colorectal Cancer Cells in Blood and Their Hetero-Adhesion to Endothelial Cells with Dual Antibody-coated Dendrimer Conjugates. 2014; Nov. 5-7; SiChun Changdu, Nanotechnology meeting.
 
92. J. Xie, H. Chen, W. Shen, R. Zhao, Y. Lu, J. Wang, Y. Zhu, X. Xie, L. Jia. Targeting Antibody-Coated Dendrimers for Biological Functions in Cancer Metastasis Prevention. Abstract AM-14-1402, 2014 AAPS annual meeting, San Diego, USA.
 
93. Y. Zhu, Y. Xiao, J. Wang, L. Wan, T. Yu, J. Ma, J. Liu, S. Yu, L. Jia. Effects of Metapristone and Mifepristone (RU486) on Murine B16-F10 Melanoma Cancer Metastasis. Abstract AM-14-1786, 2014 AAPS annual meeting, San Diego, USA.
 
94. L. Wan, H. Xu, J. Ma, Y. Zhu, J. Wang, Y. Xiao, J. Shao, L. Jia. HAMPT, a Specific Combination Designed to Control Key Cancer Metastatic Pathways: In Vitro and In Vivo Evidences for Its Cancer Metastasis Chemoprevention. Abstract AM-14-2258, 2014 AAPS annual meeting, San Diego, USA.
 
95. Y. Lu, T. Yu, H. Liang, H. Xu, Y. Zhu, Y. Pang, J. Wang, J. Xie, L. Wan, L. Jia. S-nitrosocaptopril Prevents Cancer Metastasis by Inhibiting Adhesion of Circulating Tumor Cells to Endothelial Cells. Abstract AM-14-2797, 2014 AAPS annual meeting, San Diego, USA.
 
96. J. Xie, R. Zhao, J. Shao, P. Sinko, Y. Lu, Y. Gao, J. Wang, H. Dong, L. Jia. Increased Capture and Restraint of Hepatocellular Circulating Tumor Cells in Blood by aEpCAM- and aSlex-Coated Dendrimer Conjugates. Abstract AM-14-2260, 2014 AAPS annual meeting, San Diego, USA.
 
97. J. Wang, N. Zheng, Y. Zhu, L. Wan, J. Xie, L. Jia. Metapristone Exhibits Anti-metastatic Melanoma B16F10 Activity via Inhibiting the Expression of Integrin &[alpha]4 and Inducing Apoptosis. Abstract AM-14-1672, 2014 AAPS annual meeting, San Diego, USA.
 
98. Jingjing Xie1, Haiyan Dong1, Rongli Zhao1, Songen Gu1, Jichuang Wang1, Yusheng Lu1, Patrick J. Sinko2, Ting Yu1, Fangwei Xie3, Lie Wang3，Jingwei, Shao1,4, Lee Jia1,4* Enhanced sensitivity and specificity of capturing and restraining circulating tumour cells in blood with dual antibody-coated nanomaterials2014全国纳米生物与医学学术会议-四川成都2014-11-05
 
99. Huo Xu, Yu Gao, Yewei Zhu, Jia Lee*, Formulation, Transdermal Absorption and Penis Relaxation of An Nitric Oxide Donor Drug for its Coating on Condom, 2014,NOV; International Chinese Symposium on free radical research, Hong Kong.
 
100. Haiyan Liang, Yusheng Lu, Ting Yu, Shu Lian, Haiyan Dong, Lee Jia*. Enumeration, Characterization and Proliferation of Circulating Tumor Cells for Clinical Application Potential by Flow Cytometry. The 8th Pong Ding Yuen International Symposium on Traditional Chinese Medicine cum, The 2nd International Chinese Symposium on Free Radical Research & The 6th Symposium for Three Districts of Cross-straits on Free Radical Research. November 15-16, 2014, Hong Kong.
 
101. Jian Liu, Hongning Chen, Xiaobo Yu, Liping Xiang, Qiao Tang, Ting Chi , Jinwei Shao*, and Lee Jia* Functionalized PLGA-PEG nanoparticles conjugated with aptamer for targeting circulating tumor cells for drug delivery 2015, April; China Nanomedicine杭州
 
102. Yingying Xiao, Yewei Zhu, Jianzhong chen, Tao li , Lee Jia* Bioavailability and Pharmacokinetics of Nanometer Drug of Metapristone in Different Genders, A New Cancer Metastasis Chemopreventive Agent Derived From Mifepristone (RU486) 2015, April; China Nanomedicine杭州
 
103. Jingjing Xie1, Hongning Chen1, Yewei Zhu1, Weiyu Shen1, Rongli Zhao1, Lie Wang2, Fangwei Xie2, Lee Jia1,* Dual antibody-functionalized dendrimers for the specific capture of colorectal circulating tumor cells in vitro and in vivo. 2015, April, 9; China Nanomedicine杭州
 
104. Xiao-Dong Xie , Feng-Qiao Li, Yu Gao* , Lee Jia* DUAL-APTAMER-MODIFIED-MESOPOROUS SILICA NANOPARTICLES LOADING DOXORUBICIN FOR HIGH EFFICIENT RESTRAINING CANCER METASTASIS. 2015, April 9; China Nanomedicine杭州
 
105. Haiyan Dong, Yu Gao, Jingjing Xie, Jingwei Shao, Rodney Ho, Lee Jia  From Imitation to Innovation: the Ten-year Chinese Bionanotechnology Development. 2015, April 9 China Nanomedicine April; China Nanomedicine杭州
 
106. Jianguo Xu, Haiyan Dong, Weiyu Shen, Sudan He, Hongling Li,Yusheng Lu,Zaisheng Wu*, Lee Jia*. New molecular beacon for detection of p53 gene point mutation and its potential as a primer for polymerization. 2014; Nov. 5-7; SiChuan Chengdu, Nanotechnology meeting.
 
107. Ting Chi, Liping Xiang, Xiang Yang, Qiao Tang, Xiaobo Yu, Jian Liu, Yajun Liu,Jingjing Xie, Jingwei Shao*, Lee Jia*.Preparation and Anti-Tumor Activity of mesoporous silica nanoparticles (MSN) containing both free and conjugated ursolic acid (UA@MSN-UA). 2014全国纳米生物与医学学术会议-四川成都2014-11-05
 
108. Ting Yu, Yusheng Lu, Haiyan Liang, Yaqiong Pang, Jianguo Xu, Haiyan Dong, Songen Gu, Suhong Yu, Jingwei Shao and Lee Jia*. Nitric Oxide Inhibits Adhesion of Circulating Tumor Cells to Endothelial Cells. 2014 Chemical Biology-Nitric Oxide Shanghai International Conference, Shanghai, July 4-6, 2014.
 
109. Dong, H., Lu, Y., Xu, JG., Zheng, N., Liu, J., Jia. L. Bionanotechnology used for capturing and restraining circulating tumor cells: eliminating the suffering and death from cancer metastasis. Beijing, 2015 ChinaNano, Sept. 3-5., 2015.
 
110. Jingjing Xie#, Weiyu Shen#, Rongli Zhao, Lee Jia* Enhanced binding and restraint of hepatocellular carcinoma cells by multiple antibodies-conjugated dendrimers. Beijing, 2015 ChinaNano, Sept. 3-5., 2015.
 
111. Dong, H., Ma, J., Wang, J., Zhang, T., Wu, ZS., Lu, YS., Han, LY., Jia, L. The novel aptamer cyclization technology: resistant to exonuclease degradation, good biostability and enhanced specificity in binding target cancer cells. AAPS-AM-15-2352
 
97. Y. Lu, S. Lian, T. Yu, H. Liang, Y. Zhu, H. Xu, Y. Cheng, H. Dong, L. Jia*. S-nitrosocaptopril as a Potential Cancer Metastatic Chemopreventive Agent: A Promising Molecule for Preventing Cancer Metastasis. AAPS AM-15-1598.
 
98. N. Zheng, J. Wang, H. Chen, J. Liu, Y. Lu, H. Dong, L. Jia*. Metapristone Inhibits Cell Mobility and Adhesion of Ovarian Cancer.AAPS AM-15-1737.
 
99. Y. Xiao, Y. Zhu, T. Li, Y. Lu, J. Liu, X. Yu, X. Xie, H. Dong, S. Lian, W. Chen, L. Jia*. Metapristone, an active metabolite of mifepristone (RU486), prevent Lewis lung carcinoma cell metastasis. AAPS AM-15-886.
 
100. C.Yan , S.He , X.Yang , J.Liu , J.Ma , S.Yu* , L.Jia* Functions and Mechanisms of Metapristone in Triple-negative breast cancer cells. 2015, Nov.  AACR Shanghai
 
101. H. Chen, G. Zhen, J. Liu , J. Wang , Y. Lu, N. Zhen, C. Ting, Y. Xiao, J. Shao*, L. *Jia Metapristone Reduces Cell Proliferation and Induces Apoptosis of Non-Small-Cell Lung Cancer Cells A549 in vitro. 2015, Nov.  AACR Shanghai
 
102. Jun Qian, Xiaobo Yu, Xingtian Yang, Hongning Chen, Ting Zhang, Zhou Jiang*, Suhong Yu, Lee Jia** Achyranthes bidentata saponion: a promising cancer metastatic prevention agent. 2015, Nov.  AACR Shanghai
 
103. N. Zheng, J. C. Wang, J. H. Chen, J. Liu, X. B. YU, Y. S. Lu, X. D. Xie, and L. Jia
Metapristone exhibits anti-adhesive activity via down-regulating the expression of multiple adhesion molecules in ovarian cancer SKOV3 cells. A0065 2015, Nov.  AACR Shanghai
 
104. Xiaobo Yu, Qing Shi, Jian Liu, Yusheng Lu, Ting Chi, Yajun Liu, Jingwei Shao, Lee Jia . Similarities between embryo implantation and circulating tumor cells adhesion to human umbilical vein endothelial cells. 2015, Nov.  AACR Shanghai
 
105. Ji Ma, Tao Li, Hongning Chen, Cuicui Yan, Yingying Xiao, Lee Jia* The effect of ginseng on the pharmacological function of warfarin in rats.
 
106. Yingying Xiao, Yewei Zhu, Yusheng Lu, Wenge Chen, Xiaobo Yu, Hongning Chen, Ting Chi, Jian Liu, Lee Jia* A Novel Anti-metastatic Metapristone Inhibits MCF-7 Adhesion via Down-regulating Expression of MUC-1 Pathway in Vitro and Inhibits Lung Metastasis in Vivo. 2015, Nov.  AACR Shanghai
 
107. XT. Y, SD.H, CC.Y, SH.Y, L.JIA* Metapristone inhibits cell adhesion with reversal of epithelial-mesenchymal transition in MDA-MB-231 breast cancer cells. 2015, Nov.  AACR Shanghai
 
108. S.He , C.Yan , X.Yang , S.Yu , L.Jia  A pharmacoproteomic study of metapristone: a potential cancer metastatic chemopreventive agent. 2015, Nov.  AACR Shanghai
 
109. Yusheng Lu, 1Shu Lian, 1Yunlong Cheng, 2Min-Liang Kuo, 1Haiyan Liang, 1Lee Jia*
Bioenergetic Adaptation by Metastatic Cancer Cells to Reduce the Unrequired Bioenergy in Emergencies
 
110. Shu Lian, 1Yusheng Lu, 2Min-Liang Kuo, 3Alan Yueh-Luen Lee, 1Ting Yu, 1Haiyang Liang, 1Yunlong Cheng, 1Lee Jia S-nitrosocaptopril inhibits expression of cell adhesion molecules via regulating NF-кB signal pathway  AAPS abstract poster 2098.
 
111. H. Dong1,2, T. Zhang1, L. Han1, J. Ma1, J. Wang1, J. Xie3, Z. Wu1, P.J. Sinko2, Lee Jia*In vivo specifically capturing circulating tumor cells by dual ds-aptamer ring-coated dendrimers,1  2016 AAPS  abstract poster 1882
 
112. Yunlong Cheng, Yusheng Lu, Shu Lian, Lee Jia. TGF-β Can Enhance the Invasive Ability and the Rate of Metabolism and Proliferation of Cancer Cells. 2016 AAPS abstract poster 1200
 
113. Le, JQ, Zheng, TT. Xu, JG, Jia, L. Rapid and Reliable Construction of Aptamer-tethered DNA Nanoarchitecture for Targeted Cancer Therapy. 2016 AAPS poster abstract 1156
 
114. Wang, J. Dong, HY., Jia, L. Petitive Pseudo-DNA Nanocatenane for Ultrasensitive CTCs Detection in Peripheral Blood. 2016 AAPS poster Abstract 2111.
©　2018-2020　版权所有 闽江学院海洋研究院海洋药物研发中心 地址:福建省福州市闽侯县上街镇溪源宫路200号 访问量: